Improvement of therapy for amblyopia by Loudon, S.E. (Sjoukje)
Improvement of therapy for amblyopia
Sjoukje Elizabeth Loudon
The research project was initiated by the Department of Ophthalmology, Erasmus MC Uni­
versity Medical Center Rotterdam, the Netherlands. The work described in this thesis was fi­
nancially supported by the Health Research and Development Council of the Netherlands 
(project number 2300.0020). Financial support for the printing of this thesis was received from 
the Prof.dr. Henkes Stichting, Orthopad, 3M Opticlude, the Rotterdamse Vereniging Blinden­
belangen and the Erasmus Universiteit Rotterdam.
ISBN 978­90­8559­268­2
Copyright © 2007 S.E. Loudon, Rotterdam, the Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or 
transmitted in any form or by any means, without the permission of the author, or when ap­
propriate, of the publishers of the publications.
Layout and printing: Optima Grafische Communicatie, Rotterdam, The Netherlands
Cover design: VOF Vingerling & De Bruyne
Improvement of Therapy for Amblyopia
Verbeteren van de Behandeling voor Amblyopie
Proefschrift
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 21 februari 2007 om 15:45 uur
door
Sjoukje Elizabeth Loudon
geboren te Huddersfield, Groot­Brittannië
PromoTIEcommISSIE
Promotoren Prof.dr. G. van Rij
 Prof.dr. H.J. Simonsz
overige leden Prof.dr. P.J. van der Maas
 Prof.dr. J. Passchier
 Dr. M. Fronius
 Dr. M.J. Moseley
To my parents

7conTEnTS
Publications and manuscripts on which this thesis is based 9
chapter 1 General introduction 11
chapter 2 The history of the treatment of amblyopia 19
chapter 3 Objective survey of the prescription of occlusion therapy for 
amblyopia 
39
chapter 4 Visusevaluierung in einer historischen Kohorte von 137 okkludierten 
Patienten, 30­35 Jahre nach Ende der Okklusionsbehandlung / 
Evaluation of visual acuity in a historic cohort of 137 patients treated 
for amblyopia by occlusion 30­35 years ago
49
chapter 5 Electronic recording of occlusion treatment for amblyopia: potential 
of the new technology 
65
chapter 6 Electronically measured compliance with occlusion therapy for 
amblyopia is related to visual acuity increase
77
chapter 7 Predictors and a remedy for non­compliance with amblyopia 
therapy in children measured with the Occlusion Dose Monitor
87
chapter 8 The influence of parental attitudes and behaviour on compliance 
with amblyopia therapy and the effect of an educational programme 
105
chapter 9 Physiological and mechanical properties of the eye patch: influence 
on compliance and parental satisfaction 
119
chapter 10 Account of the study population in The Hague: prevalence of 
occluded children, causes of amblyopia and final visual acuity
131
chapter 11 General discussion and future prospects 139
8References 147
Summary / Samenvatting 161
Dankwoord 171
About the author 175
List of Publications 177
Appendix / Colour figures 179
9Publications and manuscripts on which 
this thesis is based
Chapter 2 S.E. Loudon, H.J. Simonsz The history of the treatment of amblyopia. Strabismus 
2005 Jun;13(2):93­106
Chapter 3 S.E. Loudon, J.R. Polling, B. Simonsz, H.J. Simonsz Objective survey of the prescrip-
tion of occlusion therapy for amblyopia. Graefes Arch Clin Exp Ophthalmol 2004 
Sep;242(9):736­40
Chapter 4 B. Simonsz­Tóth, S.E. Loudon, H. van Kempen­du Saar, E.S. van de Graaf, J.H. Groe­
newoud, H.J. Simonsz Visusevaluierung in einer historischen Kohorte von 137 okklu-
dierten Patienten, 30-35 Jahre nach Ende der Okklusionsbehandlung / Evaluation of 
visual acuity in a historic cohort of 137 patients treated for amblyopia by occlusion 
30-35 years ago. Accepted for publication Klin Monatsbl Augenheilkd 2006
Chapter 5 Y. Chopovska, S.E. Loudon, L. Cirina, A. Zubcov, H.J. Simonsz, M. Luchtenberg, M. 
Fronius Electronic recording of occlusion treatment for amblyopia: potential of the 
new technology. Graefes Arch Clin Exp Ophthalmol 2005 Jun;243(6):539­44
Chapter 6 S.E. Loudon, J.R. Polling, H.J. Simonsz Electronically measured compliance with oc-
clusion therapy for amblyopia is related to visual acuity increase. Graefes Arch Clin 
Exp Ophthalmol 2003 Mar;241(3):176­80
Chapter 7 S.E. Loudon, M. Fronius, C.W.N. Looman, M. Awan, B. Simonsz, P.J. van der Maas, 
H.J. Simonsz Predictors and a remedy for non-compliance with amblyopia therapy in 
children measured with the Occlusion Dose Monitor. Invest Ophthalmol Vis Science 
2006 Oct;47(10):4393­400
Chapter 8 S.E. Loudon, L. Chaker, S. de Vos, M. Fronius, J. Passchier, R.A. Harrad, C.W.N. Looman, 
B. Simonsz, H.J. Simonsz Effect of an educational programme on attitudes and behav-
iour with occlusion therapy and reasons for total non-compliance. (submitted)
Chapter 9 S.E. Loudon, A.W. Wypekma, C.W.N. Looman, M. Fronius, B. Simonsz, H.J. Simonsz 
Physiological properties of the eye patch and influence on compliance with occlusion 
therapy. (submitted)

ch
ap
te
r 1
ch
ap
te
r 2
ch
ap
te
r 3
ch
ap
te
r 4
ch
ap
te
r 5
ch
ap
te
r 6
ch
ap
te
r 7
ch
ap
te
r 8
ch
ap
te
r 9
ch
ap
te
r 1
0
ch
ap
te
r 1
1
A
dd
en
da
Chapter 1
General introduction

13
ch
ap
te
r 1
General introduction
InTroducTIon 
definition
The term ‘amblyopia’ originates from the Greek language and literally means dimness or dull­
ness of vision. In time, the condition has been defined in a variety of ways, very much depend­
ing on the prevailing patho­physiological concept about its etiology. In general, amblyopia 
can be defined as a unilateral or bilateral decrease in visual acuity for which no organic cause 
can be found on physical examination of the eye. It is caused by a refractive error (one foveal 
image is more blurred than the other); strabismus (ocular misalignment causing each eye 
to have a different image on the fovea) or, more rarely, deprivation of a clear retinal image 
(physical obstruction, e.g. infantile cataract, ptosis) (von Noorden 1967; 1985; von Noorden 
and Campos 2002). Amblyopia usually presents itself during the ophthalmological examina­
tion by the ophthalmologist or the orthoptist as a reduced visual acuity in one or both eyes, 
in the presence of a refractive error and/or strabismus or a deprivation. This reduced visual 
acuity persists after optimum correction of any refractive error (i.e. a pair of spectacles) and it 
cannot be explained by another ocular abnormality (e.g. retinopathy).
Epidemiology & screening
Amblyopia is the most common cause of monocular vision loss in children, accounting for over 
90% of the visits of children to ophthalmologists and orthoptists (Attebo, et al. 1998; Moseley, et al. 
1997; Sjöstrand and Abrahamsson 1997). The general estimate of the prevalence of amblyopia is 
approximately 3.5%, but varies considerably in the literature (0.5­5.3%) due to differences in study 
design, population and the examination methods used (Attebo, et al. 1998; Cole 1959; Helveston 
1965; von Noorden and Campos 2002; Simons 1996; Theodore, et al. 1946; Vinding, et al. 1991). In 
The Netherlands, the incidence is approximately 6500 amblyopic children each year. The national 
screening programme checks for the presence of strabismus after birth, and, periodically examines 
visual acuity from the age of three. The referral procedures in the Netherlands are currently studied 
by the Rotterdam AMblyopia Screening Effectiveness Study (RAMSES) (Juttmann, et al. 2001). This 
is a 7 year follow­up study, which evaluates the effectiveness and the efficiency of screening. Ap­
parently, one third of all children with a positive screening test result (i.e. reduced visual acuity) are 
not conclusively evaluated at an ophthalmological centre and consequently fail to profit from an 
early detection and treatment. Whether this could be attributed to the many intermediate steps 
between the referral and the orthoptist (parents have to make an appointment with their general 
practitioner, are then referred to the ophthalmologist and finally to the orthoptist), or the lack of 
understanding of the necessity of the referral by the parents is still unclear. When a positive referral 
leads to a visit to the orthoptist and the reduced visual acuity is confirmed they will be prescribed 
treatment, which may continue for several months up to several years.
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Treatment
Treatment of amblyopia involves complete or incomplete exclusion of the better eye from 
visual activity; hence, the use of the amblyopic eye is stimulated. The purpose of amblyopia 
treatment is equal acuity in both eyes and, consequently, preventing any future disability (e.g. 
choice of profession, quality of life). Early treatment, i.e. during the sensitive period of visual 
development lasting up to the age of 7 years, can reduce or completely reverse the effects 
of abnormal visual experiences, whereas treatment later in the critical period becomes less 
effective (Birch, et al. 1990; Crawford, et al. 1983; Epelbaum, et al. 1993; Mintz­Hittner, et al. 
2000; Mitchell 1991).
The mainstay treatment has been occlusion of the better eye using an opaque patch. Howev­
er, as there is little consensus amongst orthoptists concerning the necessary number of occlu­
sion hours, occlusion regimens may vary from occluding the better eye a few minutes per day 
to all waking hours (Tan, et al. 2003). More recently optical penalisation (selectively fogging 
the image of the non­amblyopic eye by glasses) or pharmaceutical penalisation (cycloplegia 
by the daily instillation of drops into the fornix of the non­amblyopic eye) was described. 
Several studies have demonstrated that atropine was as effective as occlusion therapy, but 
occlusion therapy caused a more rapid response, while atropine had a somewhat higher ac­
ceptability by the families (Cole 2001; PEDIG 2002; 2003; 2004; 2005).
Despite screening and treatment, approximately a third of the affected children who have 
been prescribed occlusion therapy do not reach visual acuity of 6/12 in the amblyopic eye and 
are unable to read with the amblyopic eye. This excludes them from any future tasks that re­
quire equal good vision (Jensen and Goldschmidt 1986; Vinding, et al. 1991). Matters worsen 
when an amblyopic child ­ in one study the proportion was estimated at 0.175% (Tommila 
and Tarkkanen 1981) ­ will loose the function of the better eye later in life, because of trauma 
or, for example, macular degeneration. This will result in bilateral visual impairment causing 
job losses, an increased morbidity and social isolation (Chua and Mitchell 2004; Fronius, et al. 
2005; Rahi, et al. 2002). A decrease in quality of life in adulthood has also been described (van 
de Graaf, et al. 2004). In people aged 20­70, amblyopia is the most common cause of monocu­
lar loss of vision (Buch, et al. 2001). 
The effectiveness of occlusion therapy was questioned in a report published by Snowdon & 
Stewart­Brown in 1997, who conducted a systematic review of the literature (Snowdon and 
Stewart­Brown 1997). They concluded that occlusion therapy has not yet been subjected to 
formal controlled trials and that much of the improvement in visual acuity could be sponta­
neous and unrelated to the therapy. However, they may have overlooked the possibility that 
the lack of evidence for the efficacy of occlusion could be due to low compliance rather than 
to ineffectiveness of the treatment. Their report contributed to the set­up of five randomised 
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controlled trials (RCTs) that produced evidence for the effectiveness of occlusion therapy 
(Awan, et al. 2005; Clarke, et al. 2003; PEDIG 2002; 2004; 2005; Stewart, et al. 2004; 2005). The 
percentage of successfully treated amblyopes spans a broad range: 19­93% success rates. Fac­
tors that influence the outcome of treatment include age (Massie 1965; Stewart, et al. 2004; 
2005), visual acuity at start of treatment (Cobb, et al. 2002; Hiscox, et al. 1992; Lithander and 
Sjöstrand 1991; Smith, et al. 1995, Stewart, et al. 2004; 2005) and type of amblyopia (Cobb, et 
al. 2002). The factor most frequently quoted, however, was the degree of compliance: the bet­
ter eye is not patched according to the orthoptists’ prescription (Awan, et al. 2005; Dorey, et al. 
2001; Lithander and Sjöstrand 1991; Simmers, et al. 1999; Simons and Preslan 1999; Smith, et 
al. 1995; Stewart, et al. 2004; 2005).
compliance
In recent years, ‘compliance studies’ are receiving increased attention now that it can be mea­
sured electronically (Kass, et al. 1986a; 1986b; 1987; Urquhart, 1992; 1999), with the first con­
ference addressing the issue of patient compliance organised in 1974. Compliance is referred 
to as the degree of correspondence between the recommendations from the health care pro­
vider and the patients’ actual dosage. The first devices that measured compliance electroni­
cally were developed to monitor the administration of pilocarpine eye drops in the treatment 
of glaucoma (Kass, et al. 1986a; 1986b; Norell, et al. 1980). The results showed that only 76% of 
the pilocarpine drops were taken as prescribed, while 6% took less than one quarter and 15% 
took less than half of the prescribed dosage. However, the patients’ diaries reported to have 
taken 97% of their medication. Poor compliance decreases the effectiveness of treatment and 
increases costs to the health care system (Cleemput and Kesteloot 2002). In children, the issue 
of non­compliance is especially challenging as the relationship is compound: the orthoptist 
deals with non­compliant parents, the parents deal with a non­compliant child. In addition, 
non­compliance in a parent is regarded as a more serious fault by society than non­compli­
ance in an adult patient and may therefore cause feelings of insufficiency and shame. Com­
pliance with any treatment for children is largely dependent on the ability of the parents or 
guardian to understand and follow through with recommended treatment. Only few groups 
have studied compliance electronically in children. Milgrom, et al. (1996) found 58% use of 
prescribed inhaled corticosteroids in asthma in children electronically, whereas the diaries 
kept by the patients or their parents reported 95% use. More than 90% of the patients exag­
gerated their use of inhaled steroids, and even the least compliant reported high levels of 
adherence to prescribed therapy. The authors concluded that most of the hospital admissions 
for asthma were caused by non­compliance. 
Since the development of the Occlusion Dose Monitor (ODM) by Fielder and Moseley (Fielder, 
et al. 1994) compliance with occlusion therapy for amblyopia can be measured electronically 
and therefore objectively. They developed an ODM that measured skin conductance at the 
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border of the patch. In 1997, the department of Medical Technical Development at the Aca­
demical Medical Center, Amsterdam modified the Fielder­ODM design and made it smaller. 
It now measures 24x12x3.6 mm and weighs 1.8 g. It is taped to the outside of a standard eye 
patch and measures the temperature difference between the front and the back of the ODM 
every 2 minutes, instead of skin conductance (Figure 1). In previous pilot studies with the 
ODM in patients from the Sophia Children’s Hospital Rotterdam, it was found that compliance 
with occlusion therapy was low and the patterns of non­compliance remained the same for 
one child and were apparently case specific (Simonsz and Polling 2001). In a second pilot 
study the ODM was distributed by the orthoptist in the clinic to patients whose compliance 
was thought to be low. Parents, however, interpreted the ODM as a ‘lie­detector’, resulting in a 
breakdown in the relationship between them and the orthoptist (Simonsz, et al. 1999). 
To date, several studies have demonstrated by means of the ODM that, generally, compliance 
with amblyopia treatment is low and treatment success is related to the level of compliance 
(Awan, et al. 2005; Simonsz, et al. 1999; Stewart, et al. 2004; 2005). 
Figure 1. a the first model of the ODM developed by Prof. Alistair Fielder and Dr. Merrick Moseley in 
London, United Kingdom b: in 1997 the department of Medical Technical Development at the Academic 
Medical Center Amsterdam modified the design and made it smaller: it now measures temperature 
difference between the front and the back c & d the ODM as used in the study in The Hague: it weighs 1.8 
g and measures 24 x 12 x 3.6 mm.
Figuren bij Chapter 5 
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Figure 1. The development of the Occlusion Dose Monitor. a Year 1991: first model developed by 
Fielder and Moseley in Birmin h m, UK (with permission of M. Moseley). The ODM was a miniature 
datalogger, which logs the patch-skin contact resistance every 64 s. b Year 1997: The Academic 
Medical Center Amsterdam modified the design into an ODM containing two thermistors connected to 
either the front or the back of the ODM (35x23x4 mm, 6 g). c The 2001 type used in the Netherlands 
(24x12x3.6 mm, 1.8 g). d The 2002 type used in Germany (31x15x3.5 mm, 2.3 g) 
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Figure 2. Examples of recordings with the ODM, with measured temperature difference on the 
ordinates. a A week’s recording. Abscissa: date of the recording. The temperature difference was about 
"0" (0; 0.0625) while the child was not patched (baseline value) and higher during the periods of 
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oBjEcTIVE And ouTLInE oF ThIS ThESIS
The main objective of the research presented in this thesis is, on the one side, to determine 
whether compliance with occlusion therapy can be improved with an educational programme 
explaining, without text and no animal figures, to a 4­year­old child the reasons why the bet­
ter eye must be patched, together with a calendar, reward stickers and a sheet containing 
general information about amblyopia and its treatment; and, on the other side, to identify cer­
tain predictors leading to non­compliance. Studied were the clinical parameters of the child, 
the socioeconomic and ethnic parameters and the psychometric parameters. Compliance was 
measured electronically by means of the Occlusion Dose Monitor. 
Following this first chapter, the history of the treatment for amblyopia is given in Chapter 2. 
Chapter 3 presents an inventory made in order to try and identify the variation in prescrip­
tions of occlusion hours amongst orthoptists in the Netherlands and in Germany, their con­
sistency in prescriptions and the main determinants when prescribing a certain number of 
occlusion hours. In Chapter 4, the current visual acuity of 137 amblyopic patients treated for 
amblyopia 30 years ago, is evaluated and factors associated with a poor outcome are deter­
mined. Chapter 5 investigates whether the Occlusion Dose Monitor (ODM) that is used to 
objectively measure compliance, is able to differentiate between measurements on the eye 
and on other parts of the body. Chapter 6 presents a pilot study in which the ODM was distrib­
uted via home visits by the researcher and that determined whether children whose acuity 
had not improved sufficiently after six months of patching were indeed the children with low 
compliance. The following three chapters (number 7, 8 and 9) present studies that are carried 
out using data from the prospective randomised clinical trial in The Hague, the Netherlands. 
For 30 months all newly diagnosed amblyopic children were recruited from the four clinics 
in The Hague. Chapter 7 illustrates the effect of the educational cartoon story on compliance 
and determines the influence of clinical and socioeconomic factors on compliance. Chapter 8 
presents the effect of the educational programme on attitudes and behaviour factors and rea­
sons for total non­compliance with occlusion therapy for amblyopia. Chapter 9 investigates 
the physiological properties of the eye patch and its influence on compliance. Chapter 10 
gives an account of the study population, causes of amblyopia and the final visual acuity.
The clinical relevance of the findings and future prospects are discussed in the eleventh and 
final chapter.
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The history of the treatment of amblyopia
InTroducTIon
The Greek word amblyopia means dimness or dullness of vision (ambly αμβλυσ = dull and 
ops ωψ = vision) and the condition has been defined in a variety of ways in the literature. 
Amblyopia is a decrease in visual acuity, usually in one eye. It persists after the correction of 
the refractive error (i.e., acuity is not improved by glasses) or removal of any pathological ob­
stacle to vision (i.e. cataract) and no organic cause can normally be found (Ansons 2001; von 
Noorden 2002). 
The general estimate of the prevalence of amblyopia hovers around 3.5%. The reported preva­
lence in the literature varies considerably (0.5­5.3%) due to differences in study design, popu­
lation and the examination methods used (Attebo, et al. 1998; Ciuffreda, et al. 1999; Cole 1959; 
Helveston 1965; von Noorden 2002; Simons 1996; Theodore, et al. 1946; Vinding, et al. 1991). 
In addition, the criteria used to diagnose amblyopia differ at the start of treatment, the end of 
the treatment and later in life. 
This developmental anomaly is mainly monocular and caused by misalignment of the eyes 
(strabismus), a refractive error (anisometropia) and/or a form deprivation (for example infan­
tile cataract) (von Noorden 1967; 1985). The critical period in visual development for the de­
velopment of amblyopia is commonly thought to start approx. 6 weeks after birth up to the 
age of six (Daw 1998; Fawcett, et al. 2004). However, this remains a subject of discussion as it 
involves multiple aspects, e.g. the cause of the amblyopia, treatment efficacy, etc. Treatment 
involves complete or incomplete exclusion of the better eye from visual activity for the pur­
pose of equal acuity in both eyes. Early treatment can reduce or completely reverse the effects 
of early abnormal visual experiences, whereas treatment later in the critical period becomes 
less effective (Birch, et al. 1990; Crawford, et al. 1983; Epelbaum, et al. 1993; Mintz­Hittner, et 
al. 2000; Mitchell 1991). 
The aim of this review is to provide an historical overview of the different ways that amblyopia 
has been treated in the past. The history of the diagnosis and treatment of amblyopia is a 
remarkable one and very much influenced by the prevailing pathophysiological concepts re­
garding its etiology. It was not until the beginning of 1960, when Hubel and Wiesel performed 
their neurophysiologic experiments on cats and monkeys, that some of the basic mysteries 
regarding its etiology were solved (Wiesel, et al. 1963a; 1963b; 1965).
22
GrEEk AnTIquITy
hippocrates
As early as approx. 480 BC, Hippocrates used the term ‘amblyopia’, which was then used for a 
diminished acuity, including presbyopia, in what appeared to be healthy eyes. Strabismus was 
known as a disorder of the eye position and its movements. It was not considered as an eye 
disease as such, but as a symptom of other bodily ailments. Treatment (for both strabismus 
and amblyopia) consisted of a medicine, carefully made up of oil and vinegar, water, wine, 
honey and minerals. In addition, certain diets, for example onions and fresh vegetables, were 
thought to improve the eyes, whereas lentils were seen to be harmful. Physical exercises and 
a regular lifestyle were also said to be beneficial (Fuchs 1895). 
ByzAnTInE EmPIrE
Paulus de Aegina and Thabit ibn qurrah
During the Byzantine Empire, the surgeon and obstetrician Paulus de Aegina (Alexandria, 
Egypt; approx. 625­690) was the first person to treat strabismus rationally when he used a 
mask made from nutshells with small perforations in the centre. Strabismus was thought to be 
caused by a ‘spastic state of the muscles that move the eye’. These shells would force the stra­
bismic eye to look straight ahead, thereby correcting the deformed vision (Berendes 1914). 
Paulus lived and worked in Alexandria when the Arabs invaded the city in 642. They thought 
very highly of Paulus and his work and honoured him with the title ‘obstetrician’. He acted as a 
mediator between the traditional Greek medicine and the flourishing Arabian medicine.
Blindness was a major cause of disability in Arabian countries. Islamic physicians developed a 
particular concern and skill in the diagnosis and treatment of eye diseases. Thabit ibn Qurrah 
ibn Marwan al­Harrani was born in 836 at Harran (presently in Turkey) and died in Baghdad 
in 901 (Figure 1). He is known for his work on mechanics, astronomy, pure mathematics, ge­
ometry and anatomy and was part of the scientific team of the great Muslim mathematician 
FIGUREN BIJ HOOFDSTUK 2 
 
 
Figure 1. Thabit ibn Qurrah ibn Marwan al-Harrani was the first to describe occlusion 
therapy for the better eye until the vision in the strabismic eye had returned to normal.  
 
 
Figure 2. Remains of “Hospice des Quinze-Vingts”, the first institution for the blind 
in Paris (1254). 
 
 
 
Figure 7. Franciscus Cornelis Donders and Albrecht von Graefe, founders of the 
Dutch and German Ophthalmology, at the World’s Fair in London, 1851. 
Figure 1. Thabit ibn Qurrah ibn Marwan al­Harrani was the first to describe occlusion therapy for the 
better ey  until the vision in the strabismic eye had returned to normal. 
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Muhammad Ibn Musa Ibn Shakir at Baghdad. Thabit’s books on mathematics, astronomy and 
medicine have survived. In his book ‘Vision and Perception’ he described the treatment of 
strabismus as follows: “Strabismus should be treated by patching the normal eye. Once you 
do that, the visual power will go in its entirety to the deviating eye and vision in that eye will 
return to normal. You should not release the normal eye until the vision in the strabismic eye 
has completely returned to normal”. This description of occlusion therapy is probably the first 
as found in the literature (von Noorden 2002; Wafai 1991). 
rEnAISSAncE
Saint Louis IX, France and Georg Bartisch, Germany
Approximately 500 years later, during the time of the crusades, the first exclusive eye hospital 
was founded by Saint Louis IX in France. When he returned from his crusade in Egypt in 1254 
he founded “Les Quinze­Vingts” inside his castle in the Louvre, Paris. The hospital was intend­
ed for 300 (15 x 20 beds) of his companions who had accompanied him and now suffered from 
trachoma. Les Quinze­Vingts was the first hospital treating patients with low vision (glauco­
ma, cataract, amaurosis, and trauma) and serve as an institution for the blind, inexpensive or 
free of charge. In 1780, prior to the French Revolution, the cardinal Louis de Rohan transferred 
the institute to an old and abandoned barrack, once belonging to the Black Musketeers, in the 
suburb Saint­Antoine to aid the local population. Despite serious protests the building was 
demolished in 1957, as it was deemed unfit for modern medical practice. What remains of the 
barracks are the main entrance, the hall and its chapel (Figure 2) (Paroisse).
After Paulus de Aegina, Georg Bartisch (1535­1607) also developed masks for the purpose of 
correcting the deformed vision. Bartisch was born in Gräfenhain and moved to Königsbrück 
when he was about 12 years old. He had an early interest in medicine, but due to financial 
circumstances Bartisch was unable to enrol in a scientific study. Instead, he gained his experi­
ence working with wound healers and barber surgeons. Practicing as an itinerant surgeon, he 
often travelled to Bohemia and Prague to gain experience and became a court oculist to the 
Duke of Sachsen in Dresden. Although he was not an academically educated physician, he 
had extensive knowledge of ancient medical practice. 
Figure 2. Remains of “Hospice des Quinze­Vingts”, the first institution for the blind in Paris (1254).
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In 1583 Bartisch published “Ophthalmodouleia/Das ist Augendienst”, one of the first medical 
treatises to be published in the German language instead of traditional Latin. It contained sev­
eral woodcuts drawn by Bartisch himself. The hoods he designed to treat strabismus covered 
the head entirely, with perforations corresponding with the correct position of the eyes to en­
courage the strabismic eye to straighten; one for an esodeviation and one for an exodeviation 
(Bartisch 1583) (Figure 3a, b and c). The anatomy of the head and eye is described according 
to Galen’s ideas. Many treatments are discussed, partly displaying the mystic influences of the 
Middle Ages (“evils caused by magic, witchcraft and work of the devil”).
His book also contained a section in which he described an orbital exenteration using a ‘large 
spoon’ with sharp edges. This operation, including an enucleation, had never been performed 
before. Georg Bartisch died in 1607. 
In those days, ophthalmology as such was not a separate specialty. Oculists and barber sur­
geons performed eye surgery, as educated physicians disliked surgery. Doctors calling them­
selves ‘ophthalmologists’ were, without exceptions, general surgeons. Occasionally, a surgeon 
who specialised in eye diseases (mainly cataract extractions) was now called an ‘oculists’ (for 
example Bartisch and Taylor). In Paris, the first chair of ophthalmology was created in 1762, 41 
years after the first chair of surgery was created. It was originally intended for Jacques Daviel, 
but due to his premature death it was given three years later, in 1765, to Louis Florentin Des­
haies Gendron. This may be looked upon as the start of actual ophthalmology.
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Figure 3. Tre tment of strabismus according to Georg Bartisch (1583) for esotropia (a,b) 
and for exotropia (c). These pictures were made avail ble by the “Museum Boerhaave 
Leiden”, the Netherlands.  
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Figure 3. Treatment of strabismus according to Georg Bartisch (1583) for esotropia (a,b) and for exotropia 
(c). These pictures were made available by the “Museum Boerhaave Leiden”, the Netherlands. 
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charles de Saint-yves
Charles de Saint­Yves was born in 1677 in Maubert­Fontaine, France. He started his education 
in general surgery when he was 17 years old. Five years later he had specialised in eye diseases 
at the general hospital in Paris, a hospital supported by the Countess Françoise Anthénais 
Montespan, the mistress of King Louis XIV. In 1711, Charles de Saint­Yves left the general hos­
pital and opened his own Ophthalmology Clinic in Paris where he committed himself fully 
to eye diseases. In 1722, he wrote down his experiences in his textbook “Nouveau traité des 
maladies de yeux” (Figure 4). Chapter 24 deals with ‘Des yeux louches’ in which he wrote: “One 
was sometimes obliged to fully cover the non­strabismic eye, thereby straightening the stra­
bismic eye and so as to be dependent on this eye, it will get used to looking straight ahead” 
(De Saint­Yves 1722). He continued: “When one closes the non­strabismic eye, the squinting 
eye will now look straight ahead and when opening the eye again one now finds a squint in 
the eye that was straight before”. Based on this observation, he was one of the first to describe 
the cover test. Nowadays, the cover test is an important part of orthoptic practice. It includes 
two tests: the cover­uncover test and the alternating cover test and is the principle element in 
the detection and diagnosis of strabismus. To straighten the eyesight he also recommended 
the exercise to “sit the child in front of a mirror and that each eye looks precisely to the pupil 
of that eye which corresponds to him in the mirror. In addition, one must also read fine print 
and do handicrafts”. His book is clearly written with detailed observations, including cataract 
 
Figure 4. Charles de Saint-Yves was one of the first surgeons who specialised in eye 
diseases and wrote detailed observations about all known eye diseases in his book: 
“Nouveau traité des maladies des yeux” (1722). 
Figure 4. Charles de Saint­Yves was one of the first surgeons who specialised in eye diseases and wrote 
detailed observations about all known eye diseases in his book: “Nouveau traité des maladies des yeux” 
(1722).
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extractions (he performed 60­80 each year). His life’s work shows him to be a dedicated re­
searcher and eye specialist. Charles de Saint­Yves died in 1736.
George comte de Buffon
The person usually credited for the introduction of occlusion of the fixating eye for amblyopia 
was the French naturalist and botanist George­Louis Leclerc, Comte de Buffon (Figure 5). 
He was born in Montbard (Burgundy, France) in 1707 to rich, middle class parents and inher­
ited the title ‘Comte de Buffon et Montbard’ and a large sum of money when his mother died. 
This made him financially independent, in those days a necessity for dedicating one’s life to 
science. He studied medicine, astronomy and botany at the Angers University. He suffered 
from strabismus and poor vision of his squinting eye. According to Buffon, a strabismic eye 
was caused by poor vision in one of the eyes, which led to a disruption in binocular vision. 
This was contrary to what was generally believed, i.e. that an unequal strength of the muscles 
or lack of concordance caused the strabismus. He also rejected the masks as he recognised 
they did not have the desired effect. In 1743, in his “Dissertation sur les causes du Strabisme” 
he described the weak eye regaining all its strength by occluding the good eye (“reprendre 
toutes ses forces”) (De Buffon 1743). Buffon is probably better known for his “Histoire Naturelle 
générale et particulière (1749)”, written when he was responsible for the Royal Gardens of the 
French King Louis XV. He played an important part in the development of biology as a science. 
He was an avowed opponent of Carolus Linnaeus whose taxonomy he described as artificial, 
which is probably the reason why Linnaeus denominated an ugly toad as a “Bufonidae”. Buffon 
died in April 1788.
 
Figure 5. George-Louis Leclerc, Comte de Buffon postulated that a strabismic eye was 
caused by poor vision in one of the eyes causing a disruption in binocular vision, which 
was contrary to what was generally believed at that time (1743). 
Figure 5. George­Louis Leclerc, Comte de Buffon postulated that a strabismic eye was caused by poor 
vision in one of the eyes causing a disruption in bin cular vision, which was con rary o what was generally 
believed at that time (1743).
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john Taylor
A new idea, to treat strabismus surgically, was introduced by John Taylor, born in Norwich 
(England) in approximately 1703. He started his career as a pharmacist’s student in London 
and afterwards moved to the continent where he attended lectures on ophthalmology by 
Herman Boerhaave (1668­1738). He travelled around the major cities in Europe in a carriage 
painted with eyes, treating patients with ‘incurable eye diseases’. Taylor carried out cataract 
operations, removed blood from inflamed conjunctiva and scars and abraded weak and para­
lysed eyes with the convex side of a silver tablespoon. Occasionally, Taylor would even place 
the concave side of the spoon over a closed eye and give it a firm push (Figure 6). 
Among Taylor’s patients were Johann Sebastian Bach, on whom he operated for cataract, and 
Georg Friedrich Händel, both of whom became blind due to complications of the operation. 
The most intriguing operation he performed were those on the strabismic eye. Taylor believed 
that strabismus was caused by an imbalance between the muscles. By cutting the nerve inner­
 
 
Figure 6. Chevalier John Taylor travelled around Europe treating ‘incurable eye disease’ 
and suggested treating strabismus with surgery. However, the technique for strabismus 
surgery was not developed until approximately 100 years later. 
Figure 6. Chevalier John Taylor travelled around Europe treating ‘incurable eye disease’ and suggested 
treating strabismus with surgery. However, the technique for strabismus surgery was not developed until 
approximately 100 years later.
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vating the strongest muscle, this balance would be restored; he therefore performed a small 
cut in the conjunctiva, pretending to cut the nerve and thus so straighten the strabismic eye. 
After the procedure he covered the operated eye to demonstrate that the other eye looked 
straight ahead. The next day he would cover the other eye, thereby demonstrating the stra­
bismic eye now also looked straight ahead. When Taylor and his companions arrived in Rouen, 
France, Claude­Nicolas Lecat (or: Le Cat, the famous anatomist and surgeon) took his oppor­
tunity to study Taylor’s work so that he might improve his own surgical techniques. Lecat was 
not satisfied with the result of Taylor’s operations on the strabismic eye. He argued that it was 
unclear which nerve was to be cut in the conjunctiva. Lecat also observed that every time the 
better eye was closed, the strabismic eye looked straight ahead and vice versa. He regarded 
Taylor as a fraud, invited him to his house for dinner and served him an unexpected dessert: a 
human head with its eyes anatomically prepared. It was obvious there were no nerves in the 
conjunctiva. Taylor left Rouen the next day. All the eyes he had operated on started squinting 
as before (Crone 1992; Taylor 1756).
ThE FIrST STrABISmuS oPErATIonS
Stromeyer, dieffenbach and cunier 
It was not until a hundred years later doctors did what Taylor had intended to do: operate 
the eye muscles. The initiator was Friedrich Louis Stromeyer from Hannover, Germany. He oc­
cupied himself with orthopaedic surgery. In his book “Beiträge zur Operativen Orthopädik” 
(1838), he cut the Achilles tendon in the heel in order to treat (straighten) a clubfoot. The same 
principle could be applied to strabismus, for which he described a tenotomy of the inner eye 
muscle on corpses (Stromeyer 1838). Johann Friedrich Dieffenbach (1792­1847) was the first 
to publish his results, 10 days after operating the medial rectus muscle in Berlin (1839), when 
he wrote “Über die Heilung des angeborenen Schielens mittelst der Durchschneidung des 
inneren geraden Augenmuskels”. He performed a tenotomy on a 7­year­old boy with conver­
gent strabismus without anaesthesia (Dieffenbach 1839). Three years later, Dieffenbach had 
already operated 1200 patients with strabismus. Unfortunately, total tenotomies often led to 
an overcorrection. Meanwhile, in Brussels, Florent Cunier (1812­1852) also performed a stra­
bismus operation claiming to be the first (Cunier/Missotten 2001). However, Dieffenbach was 
able to prove that he had performed the same procedure just a few days earlier. 
Ludwig Boehm noticed that the visual acuity of the strabismic eye sometimes improved after 
the operation. He attributed this effect to the tenotomy itself and presumed that amblyopia 
could be cured by an operation (Boehm 1845). 
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dIScoVEry oF ThE oPhThALmoScoPE And ThE STArT oF modErn 
oPhThALmoLoGy 
Von helmholtz, donders and von Graefe
In 1850, Hermann Ludwig Ferdinand von Helmholtz invented the ophthalmoscope. Born in 
Potsdam, Germany in 1821, he was appointed professor of physiology at Königsberg at the 
age of 28. He was an important scientist and greatly contributed to modern ophthalmology. 
With the ophthalmoscope it was now possible to view the retina (Helmholtz 1851; Keeler 
2002). This was revolutionary in eye care and may be considered as the start of modern oph­
thalmology. It was confirmed that in most cases of amblyopia the eye was structurally sound, 
establishing the functional character of amblyopia. 
The physiologist and ophthalmologist Franciscus Cornelis Donders (1818­1889), a Dutch 
scientist, examined thousands of emmetropic and ametropic eyes and recorded the normal 
refractive error (Donders 1864). Until then, only three types of errors were known: myopia, 
presbyopia and astigmatism. In 1859, Donders described the hypermetropic error, and in 
1861 how accommodation was linked to convergence. It was apparent that Donders already 
knew about the relationship between accommodation and convergence as early as 1847. 
In a postscript to an article written by F.W.C. Krecke on the correction of strabismus using 
prisms, Donders hypothesised that convergent strabismus might be related to hyperme­
tropia (Krecke 1847). So, as a consequence, the strabismus would often improve when this 
refractive error was corrected. While studying in London he visited the World’s Fair in 1851 
and became acquainted with the German ophthalmologist Albrecht von Graefe (1828­1870, 
Berlin) (Figure 7). 
FIGUREN BIJ HOOFDSTUK 2 
 
 
Figure 1. Thabit ibn Qurrah ibn Marwan al-Harrani was the first to describe occlusion 
ther py for the bett r eye until th  vision in the stra ismic eye had returned to normal.  
 
 
Figure 2. Remains of “H spice des Quinze-Vingts”, the first institution for the blind 
in Paris (1254). 
 
 
 
Figure 7. Franciscus Cornelis Donders and Albrecht von Graefe, founders of the 
Dutch and German Ophthalmology, at the World’s Fair in London, 1851. 
Figure 7. Franciscus Cornelis Donders and Albrecht von Graefe, founders of the Dutch and German 
Ophthalmology, at the World’s Fair in London, 1851.
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Albrecht von Graefe was one of the founders of German ophthalmology. Inspired by each oth­
er’s work, Donders and Von Graefe became friends. They readily used the Ophthalmoscope to 
determine the refractive error and provoked discussions about what came first: strabismus or 
amblyopia. This chicken­or­egg discussion (Bielschowsky, 1926) continued until 1960 (Wiesel 
1963a; 1963b; 1965). Donders and Von Graefe argued that amblyopia in strabismic children 
could be the result of either ‘not using’ the eye, i.e. functional amblyopia, or of an organic vi­
sual impairment (“…wird im Folge von diesem Nichtgebrauche mit physischer Unterdrückung 
amblyopisch”) (Donders 1864; von Graefe 1854). Instead, Carl Schweigger and Alfred Graefe 
advanced the theory of organic amblyopia (Graefe 1894; Schweigger 1885). In their opinion, 
children were born with amblyopia and this caused the strabismus. They also argued that eyes 
did not become amblyopic even after a long period of nonuse, for example cataract, and that 
the acuity became normal after removal of any obstacle to vision. 
Fusion exercises
Darwin, Javal, Worth and Maddox
In England, Erasmus Darwin (1731­1802) modified Charles de Saint­Yves’ cover exercises al­
most 50 years later (Darwin 1779). Born in Lichfield near Birmingham, he was the first to pre­
scribe fusion exercises as a treatment for strabismus. Using a septum, he separated the two 
visual fields after which he presented each eye with small coloured pieces of wood to train the 
fixation. Once the child was able to fixate equally well with either eye, two pieces of wood were 
presented simultaneously to each eye and the child was asked to superimpose them. Erasmus 
Darwin worked in close association with other great scientists and highly skilled technicians 
such as Josiah Wedgwood, the porcelain manufacturer, James Watt and Joseph Priestley. His 
theory of evolution was elaborated on by his grandson Charles Robert Darwin. 
In 1897, Louis Emile Javal (1839­1907) emphasised the use of stereoscopic exercises to treat 
strabismus in his “Manuel théorique et pratique du Strabisme” (Javal 1896). Born to a business­
man, his parents wished him to study business and economics, hoping he would take over his 
father’s coal­mining business. In 1865, however, he entered medical school at the University 
of Paris. In 1878 he became the director of the Laboratory of Ophthalmology at the University. 
He took a particular interest in ophthalmology, probably because his father and sister suffered 
from strabismus and he himself from myopic astigmatism. Javal preferred non­surgical treat­
ments for ocular problems, hence his interest in orthoptics. Determined not to let his sister 
fall a victim to: “…le massacre des muscles oculaires,” he trained her with his “Stéréoscope à 
charnière”. In his manual he advised occlusion of the healthy eye, “occlusion volontaire de l’oeil 
meilleur,” as well as the use of the stereoscope to re­establish binocular vision. Even though he 
suffered from progressive glaucoma he was able to finish his manual in 1897, after which he 
dedicated himself to the further development of Braille together with Louis Braille.
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Inspired by the work of Javal, Claud Worth published his first edition of “Squint, its causes, 
pathology and treatment” at the turn of the century (Worth 1903). Born in 1869, he made 
fundamental contributions to the field of strabismus and became a member of the Ophthal­
mological Society of the United Kingdom in 1899. He was an advocate of occlusion therapy 
of the non­strabismic eye and introduced the use of atropine in mild cases of amblyopia, as 
an alternative to patching. He recorded the age of onset of the squint, the length of time the 
squint had been present before occlusion started and the final visual acuity of the deviating 
eye. From these results he developed a ratio: age in months when permanent turn became ap­
parent divided by the age in months at which training/treatment began. This ratio indicated 
the prognosis, which improved when the ratio approached unity. Worth formulated the the­
ory that strabismus was caused by a congenital defect of the fusion mechanism. He therefore 
also proposed fusion training and active stimulation of the amblyopic eye using the improved 
version of the ‘fusion tubes’ (Priestley Smith 1896), now called the ‘amblyoscope’. However, the 
use of the amblyoscope was time consuming and results were not always satisfactory. 
Ernest Edmund Maddox made use of the Worth amblyoscope in Bournemouth, England. Born 
in Shipton and educated at the University of Edinburgh he received his MD in 1889. He is re­
nowned for several inventions: the double prism, the Maddox rod, the Maddox tangent scale 
(1898), the Maddox prism verger and the cheiroscope for orthoptic training. Near the end of 
his career he developed an interest in orthoptics and the Worth amblyopscope. He found that 
he did not have enough time to use the device properly. Instead, he taught his daughter, Mary 
Maddox, to use the amblyoscope. She quickly became a professional using this device and from 
this she turned her interest to other aspects of orthoptics. In 1929 Mary Maddox opened the 
first orthoptic clinic at the Royal Westminster Ophthalmic Hospital in London (Maddox 1931).
reintroduction of occlusion therapy: mastisolverband
Sattler
Occlusion therapy was re­introduced by C.H. Sattler when he published his experiences with 
the treatment of amblyopia in Leipzig in 1927 (Sattler 1927). For the treatment of strabismus 
related amblyopia he recommended the use of so­called ‘Mastisolverband’. This occluder was 
glued to the skin around the eye so as to prevent the child from peeking and remained se­
curely fastened there for at least two to three days. This was the first description of the adhe­
sive tape patch and as such it meant the re­introduction of occlusion therapy for amblyopia. 
He reported that the best results were obtained in children up to the age of six. Of course, full 
cooperation and stimulation of the parents was essential and the acuity in the sound eye had 
to be checked frequently. Children in whom acuity failed to improve were considered either 
not to have applied the ‘Mastisolverband’ properly or not to have applied it at all.
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Two years later, F. Weckert made use of the children’s spectacles by using a spectacle ‘occluder’ 
with shields on the side to prevent light incoming from the periphery and to enable the child 
to blink behind the occluder more easily (Weckert 1929). The children had to wear these oc­
cluders full time. He reported good results using this type of occlusion, which, according to 
Weckert, was more readily accepted by the patient than Sattler’s ‘Mastisolverband’.
Arguments for and against occlusion therapy
Poulard, Uhthoff, Stenius, Fuchs and Gifford
At the time, there were many arguments for and against occlusion therapy. The Frenchmen 
Poulard shared the opinions of Alfred Graefe. He had never seen any great improvement of 
vision in the amblyopic eye with occlusion therapy (Poulard 1921) and could not but conclude 
that a deviating eye was caused by amblyopia, rather than amblyopia being caused by the 
deviating eye. This opinion he also shared with Uhthoff (Uhthoff 1927). Stenius, however, in 
1935, reported excellent results in 2­ to 6­year­olds with central fixation in their strabismic eye. 
He prescribed these children part­time occlusion therapy (1 or 2 hours daily) and encouraged 
them to read or draw pictures during the period of occlusion (Stenius 1935). The year after, 
Ernst Fuchs wrote in his “Aus meiner augenärztlichen Praxis” that the results he gained with 
occlusion therapy did not measure up to the problems parents had to endure when treating 
their children (Fuchs 1928). This opinion was supported by Gifford, who thought occlusion 
could cause a psychological trauma, leading to disorders such as stammering (Gifford 1935). 
Besides these problems, complications of occlusion therapy have also been reported, e.g. 
occlusion amblyopia, disruption of binocularity and an increase in the angle of strabismus 
(Quéré, et al. 1969). An occasional occurrence of occlusion amblyopia had already been men­
tioned by Worth and proven to be usually reversible (Burian 1966; Hardesty 1959). Other stud­
ies did not find these adverse effects on the patched eye (Holbach, et al. 1991; Lithander and 
Sjöstrand 1991).
Segment occlusion
Bangerter
Segment occlusion was introduced by Alfred Bangerter, St. Gallen, Switzerland in 1953. Self­
adhesive synthetic material was applied onto the inside of the spectacles occluding only part 
of the glass; what part depended, for instance, on the presence of accommodative or conver­
gent strabismus. The occlusion spectacles could also reduce the incoming light by means of a 
transparent foil with various densities of gratings (“Bangerter Foil”) (Bangerter 1960). He also 
suggested the use of occluders in case of undisciplined children and in warmer weather con­
ditions. In his book “Amblyopiebehandlung” (Bangerter 1953) Bangerter described the devel­
opment of amblyopia and considered system, consequence, versatility and adjustment to be 
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the basic principles of his amblyopia treatment. He developed a systematic treatment of the 
amblyopic eye according to age, diagnosis and fixation, as well as a prophylactic treatment 
of amblyopia. He was a fierce opponent of occluding the better eye in the presence of an ec­
centric fixation. In his opinion, this was not only dangerous and futile but could also reinforce 
the eccentric fixation (Bangerter 1946; 1953; 1960). 
Occlusion therapy would suffice to improve acuity in case of low­grade amblyopia; however, 
high­grade amblyopia, especially amblyopia without fixation or a paracentral fixation, needed 
more intensive and direct stimulating measures to achieve increased acuity (Bangerter 1953). 
This brings us to the pleoptic­era. 
Pleoptics
Comberg and Cüppers
Pleoptic is also a Greek word and refers to pleion=more and optikos=eyesight. In Rostock in 
the north­east of Germany, W. Comberg described an apparatus to train central vision in chil­
dren with functional amblyopia (Comberg 1936). The apparatus (1936) was designed to stim­
ulate the area of the macula in eyes with eccentric fixation by projecting brightly illuminated 
objects onto the fovea. 
Bangerter and later Cüppers introduced various other instruments based on these very same 
principles: stimulation of the fovea of the amblyopic eye to awaken central fixation. 
As he was head of the department, Bangerter had the means and opportunity to pursue his 
ideas on how to treat amblyopia the best possible way. He invented over 20 instruments and 
after more than a decade of trial and modification, Bangerter constructed the “Pleoptophor” 
(Linksz 1961; Priestley 1961; Schlossman 1961); a device that could temporarily blind the ec­
centrically fixating area and stimulate the central foveal region. 
Two years later, in Cologne, Conrad Cüppers gave a lecture on the pleoptic and orthoptic 
treatment of amblyopia and strabismus as performed at the Augenklinik Gießen (Cüppers 
1956). He was a strong advocate of occlusion therapy except, like Bangerter, when an ec­
centric fixation was present in the amblyopic eye. Cüppers’ great virtue was the development 
of the “Visuskop”, an instrument to visualize even the smallest angles of strabismus and de­
termine the fixation. He established that one­third of the children treated for amblyopia did 
not fixate with their fovea. This assumption led to the development of a different method: 
the creation of ‘after­images’ (‘Nachbilder’) supported by occlusion of the amblyopic eye. The 
after­images were created by a modified ophthalmoscope (called “Euthyskop”) operated by 
an experienced practitioner. A circular bright light blinded the retinal periphery, while a circu­
lar spot protected the fovea. A negative after­image was thus created. Now the foveola had a 
momentary physiological superiority over the retinal periphery. The patient had to fixate on 
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the centre of the after­image, thereby regaining central fixation (Cüppers 1961). Cüppers’ idea 
was that this technique would change the direction of the principal visual axis from eccentric 
to foveal. He emphasised, however, that occlusion therapy was to be preferred in younger 
children (he referred to the work of Sattler) and pleoptic therapy in older ones and in those 
with eccentric fixation. Orthoptic and pleoptic principles were to be considered as supple­
mentary treatments and not as opposites (Cüppers 1967). 
For the next decade, pleoptic treatment was a widely used and accepted way of treating am­
blyopia with an eccentric fixation. As pleoptic treatment was time consuming and generally 
limited to older and more cooperative children, so­called “Sehschulen” (Vision Schools) were 
set up where children received treatment for several weeks or even months on end. After the 
Second World War, a large number of amblyopic children were admitted. 
At that time, various articles reported on the success of this treatment (Bangerter 1960; Cüp­
pers 1967; Jablonski and Tomlinson 1979), while others were more skeptical (Koselka, et al. 
1991; Schmidt and Stapp 1977) regarding the long­term effectiveness and its economic ad­
vantage over conventional occlusion therapy. Soon after, studies reported that pleoptics failed 
to produce a significant improvement in the linear visual acuity or a permanent cure in the 
majority of amblyopic patients (Fletcher, et al. 1969; von Noorden and Lipsius 1964; Parks and 
Friendly 1966; Richter 1960; Véronneau­Troutman, et al. 1974). It was even suggested that ple­
optics might be dangerous as it could cause permanent monocular diplopia (Campos 1995). 
However, it should be acknowledged that pleoptics gave rise to further and greater insight 
into the pathophysiology of amblyopia with special emphasis on the amblyopic eye with ec­
centric fixation. 
The idea that occlusion of the better eye would only reinforce the eccentric fixation (Bangert­
er 1953) has not been confirmed. Mackensen et al. demonstrated, via fundus photography, 
that occlusion of the better eye did not induce reinforcement of the eccentric fixation. On the 
contrary, they found fixation often became foveal with occlusion of the good eye (Mackensen, 
et al. 1965).
Penalisation
To “penalise” literally means “to punish” and the term was most probably first used by J.B. Weiss 
in 1968 (in previous studies it was described as “atropinisation”) (Weiss and Bourrie 1968). The 
use of pharmacological penalisation to treat amblyopia had already been suggested by Worth 
in 1903 for children who did not or were too young to cooperate with conventional occlusion 
therapy (Worth 1903). Bangerter also used it in the first and second year of life (Bangerter 
1960). Generally, it means selectively fogging the image of the non­amblyopic eye by glasses 
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(optical penalisation) and/or cycloplegia by the daily instillation of drops into the fornix (phar­
macological penalisation). This should prevent accommodation and therefore obstruct near 
vision. In this way, one eye is used for distance vision and the other eye (the amblyopic eye) for 
near vision. Several variations of this technique have been developed (Abraham 1954; John­
son and Antuna 1965; Knapp and Capobianco 1956; Pfandl 1958; Pope 1971; 1972; Pouliquen 
1964). In 1969, Quéré, Pouliquen, Lavat, Berrondo and Weiss described several techniques of 
penalisation (Quéré 1969). 
Others who studied the effect of penalisation therapy on amblyopia reported positive results 
(Cibis 1974; Foley­Nolan, et al. 1997; Kaye, et al. 2002; Lowe 1965; McKenney and Byers 1975; 
von Noorden and Milani 1979; North and Kelly 1991; Quéré 1972; Repka and Ray 1993; Si­
mons, et al. 1997; Swann and Hunter 1974; Timmerman 1977; Wallman, et al. 1978), either 
in combination with occlusion therapy, as maintenance therapy or sometimes as the main 
therapy. It was more readily accepted by parents and patients of all age groups and allowed 
a reliable assessment of compliance. Quéré observed a decrease in the angle of strabismus 
(Quéré 1969) and claimed that penalisation prevented the development of occlusion amblyo­
pia (Quéré 1972). Due to the continued use of both eyes, occlusion amblyopia should be less 
frequent as compared to occlusion using a patch. However, occlusion amblyopia did occur 
and careful monitoring of the patient’s sound and amblyopic eye was necessary (von Noorden 
and Milani 1979; North and Kelly 1991; Repka and Ray 1993; Wallman, et al. 1978; Worth 1903). 
Aggravation of a (latent) nystagmus, another frequent obstacle to occlusion therapy, could 
also be prevented by penalisation, as both eyes were open at all times. Finally, the penalised 
eye still received images with low spatial frequency and therefore binocular vision was less 
disturbed (Foley­Nolan, et al. 1997; Lowe 1965; North and Kelly 1991; Repka and Ray 1993). 
Other authors, however, did not find substantiated evidence to support different outcomes 
for monocular or binocular vision (Simons, et al. 1997) and were hesitant to prescribe penali­
sation in very young children as the negative effect on near vision lasted too long. 
A potential disadvantage of penalisation therapy is the effect that image blur or cycloplegia 
may have on the development of the refractive error. Both experimental work in animals and 
case reports in humans have shown a myopic shift in the blurred eye leading to anisometro­
pia (Robb 1977; Wallman, et al. 1978). A second disadvantage would be the daily use of drugs 
used over a long period of time. Side effects are mainly related to systemic intoxication: a case 
of coma has been reported (Campos, et al. 1991), hypersensitivity to atropine (Lowe 1965; 
Pope 1971), iris cysts (Abraham 1954; Knapp and Capobianco 1956) and dilatation of the pupil 
causing photophobia (Campos 1997). Moreover, the acuity of the penalised eye must be less 
than that of the amblyopic eye, otherwise the patient will continue to use the sound eye de­
spite the pharmacologically or optically induced image blur. When using optical penalisation 
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it would also be possible for the child to peek around the glasses or remove them altogether. 
It seems reasonable, therefore, to limit penalisation to mild or moderate amblyopia.
other non-conventional treatments
Brinker and Katz: Red-filter treatment
In 1963, following the controversy in treating amblyopia associated with eccentric fixation, 
Brinker and Katz reported on the use of a red filter treatment (Brinker and Katz 1963). Their 
idea was to totally occlude the non­amblyopic eye and place a red filter on the spectacle 
frame in front of the amblyopic eye. The red filter excluded wavelengths shorter than 640 mm 
(the filter most often used was Kodak Wratten gelatin red filter No. 92). The rationale for this 
method lay in the theory that visual cones are sensitive to stimulation by light from the red 
end of the spectrum and visual rods are not. The rod­populated area of the retina, which is 
used for eccentric fixation, is insensitive to this red light. With the non­amblyopic eye occlud­
ed and the filter in front of the amblyopic eye, the patient was encouraged to do near work. 
After fixation became central, the red filter was removed and conventional treatment for am­
blyopia with central fixation was instituted. The results from various studies reported success 
rates ranging from 10% to 87.5% (Cowle, et al. 1967; Malik, et al. 1966; Ratiu and Reiter 1966; 
Thorleifsson 1966). This range was largely due to differences in duration of treatment and 
response was greater when initial amblyopia was less severe. Cowle et al. suggested that in 
order to achieve good results, the red­filter treatment should be used for more than 7 months 
followed by 5 months of occlusion of the non­amblyopic eye, for a total treatment time of 12 
months (Cowle, et al. 1967). 
In 1998, a blue filter was suggested instead of the red filter (Metzler, et al. 1998).
Pigassou and Garipuy: Prisms
As mentioned before, the principle of pleoptic treatment stimulated further ophthalmoscopic 
studies of amblyopia and precipitated the concept of eccentric fixation. As one result of these 
further studies, the use of prisms was introduced for the treatment of amblyopia. In 1966, 
Pigassou and Garipuy treated amblyopia with eccentric fixation by means of occlusion of the 
better eye and an inverted prism in front of the amblyopic eye (Pigassou and Garipuy 1966a; 
1966b; 1967). Other studies showed results that favoured the inverse prism method over con­
ventional occlusion therapy and pleoptics (Nawratzki and Oliver 1971).
Other therapies
In 1964, Fernando Losada wrote about functional amblyopia and its treatment with occlusion 
therapy and surgically suturing the eyelids (Losada 1964). He especially advocated the neces­
sity to suture the eyelid of the better eye in disobedient or uncooperative children in order to 
save the vision in their amblyopic eye. He was not the only person favouring this idea. As early 
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as 1932, F. Weckert had recommended the suturing of the eyelids in non­compliant children 
(Weckert 1932). 
Less harmful than suturing the eyelids seemed the advice from Fralick in 1943. In very young 
children, he applied elbow splints made from tongue blades and adhesives, or plaster cast 
arm restraints during occlusion therapy (Fralick 1943; Hiles and Galket 1974). Other methods 
tried for the treatment of amblyopia have included eyeball massage (Darier 1904) or a diet of 
white wine and veal (Devaux 1912). In 1914, the removal of the adenoids was thought to be 
of importance (Adams 1914) and in 1958 the beneficial influence of hypnosis was asserted 
(Browning, et al. 1958).
Campbell: CAM Treatment (1978)
In an attempt to improve the acceptance of occlusion therapy by the parents and the child, 
Campbell and co­workers developed an apparatus in which high­contrast square­wave grat­
ings were rotated slowly in front of the amblyopic eye while the child was performing a task 
requiring visual concentration (Banks, et al. 1978; Campbell, et al. 1978). This process took only 
7 minutes during which the non­amblyopic eye was occluded. In between the weekly ses­
sions, the non­amblyopic eye was not to be occluded. The rationale for using rotating gratings 
with different spatial frequencies was that it provided stimulation of the whole range of mo­
tion of the amblyopic visual system. However, there was a considerable danger of intractable 
diplopia in case the treatment was applied inappropriately and the use of the instrument 
ought therefore to be confined to hospitals and clinics. Campbell et al. reported success with 
this kind of minimal occlusion therapy in 73% of their patients who achieved acuities of >6/12 
after three 7­minute sessions. Willshaw et all. reported the same success rate (Willshaw, et all. 
1980). In spite of these encouraging results, other authors have not been able to confirm the 
value of the apparatus in subsequent studies (Ciuffreda, et al. 1980; Fricker, et al. 1980; Keith, 
et al. 1980; Mehdorn, et al. 1981; Schor, et al. 1981; Tytla and Labow­Daily 1981). 
commEnT
The history of treatment for amblyopia is a rather intriguing one. Throughout the ages, vari­
ous methods of treatment have been published, with occlusion of the better eye being the 
very first to be described. This method, however, frequently receded into the background 
when other types of treatment for amblyopia were tried, e.g. pleoptophor, euthyskop, CAM­
treatment, prisms and filters. These new methods became popular for a while, but were aban­
doned again, as they were time consuming and less effective. The fluctuations in popularity of 
occlusion could be explained by a limited acceptance by children and parents, resulting in low 
compliance. Ever since the first prescriptions were written, low compliance was already dis­
cerned as a problem affecting the outcome of treatment. It was acknowledged that occlusion 
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was a burden on the family life and that parents needed to be stimulated in order to achieve 
good results. Various other efforts to increase compliance included gluing the occluder to the 
skin around the eye or even suturing the eyelids in non­compliant children. Instead of imple­
menting these radical methods it would be more effective to focus our attention on ways to 
increase the acceptance of occlusion therapy by children and parents. For the last decade 
it has been possible to measure compliance with occlusion therapy electronically, yielding 
exact information on the actual duration of occlusion. This enables us to study the factors 
that influence compliance with occlusion therapy, which should be taken into account when 
developing new methods for the improvement of compliance.
SEArch STrATEGy
The selection of the literature for this review was based on the Medline database that was 
searched from its starting date in 1966, using key words such as amblyopia­treatment­his­
tory­penalisation­atropine­prisms­pleoptics­red filter­gratings­CAM­occlusion. Parts of the 
very early history were obtained from Wolfgang Münchow (“Geschichte der Augenheilkunde”, 
1984) and the Picarta database. Articles in any language were considered for inclusion. 
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objective survey of the prescription of 
occlusion therapy for amblyopia
40
ABSTrAcT
Purpose: To identify the variation within and consistency amongst orthoptists when prescrib­
ing occlusion therapy for amblyopia in an objective survey. 
methods: A questionnaire was designed with five case examples of amblyopic children and 
distributed at annual meetings of orthoptists in the Netherlands and Germany. It was filled 
out simultaneously within 15 min in complete silence to avoid any exchange of opinions be­
tween orthoptists that would reduce variability. For each case the orthoptists were asked to 
give their prescription of hours or days of occlusion. 
results: The questionnaire was completed by 177 Dutch orthoptists and 227 German orthop­
tists. Their prescriptions of occlusion therapy were classified into five main regimens: Part­
Time; Part­Time Not Every Day; Full­Time; Also Occluding the Amblyopic eye; ALTernating and 
No Occlusion Therapy. The variation was large: the standard deviation was half the average 
prescribed hours of occlusion for each regimen in each of the five cases. All orthoptists were 
assigned a rank number for each of the five cases depending on whether their prescription 
was above or below average. These five rank numbers were not consistently above or consis­
tently below average value per case. 
conclusions: The number of prescribed hours of occlusion varied widely per regimen per case. 
Orthoptists were not consistently strict or lenient in their prescription of occlusion  therapy. 
41
ch
ap
te
r 3
Objective survey of the prescription of occlusion therapy for amblyopia
InTroducTIon
Treatment for amblyopia with occlusion of the better eye dates back to at least the early 
eighteenth century. Charles de Saint­Yves first described occlusion of the dominant eye to 
promote use of the squinting eye in 1722 (De Saint­Yves 1722). After that, Allen in 1730 and 
Comte de Buffon in 1743 recommended occlusion of the good eye to straighten the squinting 
one (Allen 1730; De Buffon 1743). Javal in France and Worth (1901) in England advocated the 
use of occlusion for amblyopia (Javal 1896; Worth 1901).
Despite the fact that occlusion therapy dates back to the eighteenth century, there are still 
few guidelines for prescribing occlusion hours. This is in contrast to the prescription of an­
tibiotics or other drug medication, which is done according to protocol and to scientifically 
derived standard measures. Age, visual acuity and to a lesser extent diagnosis seem to be the 
most important determinants when prescribing a number of hours of occlusion therapy. Mein 
and Trimble stated that the lazy eye should be occluded full­time in the case of strabismic 
amblyopia and part­time in case of anisometropic amblyopia followed by full­time occlusion 
if the acuity does not improve sufficiently (Mein, et al. 1991). According to Haase the good 
eye should be occluded for a number of days per week corresponding to age of the child in 
years, followed by one day of occlusion of the amblyopic eye (Haase 1995). Von Noorden and 
Campos stated that the good eye should be occluded full­time when there is a difference in 
visual acuity between the two eyes (Von Noorden, et al. 2002). 
As there is no consensus amongst orthoptists, different orthoptists may prescribe very differ­
ent hours of occlusion for the same patient. This can lead to confusion amongst parents seek­
ing second opinions and result in non­compliance with the therapy (Tan, et al. 2003). 
A questionnaire was developed with five case examples of children diagnosed with amblyo­
pia in order to try and identify these variations in prescription of occlusion hours amongst 
orthoptists, their consistency and their main determinants. 
mEThodS
The questionnaire consisted of four example amblyopic cases and one potentially amblyopic 
case (Table 1). It was designed to imitate the clinical decision­making process in an orthop­
tist’s everyday practice. 
Cases 1, 2, and 5 were common amblyopic cases with a clear difference in acuity between the 
two eyes. Case 1 was a 3­year­old with an anisometropia and visual acuity of 5/10 and 5/5 as 
measured with a Children’s Picture Chart. Case 2 was a 2­year­old with esotropia of the right 
eye first noticed 6 months earlier. Case 3 was a 5­year­old diagnosed with slight esotropia of 
the left eye with eccentric fixation of this eye and mild anisometropia. Case 4 was a 6­month­
old baby with infantile esotropia of 30° alternating freely. Case 5 was a 3­year­old with hyper­
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metropia combined with esotropia of the left eye, an eccentric fixation and a clear difference 
in the visual acuity between the two eyes. Case 2, 3, 4 and 5 were children with a strabismic 
amblyopia, case 1 was a child with an anisometropic amblyopia. 
In March 2001, at the national Spring Meeting of the Union for Dutch Orthoptists in Utrecht, 
the questionnaire was put to Dutch orthoptists representing almost all practicing orthoptists 
in the Netherlands. In October 2001, at the annual meeting of the Union for German Orthop­
tists in Warnemünde, the questionnaire was put to the German orthoptists present. They were 
asked to determine their prescription of hours of occlusion (hours per day or days per week) 
for each of the five cases within 15 min. Additional instructions for completing the question­
naire included the statement that the prescription of glasses was not to be considered. They 
were not allowed to discuss or copy the cases and were under strict supervision from the four 
researchers present to prevent any exchange of views that might lessen variability. As a result 
the questionnaires were completed in silence. After 15 min the completed questionnaires 
were collected, also under strict supervision.
Table 1. The questionnaire containing the five sample amblyopic cases. The following instructions were 
given: Please enter below the number of hours of occlusion therapy you would prescribe in each case. 
Do not consider the prescription of glasses. Please do not discuss the cases with your neighbour, lest we 
measure less variability.
case 1 case 2 case 3 case 4 case 5
Age 3 years old 2 years old 5 years old 6 months old 3 years old
diagnosis Anisometropia Esotropia first 
noticed six months 
earlier
Microstrabismus, 
untreated amblyopia
Alternating 
esotropia
Accommodative 
esotropia
corneal reflection Straight 20° Right esotropia Slight left esotropia 30° Esotropia 15° Left esotropia 
cover test Straight Large right 
esotropia, no DVD 
/ NL
Slight left esotropia Marked esotropia, 
alternating, NL, 
DVD unclear
Large (30 cm) / 
moderate (5 m) 
left esotropia
Binocular vision Titmus Fly +, animals 
ABC +
­ Titmus Fly ­ ­ ­
Fixation rE/LE Central / Central Nasal / Central Central / Eccentric nasal Eccentric nasal
Visual acuity rE/LE 5/10 & 5/5 Pictures Cannot maintain 
fixation, saccadic 
pursuit, some 
protest when occl 
left eye
1.0 / 0.2 E­Chart Alternates freely 5/6 & 5/15 Pictures
retinoscopy rE/LE +3.5 / +2 +2 / +2 S+1.0=C­0.5axis180 / 
S+1.5=C­1.75axis50
+1 / +1 +4 / +4
hours per day
days per week
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data analysis
A database was created which consisted of four primary items; (1) the number of hours pre­
scribed per day, (2) the number of days of occlusion per week, (3) the period of occlusion and 
(4) the total number of occlusion hours prescribed per week. Both eyes were itemized this 
way. The prescriptions given by each orthoptist were recorded on a case­by­case basis in the 
database. All the variations in the prescriptions of occlusion therapy could be stored into one 
database. From there it was possible to translate them into different regimens of prescribing 
occlusion therapy. For the statistical analysis of the database we used the non­parametric­
tests (Mann­Whitney). 
To determine whether orthoptists prescribed their hours of occlusion consistently above av­
erage or consistently below average, all orthoptists were ranked according to their number 
of prescribed hours of occlusion per case. From these rank numbers percentiles were derived 
and the standard deviation (SD) of the percentiles was calculated. Due to statistical consider­
ations this SD of percentiles could not exceed 28.87%. If occlusion hours were completely ran­
domly prescribed with a uniform distribution of the percentiles between 0% and 100%, the 
SD of the percentiles would be √1/12(100%−0%)2 =28.87%. The SD would be 0% if orthoptists 
prescribed consistently above or consistently below average, i.e. if the strictest orthoptist pre­
scribed the most hours of occlusion for each of the five cases and the most lenient orthoptist 
prescribed the least hours of occlusion for each of the five cases.
rESuLTS
questionnaire
177 Dutch and 227 German orthoptists filled in the questionnaire. Seven (4%) Dutch orthop­
tists and four (2%) German orthoptists failed to complete the questionnaire properly, but in 
these cases only one of the five cases on the questionnaire had been left unanswered; there­
fore they were included in our analysis. The orthoptists wrote no negative comments on the 
forms regarding the sample cases. 
regimens
Variation in prescription of occlusion hours was large. In the effort to ascertain variation, con­
sistency and determinants in the orthoptists’ prescribing of occlusion, we identified certain 
types of regimen that were most frequently prescribed. Within the data analysis process five 
typical prescriptions were identified; Part­Time Occlusion (PTO), Part­Time Occlusion, Not 
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Every Day of the week (PTONED), Full­Time Occlusion (FTO), Also Occluding Amblyopic eye 
(AOA), ALTernating occlusion (ALT), No Occlusion Therapy (NOT), (Table 2, Figure 1).
Table 2. Definitions of the five prescribed occlusion regimens.
PTO Part­Time Occlusion, i.e. the non­amblyopic eye is occluded the same number of hours every day of the 
week
PTONED Part­Time Occlusion Not Every Day of the week, i.e. the non­amblyopic eye is occluded for the same 
number of hours, followed by days of both eyes open 
FTO Full­Time Occlusion, i.e. the non­amblyopic eye is occluded for all waking hours every day of the week 
or the non­amblyopic occluded for all waking hours followed by days when both eyes are open 
AOA Also Occluding the Amblyopic eye, i.e. the amblyopic eye is also occluded for any period of time (either 
part­time or full­time) in addition to the occlusion of the non­amblyopic eye for any period of time 
ALT ALTernating occlusion therapy, i.e. both eyes are occluded alternately for the same number of hours 
every day, part­time as well as full­time 
NOT No Occlusion Therapy of either eye
Other Pair of spectacles, foil, exercise, more complex regimens
 
Chapter 3 
Figure 1 
 
 
Figure 1. Median and interquartile range of the prescribed hours of occlusion per day of the non­
amblyopic eye per regimen per case. The abscissa represents the five cases and the chosen regimen. The 
total number of orthoptists prescribing a regimen is given below each whisker. For colour figure please see 
‘Colour figures’ on page 195.
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There was an occasional prescription of a pair of spectacles, foil, inverse occlusion only or of 
even more complex regimens. Regimens prescribed by fewer than 12 orthoptists were ex­
cluded from analysis.
Because of the different ages of the sample cases, and in order to permit comparison of the 
actual hours of occlusion that had been prescribed, the time spent awake by a 6­month­old 
baby were estimated to be 6 h per day, a 2­year­old child, 10 h per day and a 3­year­old and 
5­year­old child, 12 h per day. In this way the prescriptions of days per week were converted 
to hours per week. 
dutch and German orthoptists’ prescribing behaviour
It became apparent that the prescribing behaviour of Dutch and German orthoptists was 
similar in many ways (Table 3). For both countries the preferred occlusion regime was PTO. 
Also, the variation in number of prescribed hours for each of the cases was as high among 
German orthoptists as it was among their Dutch counterparts. Differences were found in that 
FTO and AOA were favoured more often by the German orthoptists. However, the similarities 
outweighed the differences; therefore the data derived from the Dutch and German orthop­
tists were analysed together.The main result of this study was that for each of the five pre­
scribed regimens the SD was half of the averaged prescribed hours of occlusion. This applied 
to each of the five sample amblyopic children. In addition, the following three observations 
were made:
(1) Orthoptists prescribed significantly more hours of occlusion when prescribing FTO than 
when prescribing PTO or PTONED (P < 0.005). 
(2) In case 1, 2, 3, and 5, orthoptists who prescribed PTO prescribed significantly more hours 
per week than orthoptists who prescribed PTONED. This difference was significant in cases 
1, 2, and 5 (P < 0.002). 
Table 3. The median of the prescribed hours of occlusion for the non­amblyopic eye per day distributed 
over the five regimens per case. In brackets are the percentages of Dutch and German orthoptists 
prescribing that regimen.
Case 1:
Anisometropia, 3yrs
Case 2: 
Esotropia, 2yrs
Case 3: 
Microstrabismus,5yrs
Case 4: 
Alternating, 6mo
Case 5: 
Accomm. eso, 3yrs
Dutch German Dutch German Dutch German Dutch German Dutch German
PTO 3 (72%) 3 (61%) 4 (81%) 4 (45%) 5 (85%) 6 (33%) 1 (7%) 2 (5%) 4 (79%) 4 (41%) 
PTONED 2.1 (26%) 2.6 (14%) 2.9 (19%) 2.7 (9%) 5.7 (11%) 5.7 (6%) 0.6 (1%) 0.6 (2%) 2.9 (18%) 2.9 (8%) 
FTO 9 (13%) 6.6 (28%) 12 (1%) 10 (32%) 5.1 (1%) 9 (30%) 
AOA 8.6 (2%) 10 (10%) 12 (8%) 6.7 (1%) 3.4 (1%) 12 (8%) 
ALT 4 (2%) 3.1 (1%) 1 (31%) 1 (26%) 3.4 (1%) 1.1 (2%)
NOT 0 (4%) 0 (1%) 0 (61%) 0 (65%) 0 (1%) 0 (2%)
Other (2%) (4%) (8%) (2%) (20%) (9%)
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(3) In case 2 (n = 23), 3 (n = 18) and 5 (n = 19) some German orthoptists also prescribed oc­
clusion of the amblyopic eye for a period of time. In these cases the non­amblyopic eye 
was occluded for significantly more hours than it was by orthoptists who prescribed PTO, 
PTONED or FTO (P < 0.005). 
consistency in prescription of occlusion hours
To calculate whether orthoptists prescribed their hours of occlusion consistently above aver­
age or consistently below average, each orthoptist was assigned a rank number according 
to number of prescribed hours per case. From these rank numbers the five percentiles, their 
average and their SD were derived. The average SD of the percentiles for all orthoptists was 
21%. It would have been 28.87% if occlusion hours had been prescribed completely at ran­
dom and 0% if they had been prescribed consistently above or below average (see above, 
Data analysis). 
dIScuSSIon
By distributing our questionnaire at an annual meeting for orthoptists and preventing an ex­
change of opinions we were able to gain an objective insight in the prescriptions of occlusion 
therapy for amblyopia. 
Whilst analysing the data we were taken aback not only by the amount of variation in the 
number of prescribed hours of occlusion, but also by the diversity in the ways of prescrib­
ing occlusion therapy. The number of occlusion hours was neither normally nor log­normally 
distributed in any of the five example cases. However, during the analysis on a case­by­case 
basis it became apparent that certain ways of prescribing occlusion therapy, i.e. certain regi­
mens, were more prevalent (Table 2). Within these regimens the SD was half of the average 
prescribed hours of occlusion. This applied to each of the five sample amblyopic children.
The five example amblyopic cases were chosen in order to make the difference in the pre­
scribed hours of occlusion by orthoptists more easily transparent. Cases 1, 2 and 5 were com­
mon amblyopic cases, while cases 3 and 4 were more controversial cases. The largest variation 
in the prescription was found in case 3, representing a 5­year­old child with microstrabismus 
and untreated amblyopia. To improve visual acuity long periods of occlusion could have been 
thought necessary, although the outcome of the treatment was uncertain. That may have 
been the reason why some orthoptists decided not to occlude at all, whereas other orthop­
tists prescribed long periods of occlusion. 
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Case 4, a baby with alternating fixation, may not have required any occlusion therapy as there 
was no real evidence of amblyopia. However, some orthoptists prescribed ALT with a median 
of 1 h every day of the week. This decision to commence with alternating occlusion therapy 
may well have been prompted by the desire to prevent the development of an amblyopic eye. 
It may also have been influenced by the uncertainty of the diagnosis. 
Orthoptists who prescribed FTO prescribed significantly more hours of occlusion in the same 
case than orthoptists who prescribed PTO and PTONED. This tendency can be partly explained 
by orthoptists opting for the FTO regimen when they wanted to prescribe longer periods of 
occlusion. Orthoptists wanting rapid success would select FTO rather than prescribing PTO 
or PTONED and waiting patiently. The same difference is seen between PTO and PTONED: 
orthoptists who chose PTO prescribed significantly more hours of occlusion in the same case 
than those who prescribed PTONED. It can also be partly explained by the assumption that or­
thoptists wanting to prescribe shorter periods of occlusion would opt for reducing the num­
ber of days per week rather than reducing the number of hours per day. 
Orthoptists who prescribed an AOA regimen prescribed significantly more hours of occlusion 
than orthoptists who prescribed only occlusion of the non­amblyopic eye, possibly to com­
pensate for the hours the amblyopic eye was patched. 
In our questionnaire orthoptists were asked to make their prescription on the basis of the 
main determinants: age, visual acuity and diagnosis. Not included were further determinants 
that may have influenced the results, such as personal experience, the perceived domestic 
situation, the possible interference with homework or the waiting time for a follow­up ap­
pointment. The personal attitude of the orthoptists towards the success of the treatment was 
also not taken into account when designing the questionnaire. 
Based on traditional and educational differences we expected a difference in occlusion pre­
scriptions between Dutch and German orthoptists. Indeed, German orthoptists did tend to 
prescribe slightly longer hours of occlusion and to prescribe to FTO more often than Dutch 
orthoptists. However, the amount of variation in prescribed hours of occlusion was equal in 
the Dutch and German orthoptist (Table 3). 
Neither consistently strict nor consistently lenient orthoptists of either nationality could be 
identified. 
This study clearly emphasises the need for prospective studies investigating the relationship 
between prescribed occlusion hours and actual occlusion time carried out by the parents 
(Loudon, et al. 2003). Secondly, the relationship between the patched hours and the child’s 
acuity increase should be established (Stewart, et al. 2002). The findings of such investigations 
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might lead to the development of validated guidelines or protocols for prescribing occlusion 
therapy. 
If consensus and uniformity could be achieved among orthoptists and ophthalmologists as to 
the prescription of occlusion therapy, this would go a long way towards convincing the parent 
that a specific regimen of occlusion is the best therapy for the amblyopic eye, thus promoting 
compliance.
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Chapter 4
Visusevaluierung in einer historischen 
kohorte von 137 okkludierten 
Patienten, 30-35 jahre nach Ende der 
okklusionsbehandlung
Evaluation of visual acuity in a historic 
cohort of 137 patients treated for amblyopia 
by occlusion 30-35 years ago 
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zuSAmmEnFASSunG
hintergrund: Der Visusverlauf des amblyopen Auges nach Ende der Okklusionsbehandlung 
wird unterschiedlich diskutiert. Wir untersuchten eine grosse historische Kohorte, 30­35 Jahre 
nach der Okklusionsbehandlung. 
material und methode: Von 1250 Patienten, die in der Orthoptischen Abteilung des Water­
land Krankenhauses in Purmerend zwischen 1968 und 1975 behandelt wurden, wurden 471 
Kinder okkludiert, 5%, nach Vergleich mit den örtlichen Geburtsziffern. Wir konnten davon 
203 Patienten erneut ausfindig machen, 137 wurden 2003 orthoptisch nachuntersucht. Wir 
korrelierten den aktuellen Visus mit der Ursache der Amblyopie (Anisometropie, Strabismus 
oder Kombination), dem Alter bei Beginn und Ende der Okklusion, dem Visus bei Beginn und 
Ende der Okklusionsbehandlung, der Fixation, dem Binokularsehen, der Refraktion und dem 
Refraktionsverlauf. 
Ergebnisse: Die Patienten waren bei Beginn der Okklusionsbehandlung 5,4 ± 1,9 Jahre, bei 
Ende 7,4 ± 1,7 Jahre und bei der Nachuntersuchung 37 ± 2,7 Jahre alt. Korreliert mit dem 
aktuellen Visus waren ein geringer Visus des amblyopen Auges bei Beginn (P < 0,0001) und 
Ende der Okklusionsbehandlung (P < 0,0001), eine exzentrische Fixation (P < 0,0001) und die 
Ursache der Amblyopie (P = 0,005). Am Ende der Okklusionsbehandlung betrug der Visus der 
amblyopen Augen bei Patienten mit Strabismus­Amblyopie (n = 98) 0,29 ± 0,3 logMAR und 
bei der Nachuntersuchung 0,27 ± 0,3 logMAR. Bei Patienten mit Anisometropie­Amblyopie 
(>1 D, n = 16) hatte sich der Visus von 0,17 ± 0,23 logMAR auf 0,21 ± 0,23 logMAR und bei Pa­
tienten mit Anisometropie und Strabismus als Ursache der Amblyopie (n = 23) von 0,52 ± 0,54 
logMAR auf 0,65 ± 0,54 logMAR verschlechtert. Insgesamt hatten 54 (39%) Patienten seit der 
Behandlung eine Visusabnahme, davon 18 um mindestens 50% in Bezug zum Visus nach Ende 
der Behandlung. 15 dieser 18 Patienten hatten eine Anisohyperopie, die zugenommen hatte. 
Schlussfolgerung: Assoziiert mit einer langfristigen Visusabnahme nach Ende der Okklusi­
onsbehandlung waren eine kombinierte Ursache (Anisometropie und Strabismus) der Ambly­
opie und eine Zunahme der Anisohyperopie.
kurzzusammenfassung
137 Patienten aus einer historischen Kohorte, vor 30­35 Jahren wegen Amblyopie okkludiert, 
wurden 2003 erneut untersucht. Korreliert mit dem aktuellen Visus waren ein geringer Visus 
des amblyopen Auges bei Beginn und Ende der Okklusionsbehandlung, eine exzentrische 
Fixation und die Ursache der Amblyopie. Assoziiert mit einer Visusabnahme nach Ende der 
51
ch
ap
te
r 4
Visusevaluierung in einer historischen Kohorte
Okklusionsbehandlung waren eine kombinierte Ursache (Anisometropie und Strabismus) der 
Amblyopie und eine Zunahme der Anisohyperopie. 
ABSTrAcT
Purpose: Opinions differ on the course of the visual acuity in the amblyopic eye after cessa­
tion of occlusion therapy. This study evaluated visual acuity in a historical cohort treated for 
amblyopia with occlusion therapy 30­35 years ago. 
methods: Between 1968 and 1975, 1250 patients had been treated by the orthoptist in the 
Waterland Hospital in Purmerend, the Netherlands. Of these, 471 received occlusion treat­
ment for amblyopia, corresponding to 5% of the local birth rate. We were able to contact 203 
of these, 137 were orthoptically re­examined in 2003. We correlated the current visual acuity 
with the cause of amblyopia, the age at start and end of treatment, the visual acuity at start 
and end of treatment, fixation, binocular vision and refractive errors. 
results: Mean age at the start of treatment was 5.4 ± 1.9 years old, 7.4 ± 1.7 years old at 
the end and 37 ± 2.7 years old at follow up. Current visual acuity in the amblyopic eye was 
correlated with a low visual acuity at the start (P < 0.0001) and end of occlusion therapy (P < 
0.0001), an eccentric fixation (P < 0.0001), and cause of amblyopia (P = 0.005). At the end of the 
treatment, patients with a strabismic amblyopia (n = 98) had a visual acuity in the amblyopic 
eye of 0.29 ± 0.3 logMAR, and in 2003 0.27 ± 0.3 logMAR. In patients with an anisometropic 
amblyopia (>1 D, n = 16) visual acuity had decreased from 0.17 ± 0.23 logMAR to 0.21 ± 0.23 
logMAR. In patients with both strabismic and anisometropic amblyopia (n = 23), visual acuity 
had decreased from 0.52 ± 0.54 logMAR to 0.65 ± 0.54 logMAR. Overall, acuity had decreased 
in 54 patients (39%) after cessation of treatment. Of these, 18 patients had an acuity decrea­
se to less than 50% of their initial acuity. In 15 of these 18 patients anisohypermetropia had 
increased. 
conclusions: A decrease in visual acuity after cessation of occlusion therapy occurred in pati­
ents with a combined cause of amblyopia and an increase in anisohypermetropia. 
For an English translation of Chapter 4, please see Appendix.
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EInLEITunG
In der Literatur wird die Prävalenz von Amblyopie mit 3,25% angegeben (Attebo, et al. 1998). 
Die Behandlung der Amblyopie mit Okklusion stellt seit Jahrzehnten eine etablierte Methode 
dar. Der Nutzen der Okklusionsbehandlung liegt vor allem in der Vermeidung von Kosten, die 
entstehen, wenn Patienten mit unzureichend behandelter Amblyopie im Laufe des Lebens ihr 
gutes Auge verlieren (Neubauer and Neubauer 2005). Der Zeitraum, den ein solcher Patient 
beidseitig sehbehindert (Visus beidseits >0,3 logMAR) verbringt, verlängert sich etwa von 8 
auf 15 ½ Monate (van Leeuwen, et al. 2002). 
Mit der Einführung des Screenings konnte Amblyopie früher erfaßt und damit erfolgreicher 
behandelt werden, so dass die Zahl der Patienten ohne Lesefähigkeit auf dem amblyopen 
Auge reduziert werden konnte. Seit Mütterberatungsstellen in den Niederlanden Kinder auf 
Strabismus und Amblyopie testen und den Visus im Alter von 3 sowie 3 ¾ Jahren bestimmen, 
ist eine zu spät entdeckte Amblyopie selten. Trotzdem misslingt bei etwa einem Drittel aller 
amblyoper Patienten (Jensen and Goldschmidt 1986) die Okklusionsbehandlung (Visus des 
amblyopen Auges > 0,3 logMAR). In der Vergangenheit wurde ein Misslingen der Okklusi­
onsbehandlung durch zu späte Diagnosestellung (Bowman 1998) verursacht, heutzutage ist 
primär die Therapieuntreue (Dorey, et al. 2001; Loudon, et al. 2003) bei der Okklusionsbe­
handlung dafür verantwortlich. 
Der Langzeiterfolg einer Okklusionsbehandlung wird in der Literatur unterschiedlich ange­
geben. Ein Vergleich der Studien ist schwierig aufgrund der unterschiedlichen Patientgrup­
pen: Rekrutierung von verschiedenen Kliniken (Woodruff, et al. 1994) oder im Rahmen eines 
Vorschulscreenings (Bowman, et al. 1998); aufgrund der underschiedlichen Einslusskriterien: 
z.B. nur Patienten, die alle Kontrolltermine einhielten (Levartovsky, et al. 1995; Malik, et al. 
1975); und aufgrund verschiedener Behandlungsmethoden: z.B. nur mit Vollokklusion (Scott 
and Dickey 1988) oder auch mit Pleoptik, Brillenokklusion oder inverser Okklusion behan­
delt (Schröpfer and Meinert 1975; Sparrow and Flynn 1977). Zudem variiert der Zeitpunkt 
der Nachuntersuchung nach Ende der Okklusionsbehandlung, Monate (Malik, et al. 1975) bis 
maximal zwei Jahrzehnte (Leiba, et al. 2001).
Einige Autoren berichten, dass der Visus nach Ende der Okklusionsbehandlung überwiegend 
unverändert blieb (Ohlsson, et al. 2002; Scott and Dickey 1988) oder besser (Leiba, et al. 2001) 
wurde, andere Autoren wiesen überwiegend eine geringe Visusabnahme von ein bis zwei 
Zeilen nach (Levartovsky, et al. 1995; Schröpfer and Meinert 1975). Negative Faktoren für das 
Langzeitergebnis nach abgeschlossener Okklusionsbehandlung waren ein relativ hohes Alter 
bei Beginn der Okklusionsbehandlung (Ham, et al. 1985; Levartovsky, et al. 1995; Meyer, et 
al. 1991; Stewart, et al. 2004) und ein geringer Startvisus (Meyer, et al. 1991; Scott and Dickey 
1988; Sparrow and Flynn 1977; Woodruff, et al. 1994), eine exzentrische Fixation (Ham, et al. 
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1985; Sparrow and Flynn 1977) und eine kombinierte Ursache der Amblyopie: Strabismus und 
Anisometropie (Levartovsky, et al. 1995; Woodruff, et al. 1994).
Wir untersuchten den Visus sowie prognostische Faktoren für den aktuellen Visus nach Ende der 
Okklusionsbehandlung in einer Kohorte von 137 Patienten, die vor 30­35 Jahren in Waterland, 
einer ländlichen Region in Holland, wegen Amblyopie mit Okklusion behandelt wurden. Für 
die gesamte Region waren damals nur ein Augenarzt und eine Orthoptistin (HvK, damlas 40% 
Arbeitspensum) zuständig. Dieser Orthoptistin wurden von den Mütterberatungsstellen oder 
den Hausärzten, die die Kinder auf Amblyopie screenten, alle Amblyopieverdächtigen Kinder 
überwiesen. Gemeinsam mit dieser Orthoptistin wurden die Patienten 2003 erneut untersucht.
mATErIAL und mEThodEn 
hintergrund
Zum Zeitpunkt der Untersuchung stellte das Waterland Krankenhaus die medizinische Ver­
sorgung der Gemeinden Purmerend, Beemster, Waterland, Zeevang, Wormer, (einschliesslich 
Edam und Volendam) und Landsmeer (Anteil 50%, weil etwa die Hälfte der Einwohner nach 
Amsterdam­Nord überwiesen wurden) sicher. Ihre Population setzte sich aus Personen zu­
sammen, die ursprünglich aus Purmerend oder den angrenzenden Gemeinden stammten so­
wie aus einzelnen Familien mit jungen Kindern, welche aus Amsterdam zugewandert waren. 
Bestimmung der daten
Es wurden alle Krankenakten von Patienten herausgesucht, die zwischen 1968 und 1975 in 
der Orthoptischen Abteilung des Waterland Krankenhauses in Purmerend, kurz­ oder langfri­
stig, behandelt wurden (n = 1250). Bei 471 (38%) Kindern wurde eine Okklusionsbehandlung 
durchgeführt. Aus den Krankenakten erhoben wir demografische Angaben der Patienten (Ge­
schlecht, Geburtsdatum, Telefonnummer) und orthoptische Daten (Alter bei Beginn und Ende 
der Okklusionsbehandlung, Visus des amblyopen Auges bei Beginn und Ende der Okklusions­
behandlung, Ursache der Amblyopie). 
Behandlung
Eine Amblyopie wurde damals mit Okklusion behandelt, wenn nach einer adäquaten Bril­
lenverschreibung bei der folgenden Kontrolluntersuchung noch eine Visusdifferenz von ei­
ner Zeile bestand und amblyogene Faktoren vorhanden waren. Konnte kein Visus bestimmt 
werden, wurde das Führungs­ und Fixationsverhalten bei Strabismus beurteilt und bei einem 
asymmetrischen Befund eine Okklusionsbehandlung eingeleitet. 
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Damals wurde der Visus monokular bis zum vierten Lebensjahr mit Kinderbildern (Amsterda­
mer Bilder­Karte; Visusbereich 6/30 bis 6/5) getestet. Ab dem vierten Lebensjahr wurde der 
Visus mit Landoltringen und etwa ab dem siebten Lebensjahr mit Buchstaben in 6m getestet 
(Snellen) und in einem Dezimalwert notiert. Bei diesen zwei Tests war der Abstand zwischen 
den Visusstufen linear, der Sehzeichenabstand war grösser als 2,6 Bogenminuten und wurde 
als ‚single’ beschrieben. Alle Visuswerte wurden für die Analyse in logMAR umgerechnet (Ta­
belle 1).
nachuntersuchung 2003
Von 471 Patienten konnten 203 (43%) Patienten ausfindig gemacht und telefonisch kontak­
tiert werden. Diesen Patienten wurde ein Fragebogen zur Beurteilung der Lebensqualität 
bei Amblyopie und/ oder Strabismus zugesandt, der Amblyopia & Strabismus Questionnaire 
(A&SQ) (van de Graaf, et al. 2004). Die anderen Patienten konnten aus verschiedenen Gründen 
nicht kontaktiert werden: Zwei Patienten waren verstorben, bei den anderen Patienten konn­
te die Telefonnummer nicht ausfindig gemacht werden, oder sie waren nicht erreichbar. 174 
Patienten sendeten den ausgefüllten Fragebogen zurück. Im Herbst 2003 konnten davon 137 
Tabelle 1. Umrechnungstabelle Visus in Dezimalen ­ Visus in logMAR
umrechnungstabelle 
Visus in dezimalen - Visus in logmAr
Visus LogmAr
1,6 ­0,2
1,25 ­0,1
1,0 0,0
0,8 0,1
0,63 0,2
0,5 0,3
0,4 0,4
0,32 0,5
0,25 0,6
0,2 0,7
0,16 0,8
0,12 0,9
0,1 1,0
0,08 1,1
0,06 1,2
0,05 1,3
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Patienten in der Orthoptischen Abteilung des Waterland Krankenhauses in Purmerend orth­
optisch und augenärztlich nachuntersucht werden. Von den 27 Patienten, die den Fragebo­
gen zurückgesendet hatten, aber nicht nachuntersucht werden konnten, waren elf nicht er­
reichbar, sechs wollten nicht teilnehmen und neun konnten nicht zur Untersuchung kommen, 
weil sie hospitalisiert waren, im Ausland weilten oder einen langen Anfahrtsweg hatten.
Wir verfügten über Visusangaben zu drei Zeitpunkten (Beginn, Ende der Okklusionsbehand­
lung, sowie 2003, 30­35 Jahre nach Ende der Okklusionsbehandlung). 
Folgende Untersuchungen wurden bei der Nachuntersuchung durchgeführt: Binokularsehen 
wurde mit dem Streifentest nach Bagolini in 6m und 0,4m getestet, Stereosehen mit Titmus­
Test, Stereotest nach Lang II und TNO­Test. Der Schielwinkel wurde mittels monolateralem 
und alternierenden Abdecktest in 6m und 0,3m gemessen sowie eine dissoziierte Vertikaldi­
vergenz notiert. Die Refraktion wurde mittels einer Skiaskopie ohne Zykloplegie, jedoch im 
abgedunkelten Raum und nachfolgendem subjektiven Abgleich geprüft. Der Visus wurde 
mittels Projektor (OCULUS, Medical Workshop Niederlande) mit linearen Visusstufen (Sehzei­
chenabstand „single“) monokular in 6m Zahlen gemäss DIN EN ISO 8596 mit bestmöglicher 
Korrektion getestet und in Dezimalwerten notiert. Die Lesefähigkeit wurde mit einem nieder­
ländischen Lesetext bestimmt, der aus fünf Visusstufen bestand (D=0,5; D=0,8; D=1; D=1,25; 
D=2). D=1 entspricht Zeitungsdruckgrösse. Ferner wurde die Fixation ophthalmoskopisch ge­
prüft. Es wurden die Vorderabschnitte und der Fundus beurteilt. 
Alle Visuswerte, ausser dem Lesetext, wurden für die Analyse in logMAR umgerechnet.
Anisometropie wurde definiert als eine Differenz von mehr als 1 D sphärischem Äquivalent 
zwischen dem rechten und linken Auge. Eine Kombination beider Ursachen (Strabismus und 
Anisometropie) definierten wir als kombinierte Amblyopie.
Statistische Analyse
Wir haben eine Regressionsanalyse durchgeführt, um Parameter zu bestimmen, welche den 
aktuellen Visus am meisten beeinflussen. Um mögliche Störfaktoren auszuschliessen, wurde 
eine multivariante Analyse durchgeführt. Für die statistische Analyse wurde SPSS angewandt, 
Version 10.0. Als Schwelle für statistische Signifikanz wurde P < 0,05 bestimmt.
ErGEBnISSE
Gesamtgruppe
Die Patientengruppe bestand aus 65 Frauen und 72 Männern. Das durchschnittliche Alter bei 
Beginn der Okklusionsbehandlung betrug 5,4 ± 1,9 Jahre, am Ende 7,4 ± 1,7 Jahre. Zwölf (9%) 
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der 137 Kinder wurden bereits vor dem dritten Lebensjahr okkludiert, durchschnittlich ab 2,4 
Jahren, bei ihnen bestand ein grosswinkliger Strabismus. 
Der durchschnittliche Visus der amblyopen Augen bei Beginn betrug 0,6 ± 0,7 logMAR und 
0,3 ± 0,5 logMAR am Ende der Okklusionsbehandlung. 98 Patienten (71%) wiesen eine Stra­
bismus­Amblyopie auf, 16 Patienten (12%) eine Anisometropie­Amblyopie und 23 Patienten 
(17%) eine kombinierte Amblyopie. 
Zu Beginn der Okklusionsbehandlung hatten 116 Patienten ein Visusunterschied zwischen 
dem Führungsauge und dem amblyopen Auge von mindestens 0,5 logMAR. 13 Patienten 
hatten ein Visusunterschied zwischen 0,2 und 0,5 logMAR, acht Patienten von < 0,2 logMAR. 
Bei fünf Patienten konnten aufgrund des Alters keine Visusangaben erhoben werden, anstatt 
dessen hat die Orthoptistin das Führungs­ bzw. Fixationsverhalten der Patienten beschrie­
ben. Bei allen fünf Patienten lag ein Strabismus vor: zwei Patienten hatten nur geringe Folge­
bewegungen bei Okklusion des Führungsauges, drei nahmen die Fixation auf, hielten diese 
aber nicht. Wir haben ein Visusäquivalent von 0,4 logMAR bzw. 0,2 logMAR angenommen. 
Der Visus bei Beginn der Okklusion wurde nur für die Korrelation des Startvisus mit dem ak­
tuellen Visus verwendet, jedoch nicht für die prognostischen Faktoren. Diese Gleichsetzung 
kann man unterschiedlich interpretieren, es gilt aber zu beachten, dass es sich nur um fünf 
Patienten handelt. 
Patienten mit Strabismus­Amblyopie wurden ab 5,1 ± 1,9 Jahren okkludiert, durchschnittlich 
2,3 ± 1,3 Jahre. Patienten mit reiner Anisometropie­Amblyopie waren zu Beginn der Okklusi­
onsbehandlung 7,2 ± 2,2 Jahre alt und wurden 1,4 ± 1,0 Jahre okkludiert. Patienten mit einer 
Tabelle 2. Visus bei Beginn, Ende und 30­35 Jahre nach Okklusionsbehandlung sowie Alter bei Beginn der 
Behandlung, Dauer der Okklusion und Fixationsverhalten nach Ursache der Amblyopie.
Faktoren
Strabismus-Amblyopie 
(n = 98)
Anisometropie-
Amblyopie (n = 16)
kombinierte 
Amblyopie (n = 23)
Visus Beginn okklusion
(logmAr)
0,69* ± 0,5 0,53* ± 0,3 0,82* ± 0,54
Visus Ende okklusion (logmAr) 0,29 ± 0,3 0,17 ± 0,23 0,52 ± 0,54
Visus nachuntersuchung (logmAr) 0,27 ± 0,3 0,21 ± 0,23 0,65 ± 0,54
Alter Beginn okklusion (jahre) 5,1 ± 1,9 7,2 ± 2,2 5,8 ± 0,7
dauer okklusion (jahre) 2,3 ± 1,3 1,4 ± 1,0 1,6 ± 1,3
Fixation
     zentral n = 63* n = 16 n = 14
     Exzentrisch n = 35* n = 0 n = 9
Sowohl bei der uni­ als auch multivariaten Analyse waren der Visus des amblyopen Auges bei Beginn der 
Behandlung (P < 0,0001), die Ursache der Amblyopie (P = 0,001) (Strabismus, Anisometropie, kombinierte 
Amblyopie) sowie eine exzentrische Fixation (P < 0,0001) bei Strabismus signifikant in Bezug auf den 
aktuellen Visus in logMAR.
*Signifikante Parameter für den Visus 2003 in logMAR bei der Regressionsanalyse.
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kombinierten Amblyopie waren 5,8 ± 0,7 Jahre alt und wurden 1,6 ± 1,3 Jahre okkludiert (Ta­
belle 2). Das Binokularsehen verbesserte sich in der Gesamtgruppe der Patienten gering 
(Abbildung 1). 
Visus nach ursache der Amblyopie 
Bei Patienten mit kombinierter Amblyopie hatte sich der Visus seit der Behandlung von 0,52 
± 0,54 logMAR auf 0,65 ± 0,54 logMAR und bei Patienten mit Anisometropie­Amblyopie von 
0,17 ± 0,23 logMAR auf 0,21 ± 0,23 logMAR verschlechtert. Bei Patienten mit Strabismus­Am­
blyopie hatte sich der Visus von 0,29 ± 0,3 logMAR auf 0,27 ± 0,3 logMAR verbessert (Abbil­
dung 2). Diese Verbesserung war signifikant (P < 0,001). Der Visus am Führungsauge dieser 
Patienten zeigte ebenso eine Zunahme von 0,01 ± 0,15 logMAR auf 0,05 ± 0,07 logMAR und 
war auch signifikant (P = 0,04).
 
Chapter 4 
Abbildung 1. Binokularsehen der Gesamtgruppe während der Okklusionsbehandlung und bei der 
Nachuntersuchung 2003. 
Der Grad von Binokular- und Stereosehen (Abszisse) wurde in sieben Stufen eingeteilt:  
1: Lichtschweiftest nach Bagolini negativ, 2: Lichtschweiftest nach Bagolini positiv, 3: 
Lichtschweiftest nach Bagolini und Titmus-Stereotest Fliege positiv, 4: mindestens Titmus-Stereotest 
Ringe 200” bis 140” positiv, 5: mindestens Titmus-Stereotest Ringe 100” bis 40” positiv,  6: Stereotest 
nach Lang oder mindestens TNO-Test Abbildung V (480” & 240”) positiv, 7: TNO-Test Abbildung VI 
oder VII (120” – 15”) positiv. Der schwarze Balken zeigt den Grad von Binokularsehen während der 
Okklusion in der Gesamtgruppe (n = 137), der graue Balken bei der Nachuntersuchung 2003. Die 
Ordinate repräsentiert die Anzahl der Patienten.  
Abbildung 1. Binokularsehen der Gesamtgruppe während der Okklusionsbehandlung und bei der 
Nachuntersuchung 2003. Der Grad von Binokular­ und Stereosehen (Abszisse) wurde in sieben Stufen 
eingeteilt: 1: Lichtschweiftest nach Bagolini negativ, 2: Lichtschweiftest nach Bagolini positiv, 3: 
Lichtschweiftest nach Bagolini und Titmus­Stereotest Fliege positiv, 4: mindestens Titmus­Stereotest 
Ringe 200” bis 140” positiv, 5: mindestens Titmus­Stereotest Ringe 100” bis 40” positiv, 6: Stereotest nach 
Lang oder mindestens TNO­Test Abbildung V (480” & 240”) positiv, 7: TNO­Test Abbildung VI oder VII (120” 
– 15”) positiv. Der schwarze Balken zeigt den Grad von Binokularsehen während der Okklusion in der 
Gesamtgruppe (n=137), der graue Balken bei der Nachuntersuchung 2003. Die Ordinate repräsentiert die 
Anzahl der Patienten. 
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Der Visus des amblyopen Auges zeigte sich bei 14 (10%) Patienten unverändert in Bezug zum 
Visus nach Ende der Okklusion. 70 (51%) Patienten wiesen eine Visusverbesserung auf. 54 
(39%) Patienten hatten einen Visusabnahme, davon 18 Patienten um 50% und mehr in Bezug 
zum Visus des amblyopen Auges nach Ende der Okklusionsbehandlung. 
47 (34%) von 137 Patienten hatten am Ende der Okklusionsbehandlung auf dem amblyopen 
Auge einen Fernvisus >0,3 logMAR, durchschnittlich 0,48 ± 0,6 logMAR. 55 (40,1%) von 137 
Patienten hatten keine Lesefähgkeit (> D=1).
 
Abbildung 2. Visus des amblyopen Auges, nach Diagnose, bei Beginn der Okklusionsbehandlung und 
bei der Nachuntersuchung 2003. 
Die Ordinate zeigt den Visus bei der Nachuntersuchung in logMAR, die Abszisse den Visus in 
logMAR bei Beginn der Okklusion. Patienten mit einer kombinierten Amblyopie sind dargestellt als 
schwarzes Viereckg, Patienten mit Anisometropie-Amblyopie als Dreieck ▲ und  Patienten mit 
Strabismus-Amblyopie als weisses Viereck □. Die ausgezogene Linie zeigt die Regressionslinie der  
kombinierten Amblyopi , die breitgestr elte Linie die der Anisomet opi -Amblyopien und die 
feingestrichelte Linie die der Strabismus-Amblyopien. 
Sowohl Patienten mit Strabismus-Amblyopie als auch solche mit kombinierter Amblyopie hatten einen 
niedri n Visus bei Beginn der Behan lung, Patienten mit Strabismus-Amblyopie erreichten bei der 
Nachuntersuchung, 2003, jedoch einen besseren Visus als diejenigen mit kombinierter Amblyopie. 
 
Abbildung 2. Visus des amblyopen Auges, nach Diagnose, bei Beginn der Okklusionsbehandlung und bei 
der Nachuntersuchung 2003.
Die Ordinate zeigt den Visus bei der Nachuntersuchung in logMAR, die Abszisse den Visus in logMAR 
bei Beginn der Okklusion. Patienten mit einer kombinierten Amblyopie sind dargestellt als schwarzes 
Viereck ˙, Patienten mit Anisometropie­Amblyopie als Dreieck p und Patienten mit Strabismus­Amblyopie 
als weisses Viereck ß. Die ausgezogene Linie zeigt die Regressionslinie der kombinierten Amblyopien, 
die breitgestrichelte Linie die der Anisometropie­Amblyopien und die feingestrichelte Linie die der 
Strabismus­Amblyopien.
Sowohl Patienten mit Strabismus­Amblyopie als auch solche mit kombinierter Amblyopie hatten einen 
niedrigen Visus bei Beginn der Behandlung, Patienten mit Strabismus­Amblyopie erreichten bei der 
Nachuntersuchung, 2003, jedoch einen besseren Visus als diejenigen mit kombinierter Amblyopie.
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Patienten mit starker Visusabnahme 
Bei 15 von 18 Patienten, die nach Ende der Okklusionsbehandlung eine Visusabnahme um 
mindestens 50% in Bezug zum Visus am Ende der Okklusionsbehandlung hatten, bestand 
eine Zunahme der Anisohyperopie. Von den 15 Patienten entwickelten neun Patienten bis zur 
Nachuntersuchung eine Anisohyperopie von 2,2 ± 1,7 D. Bei sechs Patienten bestand bereits 
während der Behandlung eine Anisohyperopie von 2,9 D, die auf 3,5 ± 1,8 D zugenommen 
hatte. Bei diesen 18 Patienten nahm das sphärische Äquivalent (Skiaskopiewerte) auf dem 
amblyopen Auge von +2,7 D auf +2,8 D zu und auf dem Führungsauge von +1,9 D auf +0,7 D 
ab. Nur fünf der 18 Patienten trugen bei der Nachuntersuchung eine adäquate Brille. Von die­
sen fünf waren drei Patienten auf dem Führungsauge myop und zwei durchschnittlich +2,75 
D hyperop.
Prognostische Faktoren
Die univariate Analyse zeigte eine statistisch signifikante Korrelation zwischen dem aktuellen 
Visus und dem Visus bei Beginn der Okklusionsbehandlung (P < 0,001), dem Visus am Ende 
der Behandlung (P < 0,001), einer exzentrischen Fixation (P < 0,001) sowie der Ursache (Stra­
bismus, Anisometropie oder kombinierte Amblyopie) der Amblyopie (P = 0,005) (Tabelle 2). 
Nicht signifikant waren die Dauer der Okklusion (P = 0,622) sowie das Alter bei Beginn (P = 
0,320) und Ende der Okklusionsbehandlung (P = 0,119). In der korrigierten Analyse zeigte 
sich der Visus bei Beginn der Behandlung signifikant (P < 0,001), die Ursache der Amblyopie 
(P = 0,018) und die Fixation (P = 0,004). Patienten mit Anisometropie­Amblyopie hatten im 
Vergleich zu Patienten mit Strabismus­Amblyopie sowie mit kombinierter Amblyopie einen 
signifikant besseren Visus bei Beginn der Okklusionsbehandlung. Patienten mit kombinierter 
Amblyopie wiesen sowohl bei Beginn der Behandlung, als auch bei der Nachuntersuchung 
den niedrigsten Visus auf. Nur Patienten mit Strabismus­Amblyopie hatten, im Vergleich zum 
Visus am Ende der Behandlung, eine geringe Visusverbesserung. Die Fixation war bei Pati­
enten mit Strabismus korreliert mit dem Visus. Es zeigte sich eine Korrelation zwischen der 
Visusabnahme und dem Verlust von Binokularsehen (r = 0,38). 
Prävalenz der okklusionsbehandlung
Wir wollten festzustellen, ob die historische Kohorte okkludierter Kinder für die damalige Ok­
klusionsbehandlung repräsentativ war, bzw. ob ein Selektion Bias aufgetreten sein könnte. 
Die Prävalenz von Amblyopie wird mit etwa 3,25% angegeben (Attebo, et al. 1998). Wir erwar­
teten eher eine niedrigere Prävalenz zu finden, falls unsere historische Kohorte eine gebiaste 
Unterrepräsentation darstellte.
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Von den 471 okkludierten Kindern waren die meisten Kinder 1965, 1966 und 1967 geboren 
(Abbildung 3). 
Es waren 66 Kinder im Jahr 1965, 64 im Jahr 1966 und 68 Kinder im Jahr 1967 geboren. In der 
gesamten Region des Waterland Krankenhauses wurden in den Jahren 1965, 1966 und 1967 
1286, 1328 und 1355 Geburten registriert. Dies würde, unter 1965­1967 geborenen Kindern, 
einer Prävalenz von okkludierten Kindern von etwa 5,0% entsprechen. Nur bei sieben der 
137 Kinder, die okkludiert wurden, war die Diagnose im nachhinein diskutabel: Diese Patien­
ten hatten einen Visusunterschied von <0,2 logMAR zwischen dem Führungsauge und dem 
amblyopen Auge, eine Anisometropie <1 D oder ein alternierendes Schielen, was nicht bei 
Anfang der Behandlung festgestellt werden konnte. Nach entsprechender Korrektion betrug 
die Prävalenz von okkludierten Kindern etwa 4,7%. Theoretisch wäre es möglich, dass Kinder, 
die ausserhalb der Region wohnten, im Waterland Krankenhaus behandelt wurden. Dies kam 
in unserer Gruppe aber nicht vor. 
 
Abbildung 3.  
Übersicht der Patientenanzahl pro Geburtsjahr für alle im Waterland Krankenhaus okkludierten 
Patienten (n = 471, hellgrau) und für die historische Kohorte (n = 137, schwarz). Außerdem sind für die 
historische Kohorte Okklusionsbeginn (weiß) und Okklusionsende (dunkelgrau) angegeben. Von den 
471 Okkludierten waren 66, 64 und 68 in den Jahren 1965, 1966 und 1967 geboren. Dies entsprach 5,0 
% der in der gesamten Region des Waterland Krankenhauses in diesen Jahren registrierten Geburten. 
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okkludierten Patienten (n = 471, hellgrau) und für die historische Kohorte (n = 137, schwarz). Außerdem 
sind für die historische Kohorte Okklusionsbeginn (weiß) und Okklusionsende (dunkelgrau) angegeben. 
Von den 471 Okkludierten waren 66, 64 und 68 in den Jahren 1965, 1966 und 1967 geboren. Dies 
entsprach 5,0% der in der gesamten Region des Waterland Krankenhauses in diesen Jahren registrierten 
Geburten.
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dISkuSSIon
Es war uns möglich, bei 137 Patienten, länger als drei Jahrzehnte nach Ende der Okklusions­
behandlung, eine Visusevaluierung durchzuführen. Wir fanden, dass ein niedriger Visus bei 
Beginn der Behandlung, eine exzentrische Fixation sowie eine kombinierte Amblyopie am 
meisten mit dem bei der Nachuntersuchung erhobenen Visus korrelierten. Die schlechte Aus­
gangslage bei einem niedrigen Startvisus des amblyopen Auges und bei einer kombinierten 
Ursache der Amblyopie bestätigt die Beobachtung anderer Autoren, acu bei einem weitaus 
längeren Beobachtungszeitraum als bisher beschrieben. Eine kombinierte Ursache der Am­
blyopie und eine Zunahme der Anisohyperopie waren assoziiert mit einer langfristigen Vi­
susabnahme nach Ende der Okklusionsbehandlung. 
Der Visus konnte aufgrund des Schulalters der Kinder sowohl bei Beginn und bei Ende der 
Okklusion grösstenteils mit Landoltringen getestet werden. Der Visus bei Beginn der Okklu­
sion, wobei die grösste Varianz zu erwarten war, wurde lediglich für die Korrelation mit dem 
aktuellen Visus verwendet. Bei der Bestimmung der prognostischen Faktoren haben wir Visus­
werte bei Ende der Okklusionsbehandlung mit dem aktuellen Visus verglichen, der jedoch mit 
unterschiedlichen Visustest bestimmt wurde. Dies kann zu nicht ganz vergleichbaren Werten 
führen (Gräf 2004), denn Visusprüfungen mit Optotypen können nur im oberen Visusbereich 
gleiche Werte wie der Landoltring erzielen, im unteren Bereich tritt eine leichte Überschät­
zung des mit Optotypen gemessenen Visus auf (Rassow and Wang 1999). Trotzdem fanden 
wir eine deutliche Signifikanz. 
Bei Patienten mit Strabismus­Amblyopie trat nach Ende der Okklusionsbehandlung sowohl 
im amblyopen Auge als auch im Führungsauge eine geringe Visusverbesserung auf. Wir ver­
muten daher einen natürlichen Verlauf der Visusentwicklung. Über die Entwicklung der Füh­
rungsaugen wird bisher kaum berichtet, man fand, ohne nach der Ursache der Amblyopie zu 
unterscheiden, eine geringe Visusverbesserung (Ohlsson, et al. 2002). Studien, die den natür­
lichen Verlauf bei Patienten mit unbehandelter Amblyopie untersucht haben, zeigten sowohl 
im Vorschulalter (Simonsz and Preslan 1999), als auch im Erwachsenenalter (Haasse and Wen­
zel 1996) eine Verschlechterung im amblyopen Auge auf. Hierbei ist anzumerken, dass eines 
der Einschlusskriterium dieser Studie ein niedriger Visus (>0,18 logMAR) war und Kinder mit 
nur geringer Visusminderung nicht vorkamen. Es ist daher ein Selektion Bias wahrscheinlich.
Wie andere Autoren (Levartovsky, et al. 1995; Woordruff, et al. 1994) konnten wir keine Kor­
relation zwischen dem Alter bei Beginn und Ende der Okklusionsbehandlung und dem 2003 
erhobenen Visus des amblyopen Auges nachweisen. Man kann daraus aber nicht schliessen, 
dass ein Patient nicht erfolgreicher behandelt werden kann, wenn dieser Patient bereits zu 
einem früheren Zeitpunkt okkludiert würde. 
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Das Alter bei Beginn der Okklusionsbehandlung ist in unserem Krankengut relativ hoch, 
wahrscheinlich, weil Amblyopiescreening zum Zeitpunkt der Behandlung nicht ganz flächen­
deckend durchgeführt wurde. Die Mütterberatungsstellen und, ausserhalb der Stadt, die 
Hausärzte führten keine Visusmessung durch, so dass Amblyopie ohne auffälliges Schielen 
meist erst im Alter von fünf bis sieben Jahren diagnostiziert wurde. In den Niederlanden wird 
heutzutage von den Mütterberatungsstellen flächendeckend mit 3 sowie 3¾ Jahren ein Am­
blyopiescreening duchgeführt. Das Durchschnittsalter bei Beginn der Okklusionsbehandlung 
bei okkludierten Kindern in Den Haag lag in den Jahren 2001­2006 bei 4,6 Jahren (Loudon, et 
al. 2006).
Bei 15 von 18 Patienten, die nach Ende der Okklusionsbehandlung eine Visusabnahme von 
mindestens 50% hatten, bestand eine Zunahme der Anisohyperopie. Wichtig erscheint, dass 
nur fünf der 18 Patienten bei der Nachuntersuchung eine Brille trugen. Die anderen gaben 
an, die Brille seit ihrem 14./ 15. Lebensjahr nicht mehr zu tragen. Es ist denkbar, dass diese 
Patienten bereits kurze Zeit nach Erhalt der neuen Korrektion aufgrund der kontinuierlichen 
Zunahme der Anisometropie auf dem amblyopen Auge wieder unscharf sahen und deshalb 
die Brille nicht gerne tragen. 
Es ist empfehlenswert, Patienten, bei denen eine Anisometropie festgestellt wurde und eine 
Zunahme dieser Anisometropie zeigen, häufiger zu kontrollieren und die Brille anzupassen. 
In anderen Studien (Attebo, et al 1998; Leiba, et al. 2001; Levartovsky, et al. 1995; PEDIG 2002; 
Woodruff, et al. 1994) beträgt der Anteil reiner Anisometropie­Amblyopien im Patientengut 
etwa 30%, variiert aber zwischen 11% (Leiba, et al. 2001) und 50% (Attebo, et al. 1998). In un­
serer Studie waren nur Kinder inkludiert, die okkudiert wurden. Patienten, bei denen die Ani­
sometropie­Amblyopie ausschliesslich mit einer Brillenkorrektion behandelt wurde, meistens 
nur vom Augenzarzt, kamen in unserer Studie daher nicht vor. Ob und zu welchem Zeitpunkt 
eine Okklusionsbehandlung, nebst der Verschreibung einer Brillenkorrektion, bei Patienten 
mit leichten Anisometropie­Amblyopien durchgeführt werden sollte, wird verschieden ge­
handhabt.
Erstaunlicherweise fanden wir eine höhere Prävalenz von okkludierten Kindern (4,7%) als die 
in anderen Studien genannte Prävalenz der Amblyopie (3,25%) (Attebo, et al. 1998). Wie er­
klärt sich diese Diskrepanz? Die Prävalenz der Amblyopie wird in den meisten Studien bei 
erwachsenen Patienten mit unbehandelter Amblyopie bestimmt. Aus unserer Studie geht 
hervor, dass der Visus nach Ende der Okklusionsbehandlung bei den meisten Patienten leicht 
ansteigt, bei einigen aber abnimmt. Die Orthoptistin weiss aber zu Beginn der Behandlung 
nicht, bei welchen Kinder, die wegen einer geringen Visusreduktion (>0,1 logMAR) von den 
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Mütterberatungsstellen oder Kinderärzten überweisen werden, sich der Visus spontan bes­
sern wird und ‚überbehandelt’ daher.
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Electronic recording of occlusion treatment 
for amblyopia: potential of the new 
technology
66
ABSTrAcT
Purpose: Approximately one third of all amblyopic eyes do not reach visual acuity of 20/40 in 
spite of occlusion therapy. One of the reasons is a lack of adherence to therapy, which, how­
ever could not be quantified in the past. Experience with new devices (Occlusion Dose Moni­
tors, ODMs) for electronic recording of occlusion has recently been reported. The aim of the 
present study was to evaluate the potential the ODMs developed in the Netherlands. Various 
features were tested, including the reliability of the ODM recordings compared to diaries, two 
ODMs used simultaneously on one patch, the influence of the ambient temperature, and the 
specificity of the recording pattern for measurements on the eye. 
methods: The ODMs were taped to the outside of the standard occlusion patch and measured 
the temperature difference between their front and back surfaces. Members of the research 
group and the families of two patients kept occlusion diaries while using the ODMs. Recorded 
and written occlusion periods were compared. Measurements were carried out under various 
conditions: patch with one ODM tightly on the eye or detached (allowing peeping); ODMs 
taped to various parts of the body; two ODMs simultaneously on one patch; variation of room 
temperature. 
results: There was good correspondence between the occlusion times recorded by the ODMs 
and those from the diaries, as well as between the recordings of two ODMs used simultane­
ously on one patch. High ambient temperatures (33°C to 37°C) prevented reliable ODM mea­
surements. Measurements on other parts of the body were misclassified with probabilities 
between P = 0.099 and P = 0.325 as measurements with the patch tightly on the eye. 
conclusions: In spite of some technical limitations, the ODMs provide a chance for reliable 
assessment of compliance and therefore objective information on dose­response function for 
occlusion therapy. This will lead to a more evidence based treatment for amblyopia.
The data for this chapter were collected in collaboration with the Department of Ophthalmol­
ogy, J.W. Goethe University, Frankfurt am Main, Germany, and the majority of them are part of 
the Dr.med thesis of Yaroslava Chopovska.
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InTroducTIon
Amblyopia is the most common visual defect of childhood (Attebo, et al. 1998). Introduced 
more than 1000 years ago the accepted treatment for children with amblyopia is occlusion 
of the non­amblyopic eye, with prescribed regimens between a quarter of an hour and all 
waking hours (Loudon, et al. 2004). However, between 26% and 40% of patients do not reach 
20/40 acuity in spite of occlusion therapy (Flynn, et al. 1999). One of the reasons is a lack of 
adherence to therapy (Dorey, et al. 2001), which could not be quantified in the past. This led 
to doubts about the effectiveness of occlusion and to discussions about the justification of 
screening for amblyopia (Clarke, et al. 2003; Snowdon and Stewart­Brown 1997; Williams, et 
al. 2002). Continuous objective compliance monitoring could be the key to a more evidence 
based treatment for amblyopia. 
In 1991, Fielder et al. developed the first prototype electronic occlusion dose monitor (ODM) 
(Figure 1a). This prototype was changed into a modified occlusion patch with two miniature 
electrocardiogram electrodes attached to its undersurface (measuring patch­skin resistance) 
and connected with leads to the datalogger which was carried in a shoulder bag (Fielder, et 
al. 1995). 
The design was modified in 1997 (Figure 1b) (Simonsz, et al. 1999) and again in 2001 and 2002 
(Figure 1c, d). A different technical approach, measuring the temperature difference between 
the surface of the eye and the ambient temperature, was used. The devices were made smaller 
and everything including data storage was built into the ODM. All ODMs were developed in 
the public domain. 
Although the devices are being used in large amblyopia therapy studies (Loudon, et al. 2004; 
Stewart, et al. 2004), details on technical features have not been made available for either of 
the technologies. The aim of the present study was to test the potential of the ODM types 
2001 and 2002. Although it was assumed that the device might become unreliable in the 
summer months (Simonsz, et al. 1999), the respective temperature range is still unclear. Pa­
tients and parents might perceive the ODM to be a control and might seek ways of deceiving 
the system. While Fielder et al. reported their ODM to reveal episodes of peeping due to the 
monitoring of the patch­skin contact (Fielder, et al. 1995), this has not yet been tested for the 
new temperature­measuring devices.
The following aspects of the new technology were tested by two members of the ERPAG study 
(ophthalmology departments of the universities of Frankfurt, Germany and Rotterdam, the 
Netherlands): reliability of the ODM recordings compared to diaries; two ODMs used simulta­
neously on one patch; the temperature range preventing reliable measurements; the specific­
ity of the recording pattern for measurements on the eye. 
In addition to these quantitative assessments, information was obtained from two families 
about the long­term use of the devices.
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design and function of the odms
The ODM is composed of a microcontroller, two temperature sensors, a clock and a recharge­
able battery (Simonsz, et al. 1999). It is taped to the outside of a standard eye patch using 
double­sided Scotch tape. When the patch with the ODM is worn on the eye, the temperature 
at the back of the device is higher than at the front. A microcontroller subtracts the tempera­
ture measured by the sensor at the front of the ODM from the temperature measured at the 
back. The temperature is sampled every 120 seconds. The sensitivity is set at 1/16ºCelsius. 
There are no patient operated controls. After a period of recording the data are saved on a 
personal computer by means of the docking system.
ODM types 2001 and 2002 (Figure 1c, d) were used. The two differ mainly in size, while the 
features mentioned above are the same.
An example for a week’s recording is shown in Figure 2a. By displaying a day’s recording with 
better temporal resolution, the exact starting and ending times of occlusion may be deter­
mined (Figure 2b).
methods of evaluation of the odm features
Reliability of time recordings
Members of the research groups and the families of amblyopic patients from Frankfurt kept 
occlusion diaries while using the ODMs. Recordings of two compliant families were selected 
for the purpose of testing the equipment. One child had was prescribed 4 h and the second 12 
h of occlusion daily. The diaries and the ODM recordings were evaluated and compared. Prior 
to participation, written consent was obtained from the parents after the nature of the tests 
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Figure 1. The development of the Occlusion Dose Monitor. a Year 1991: first model developed by 
Fielder and Moseley in Birmingham, UK (with permission of M. Moseley). The ODM was a miniature 
datalogger, which logs the patch-skin contact resistance every 64 s. b Year 1997: The Academic 
Medical Center Amsterdam modified the design into an ODM containing two thermistors connected to 
either the front or the back of the ODM (35x23x4 mm, 6 g). c The 2001 type used in the Netherlands 
(24x12x3.6 mm, 1.8 g). d The 2002 type used in Germany (31x15x3.5 mm, 2.3 g) 
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Figure 2. Examples of recordings with the ODM, with measured temperature difference on the 
ordinates. a A week’s recording. Abscissa: date of the recording. The temperature difference was about 
"0" (0; 0.0625) while the child was not patched (baseline value) and higher during the periods of 
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Figure 1. The development of the Occlusion Dose Monitor. a Year 1991: first model developed by Fielder 
and Moseley in Birmingham, UK (with permission of M. Moseley). The ODM was a miniature datalogger, 
which logs the patch­skin contact resistance every 64 s. b Year 1997: The Academic Medical Center 
Amsterdam modified the design into an ODM containing two thermistors connected to either the front or 
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Figure 2. Examples of recordings with the ODM, with measured temperature difference on the ordinates. 
a A week’s recording. Abscissa: date of the recording. The temperature difference was about “0” (0; 0.0625) 
while the child was not patched (baseline value) and higher during the periods of occlusion. The child’s 
eye was occluded every day except one (12.04.03) for several hours. b A day’s recording. Abscissa: time. The 
measured temperature difference increased at the beginning of the occlusion and dropped at the end, 
thus showing the duration of the measurement. Specific features of every measurement are the “mean 
temperature difference” and the “standard deviation”, which describes the dimension of the temperature 
fluctuations .
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was explained fully. All procedures followed the guidelines of the Declaration of Helsinki and 
were approved by the medical ethical committee of the University Clinic Frankfurt.
Comparison of recordings with two ODMs used simultaneously
Both groups performed tests placing two ODMs of the same type on one patch together and 
sticking the latter to different parts of the body. The mean temperature difference and the 
standard deviation of all temperature differences (Figure 2) sampled during each period of 
occlusion with both ODMs were compared by means of the Passing­Bablok regression. The 
duration of the occlusion periods was compared.
Influence of the ambient temperature
The investigators carried out measurements with ODM 2002 on the eye varying the room 
temperature from 18°C to 38°C to determine the temperature range preventing reliable mea­
surements. The relationship between the measured mean temperature difference and the am­
bient temperature was evaluated by means of the Pearson regression test.
Specificity of pattern of measurements on the eye
We tested several possible ways of deceiving the system. Measurements were carried out with 
ODM 2002 while the patch was tightly on the eye, detached on the eye (peeping), on the 
forehead, on the arm covered with a sleeve, on the arm uncovered and in the pocket of the 
trousers. Room temperature was between 18°C and 23°C. Parameters “mean temperature dif­
ference” and “standard deviation” were compared by means of the Hotelling’s­T2 test (method 
of multivariate analysis) and the discriminant analysis.
rESuLTS
reliability of the odms compared to diaries
Correspondence between the occlusion times recorded by the ODMs and those from the dia­
ries was about 99%, not only for measurements of short duration, but also for those lasting 
more than 11 h. The mean time difference between ODM records and the researchers’ diary 
was about ­0.5 min in both groups. This was due to the sampling rate of the ODM of 2 min. 
Only one fifth of the data differed by more than 2 min (maximum 5 min). In both children 
the mean time difference between ODM records and the occlusion diary was about ­3.5 min, 
probably because parents kept less precise records than the researchers.
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comparison of recordings with two odms used simultaneously
The difference in data between two ODMs on one patch was minimal. Passing­Bablok regres­
sion revealed highly significant agreement both between the mean temperature differences 
(r = 0.93; P< 0.01) and between the standard deviations (r = 0.624; P < 0.01). The mean time 
difference between two ODMs on one patch was 0 min (SD = 1.6 min).
Influence of the ambient temperature on the measurements
The ambient temperature had a significant influence on the temperature difference measured 
by the ODM: y = ­0.0556x + 1.98; P < 0.01; r= ­0.966 (Figure 3a). 
As expected, the measured temperature difference was “0” when the ambient temperature 
approached the temperature 36°C and became negative when the temperature increased fur­
ther. High ambient temperatures (33°C to 37°C) prevented reliable ODM measurements (see 
Figure 3b for an example).
Is there a specific pattern for the measurement on the eye?
Figure 4 shows an example of the results of the discriminant analysis comparing measure­
ments with the patch tightly on the eye with those when the patch was partly detached. The 
probability of false classification was P = 0.154. The mean temperature difference tended to 
be higher for the measurements with the patch tightly on the eye (P < 0.01, t­test), while the 
standard deviation was similar for both data groups (P = 0.885, t­test).
Table 1 summarises the results of all the situations tested.
The rate of misclassification increased from the ODM placed in the trouser pocket (P = 0.099) 
to the ODM worn on an uncovered arm (P = 0.325). The researchers were able to discern when 
Table 1. Confidence intervals (CI) of the mean temperature differences (TD) and of the standard deviations 
of temperature differences measured by the ODM on different locations; results of the discriminant 
analysis (rate of false classification) and Hotelling’s­T2 test for the comparison between measurements with 
the patch put tightly on the eye and measurements made elsewhere.
eye (patch 
tight) 
eye (patch 
detached) 
forehead arm covered arm 
uncovered 
trouser pocket 
number of tests 38 23 31 26 25 30 
cI of mean Td (°c) 0.679­1.130 0.345­1.020 0.750­1.369 0.479­1.154 0.530­1.128 0.350­0.919 
cI of Sd of the Td (°c) 0.039­0.199 0.044­0.197 0.051­0.248 0.034­0.240 0.045­0.270 0.039­0.457 
discriminant analysis: rate 
of false classification 
­­­­­­­­ P = 0.154 P = 0.242 P = 0.212 P = 0.325 P = 0.099 
hotelling’s-T2 test ­­­­­­­­ P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 
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occlusion. The child's eye was occluded every day except one (12.04.03) for several hours. b A day’s 
recording. Abscissa: time. The measured temperature difference increased at the beginning of the 
occlusion and dropped at the end, thus showing the duration of the measurement. Specific features of 
every measurement are the "mean temperature difference" and the "standard deviation", which 
describes the dimension of the temperature fluctuations  
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Figure 3. Influence of ambient temperature on ODM measurement. Abscissa: room temperature; 
ordinate: mean temperature differences measured by the ODMs. The regression line is shown together 
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occlusion. The child's eye was occluded every day except one (12.04.03) for several hours. b A day’s 
recording. Abscissa: time. The measured temperature difference increased at the beginning of the 
occlusion and dropped at the end, thus showing the duration of the measurement. Specific features of 
every measurement are the "mean temperature difference" and the "standard deviation", which 
describes the dimension of the temperature fluctuations  
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Figure 3. Influence of ambient temperature on ODM measurement. Abscissa: room temperature; 
ordinate: mean temperature differences measured by the ODMs. The regression line is shown together 
3b
Figure 3. Influ nce of ambient temp atur  on ODM measurement. a Abscissa: room temperature; 
ordinate: mean temperature differences  measured by the ODMs. The regression line is shown together 
with the confidence interval (95%). Horizontal lines indicate the range of baseline fluctuations. 
Temperatures between 33°C and 37°C (see vertical line) prevented reliable ODM measurements. b Example 
of a measurement at 35°C. Abscissa: time; ordinate: temperature difference measured by the ODM. 
According to the occlusion diary, measurement on the eye started at 19:58 hours and ended at 20:14 
hours. It is not possible to distinguish the measurement on the eye from the baseline fluctuations. 
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parents put the device into their pocket after occluding the child’s eye. 
Hotelling’s­T2 test (comparing the averages of the variables) yielded significant differences be­
tween the measurements with the patch tightly on the eye and the other situations (Table 1). 
This is not a contradiction to the results of the discriminant analysis, which explores whether 
a specific measurement was on the eye or not. 
dIScuSSIon
Our tests proved that the ODM measures the duration of patching with high certainty. Parents’ 
diaries were in excellent agreement with the objective records. This was not unexpected, as 
compliant families were selected.
The correspondence with diaries was as good for the measurements with long duration as for 
the shorter ones. Longer duration of the measurement was not a cause for data loss, which 
was different from experiences reported with the first ODMs (Fielder, et al. 1995). A different 
source of data loss with the ODMs measuring temperature difference was occasional battery 
failure. 
with the confidence interval (95%). Horizontal lines indicate the range of baseline fluctuations. 
Temperatures between 33°C and 37°C (see vertical line) prevented reliable ODM measurements. b 
Example of a measurement at 35°C. Abscissa: time; ordinate: temperature difference measured by the 
ODM. According to the occlusion diary, measurement on the eye started at 19:58 hours and ended at 
20:14 hours. It is not possible to distinguish the measurement on the eye from the baseline fluctuations.  
 
 
 
Figure 4. Discriminant analysis of patch tightly on the eye against patch detached on the eye, allowing 
peeping. Abscissa: mean temperature difference measured by the ODM; ordinate: SD of temperature 
differences measured by the ODM. Dark squares represent the recordings performed with the patch 
tightly on the eye, lighter squares those with the patch detached on the eye. The line represents the 
ptimal separation of the data s calculated by the discriminant analysis. Th  recordings classified by 
discriminant analysis as those being tightly on the eye are to the right of the line, as those being 
detached on the eye to its left. 
Figure 4. Discriminant analysis of patch tightly on the eye against patch detached on the eye, allowing 
peeping. Abscissa: mean temperature difference measured by the ODM; ordinate: SD of temperature 
differences measured by the ODM. Dark squares represent the recordings performed with the patch tightly 
on the eye, lighter squares those with the patch detached on the eye. The line represents the optimal 
separation of the data as calculated by the discriminant analysis. The recordings classified by discriminant 
analysis as those being tightly on the eye are to the right of the line, as those being detached on the eye to 
its left.
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We showed the ODM recordings to be reproducible, since the correspondence in data be­
tween two ODMs on one patch was highly significant.
We confirmed that the device might become unreliable in summer, showing that tempera­
tures between 33°C and 37°C prevent reliable measurements. However, such temperatures 
are rare in our climate, and it is hard to imagine that children would choose to spend a lot of 
time in conditions that were hardly bearable for the researchers. During very warm periods 
in summer both patches and ODMs occasionally came off, which could be another source of 
data loss.
Episodes of peeping could be discerned especially well with the devices monitoring patch­
skin contact (Fielder, et al. 1995), but in most cases also with the ODMs measuring tempera­
ture difference. While the probability of misclassification was low for the ODM carried in the 
trouser pockets, it was higher when placed on the arm or forehead. The recognition of cheat­
ing could be improved if not only the information about the temperature difference, but also 
about the ambient temperature (Figure 3) would be stored. While ODMs measuring tempera­
ture difference often allow differentiation of whether the patch was on the eye or not, the 
devices recording patch­skin contact only provide the information whether the patch was 
detached. Obviously neither device is able to detect patching of wrong eye. Hence the ODM 
helps to recognise many deceptions but it cannot be used as a lie detector. Cooperation of 
patients and parents remains important. However, it is easier for parents to say that the child 
does not like the patch than to stick the ODM for weeks somewhere else than to their child’s 
eye (Fielder, et al. 1995). 
Apart from some technical limitations, ODMs provide objective information on dose­response 
function for occlusion therapy and compliance (Loudon, et al. 2004; Stewart, et al. 2004). Low 
acuity increase of the amblyopic eye has been shown to be caused by the lack of adherence 
to prescribed therapy (Loudon, et al. 2003). Recent studies monitoring occlusion revealed av­
erage compliance of 50­60% (Loudon, et al. 2004; Stewart, et al. 2002). This raised concerns 
(Fleck, et al. 2003) about the reliability of the occlusion treatment trials without electronic 
compliance monitoring. The ATS (Holmes, et al. 2003) and ROTAS (Stewart, et al. 2004) studies 
both found that 6 h and 12 h of prescribed occlusion led to similar visual outcomes. However, 
electronic monitoring revealed significantly more visual improvement in children receiving 
the higher occlusion dose (Stewart, et al. 2004). 
Using the ODMs was convenient for the parents. They found the documentation of the occlu­
sion duration more bothersome and sometimes forgot it. Carrying the patch with the device 
on it was no more inconvenient for children than the patch alone, because the patch itself 
was the bothering factor. However, the long­term use of the ODMs was time­intensive for the 
researches: to achieve a continuous registration of occlusion, families had to be visited every 
week because the capacity of the battery and the memory of the device were limited. Evalu­
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ation of the record for 1 week took about 30 min. A programmeme for quick and convenient 
data evaluation has just been completed (Kosowski, Chopovska, manuscript in preparation). 
Higher capacity of the battery and memory would enable use the ODMs on a larger scale.
It would be an important advance if patients could be offered amblyopia therapy that consid­
ers established and evidence­based factors influencing the outcome. The ODM may be an 
important contribution. 
AcknowLEdGEmEnTS
We gratefully acknowledge the Albert von Metzler and Edith von Heyden Foundations and 
the association “Augenstern e. V.” for financial support of this study. Thanks are due to Prof. 
Ohrloff for continuous support of our research, to Dr. Ackermann from the Biomathematics 
Department of the University of Frankfurt for help with statistics and to Valeria Petkova for 
research assistance.

ch
ap
te
r 1
ch
ap
te
r 2
ch
ap
te
r 3
ch
ap
te
r 4
ch
ap
te
r 5
ch
ap
te
r 6
ch
ap
te
r 7
ch
ap
te
r 8
ch
ap
te
r 9
ch
ap
te
r 1
0
ch
ap
te
r 1
1
A
dd
en
da
Chapter 6
Electronically measured compliance with 
occlusion therapy for amblyopia is related to 
visual acuity increase
78
ABSTrAcT
Purpose: We set out to determine whether the children who have low compliance (measured 
electronically) with occlusion therapy for amblyopia are those with insufficient increase of 
visual acuity. 
methods: In 14 newly identified amblyopic children (mean age 4.3 ± 1.9 years), compliance 
was measured electronically over a period of 1 week, 6 months after the start of occlusion 
therapy. Compliance was measured with an Occlusion Dose Monitor (ODM). The measure­
ments took place during planned domiciliary visits. The children were diagnosed with aniso­
metropia (n = 5), strabismus (n = 4) and anisometropia and strabismus (n = 5). Compliance was 
expressed in percentages of the electronically registered time compared with the prescribed 
occlusion time. Satisfactory acuity increase following 6 months of occlusion therapy was de­
fined on reaching any of the following criteria: acuity increase expressed as a ratio between 
acuity of the amblyopic eye and acuity of the good eye more than 0.75, acuity of the amblyo­
pic eye exceeding 0.5 as measured on the E­Chart or Landolt­C, or three logMAR lines of acuity 
increase.
results: Measured compliance averaged 80% in the eight children who had a satisfactory 
acuity increase and 34% in the six children who had an unsatisfactory visual acuity increase. 
Children with low acuity increase had statistically significant lower compliance (P = 0.038). 
conclusions: The general assumption among orthoptists, that compliance with occlusion 
therapy for amblyopia is low in children with insufficient acuity increase, has been validated 
by electronic, objective means.
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InTroducTIon
Amblyopia is a reduction in best corrected visual acuity without any evidence of an organic 
eye disease. It affects up to 3.25% of the children and is the most common eye disorder in 
childhood, accounting for over 90% of the visits of children to ophthalmologists and orthop­
tists (Moseley, et al. 1997; Sjöstrand and Abrahamsson 1997; Attebo, et al. 1998). As Child 
Health Care Centres in The Netherlands check for the presence of strabismus from birth and 
measure visual acuity at the age of 3 years, it is rare for amblyopia to go undetected (Lantau, et 
al. 1999). The primary treatment for children with amblyopia is to occlude the better eye, with 
regimens ranging from a few hours of occlusion per day to all waking hours. Approximately 
a third of the children diagnosed do not attain visual acuity of 0.5 and are therefore unable 
to read with the amblyopic eye (Jensen and Goldschmidt 1986). Some amblyopic children 
­ in one study the proportion was estimated at 0.175% (Tommila and Tarkkanen 1981) ­ will 
loose the function of the better eye later in life. Low acuity increase of the amblyopic eye is 
frequently caused by lack of compliance with prescribed therapy. This was confirmed in a 
recent study by Dorey et al., which indicated that when offering occlusion on an in­patient 
supervised basis for a period of five days to patients with low compliance, an acuity increase 
of three lines could be measured in the amblyopic eye during these five days (Dorey, et al. 
2001). 
In 1991 Fielder and Moseley developed an Occlusion Dose Monitor (ODM), enabling the elec­
tronic measurement of compliance with the prescribed occlusion regime for the treatment 
of amblyopia (Fielder, et al. 1994; 1995). Stewart et al. are currently investigating the relation­
ship between prescribed hours of occlusion and the increase in visual acuity (dose­response 
relationship) with the ODM. They concluded that occlusion therapy was most effective in the 
first few weeks of treatment. Moreover, the acuity increase is positively related to the actual 
hours of occlusion and age of the patient; children younger than five years showed a greater 
improvement (Moseley, et al. 2001; Stewart, et al. 2002).
In 1996 and 1997 we were able to reduce the ODM to the size of a coin (Simonsz, et al. 1997) 
and it was used in a first pilot study. In that study compliance was found to be moderate in 
many cases. In some children compliance was measured four to seven times over a 2­year 
period. Interestingly, the patterns of non­compliance remained the same for one child and 
were apparently case specific (Simonsz and Polling 2001). In 1999 a second pilot study was 
conducted to determine whether the ODM could be used in a clinical setting. In the clinic 
of the Sophia Children’s Hospital Rotterdam the orthoptists distributed the ODM to patients 
whose compliance was thought to be low. Parents, however, interpreted the ODM as a ‘lie­de­
tector’, resulting in a breakdown in the relationship between them and orthoptist (Simonsz, 
et al. 1999).
In this present study, compliance was measured in all newly identified amblyopic children 
over a period of 1 week, 6 months after the start of occlusion therapy. The purpose was to 
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determine whether the children whose acuity had not improved sufficiently after six months 
of patching were indeed the children with low compliance.
mEThodS And mATErIALS
Subjects
For the period July to December 2000 all newly identified amblyopic children visiting the 
Sophia Children’s Hospital in Rotterdam were registered. On their first visit to the clinic, age, 
diagnosis, acuity, ocular alignment, binocular vision, fixation, cycloplegic refraction and ther­
apy were documented. Acuity was measured every 3­4 months using the Amsterdam Picture 
Chart (APK) and, in older children, the E­Chart or the Landolt­C. Compliance was measured 
electronically over a time period of 1 week, 6 months after the start of occlusion therapy. 
Parents were first contacted by telephone and were asked to give full oral informed consent 
during a subsequent domiciliary visit. The parents were provided with information on the 
exact purpose of the study, how the device worked and were shown exactly how to apply the 
patch with the ODM on the eye. Any questions put forward by the parents were answered. The 
ODM was collected after 1 week. In total, 19 children were recruited. However, the ODM failed 
Table 1. Characteristics of 14 patients in whom compliance was measured: in particular, the acuity in the 
amblyopic eye before and after 6 months of occlusion therapy and the method used to measure visual 
acuity (APK=Amsterdam Picture Chart).
No Age 
(yrs)
Diagnosis Prescribed 
occl per day
Percentage 
compliance
Acuity ambl 
eye before 
occl 
Acuity ambl 
eye after 6 
mo. 
Method
1 5.5 anisometropia & strabismus 1 h 100% 0.5 1.25 Landolt­C
2 5.3 anisometropia & strabismus 30 min 87% 0.25 1 E­Chart
3 4.5 anisometropia 4.5 h 98% 0.1 1 APK
4 5 anisometropia 1 h 81% 0.63 1 APK
5 2 strabismus 30 min 83% 0.5 0.9 APK
6 6.7 anisometropia & strabismus 3 days/week 51% 0.32 0.63 APK
7 2.5 strabismus 1 h 84% 0.5 0.7 APK
8 1.5 strabismus 1 h 100% 0.1 0.8 APK
9 4.9 anisometropia 2 h 5% 0.63 1.25 APK
10 5 anisometropia & strabismus 4 h 2% 0.15 0.5 E­Chart
11 2 strabismus 15 min 41% 0.7 0.7 APK
12 6.7 anisometropia 1 h 9% 0.03 0.17 APK
13 6.4 anisometropia 1 h 80% 0.78 1.25 Landolt­C
14 1.9 anisometropia & strabismus 1 day/week 19% 0.3 0.5 APK
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in two cases due to technical difficulties and in two other children reliable visual acuity could 
not be obtained. Also, one parent experienced problems with occluding her child’s eye due 
to the child’s other difficulties (Down syndrome). Thus, 14 reliable recordings were obtained. 
These fourteen children (mean age 4.3 ± 1.9 years) had diagnoses of anisometropia (n = 5), 
strabismus (n = 4) and anisometropia and strabismus (n = 5). Prescribed occlusion time varied 
from 15 min per day to 3 full days of occlusion per week (Table 1). The children were assigned 
a number corresponding to their date of entry into the study.
occlusion dose monitor (odm)
Compliance was determined by means of the ODM. The ODM measured 35x23x4 mm and 
weighed 6 g. The back of the ODM was fixed to the front of the patch with double­sided ad­
hesive tape. At 3­min intervals the ODM registered the temperature difference between the 
front and back of the device. Applying the patch with the ODM to the child’s eye resulted in 
a typical temperature difference for as long as the patch remained on the eye; the difference 
was zero the rest of the time. After 1 week the ODM was collected and the computerised read­
out provided information on when and for how long the child had worn the patch. 
outcome variables
Compliance was defined as the number of hours of patch wear per week (as measured by the 
ODM) divided by the number of hours prescribed by the orthoptist. In this way compliance 
could be expressed as a percentage.
Sufficient acuity increase after 6 months of occlusion therapy was defined as attainment of 
any one of the following criteria: a ratio between acuity of the amblyopic eye and acuity of 
the good eye of more than 0.75 using the APK, acuity of the amblyopic eye exceeding 0.5 as 
measured on the E­Chart or Landolt­C or three LogMAR lines of increase in acuity. If the acuity 
increase of the child fulfilled any of these criteria, he/she was categorized as having sufficient 
acuity increase.
rESuLTS
Three cases selected arbitrarily from our study serve to illustrate our method.
Case 3
A 4.5­year­old patient with anisometropia was prescribed 4.5 h of occlusion every day. The 
patient had an acuity increase in the amblyopic eye from 0.1 to 1.0 at 6 months after the start 
of occlusion therapy, measured with the APK. Acuity in the good eye was 1.0. His recordings 
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showed that occlusion was carried out for 4.4 h per day on average, resulting in a compliance 
of 98%.
Case 6
A 6.7­year­old girl with anisometropia and strabismus was prescribed 3 days of occlusion per 
week. Acuity in the amblyopic eye improved from 0.32 to 0.63. Recordings showed only 1.5 
days of occlusion was managed, compliance averaging 51%.
Case 8
A 1.5­year­old patient with strabismus was prescribed 1 h of occlusion daily. Figure 1 illus­
trates the occlusion routine as measured by the ODM. 
From the recordings compliance was 100%; the patient wore the patch every day late in the 
afternoon for 1 h, except for one day. To compensate for this the mother had her child wear 
the patch for 2 h the next day. The flutter in the ODM reading was caused by minimal tempera­
ture fluctuations around the threshold value. The acuity in the patient’s amblyopic eye had 
improved from 0.1 to 0.8 at 6 months after commencing the occlusion therapy.
In the 14 children in the study acuity was measured at each visit to the orthoptist. The acu­
ity increase was assessed according to the given criteria. Based on these criteria the children 
were divided into two groups, those with satisfactory and those with unsatisfactory acuity 
increase after 6 months of occlusion therapy. These criteria were based upon our clinical ex­
perience and may be arbitrarily chosen. 
Figuren bij Chapter 6. 
 
 
 
Figure 1. One-and-a-half-year-old patient with Cohen Syndrome, craniosynostosis, infantile esotropia; 
1h of occlusion every day. The ordinate represents the temperature difference between the front and 
back of the ODM. The ODM is set at 1260 mV, meaning no temperature difference between the front 
and back of the ODM. The abscissa represents the corresponding days; vertical lines indicate midnight. 
The child wore the patch every day (rectangular peaks), except for one, so she wore a patch for 2 h the 
following day. 
 
 
Figure 1. One­and­a­half­year­old patient with Cohen Syndrome, craniosynostosis, infantile esotropia; 1h 
of occlusion every day. The ordinate represents the temperature difference between the front and back of 
the ODM. The ODM is set at 1260 mV, meaning no temperature difference between the front and back of 
the ODM. The abscissa represents the corresponding days; vertical lines indicate midnight. The child wore 
the patch every day (rectangular peaks), except for one, so she wore a patch for 2 h the following day.
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The electronically measured compliance was compared in the two groups. In the children 
who achieved satisfactory acuity increase after 6 months of occlusion (n = 8), average compli­
ance was found to be 80% (SD 32%). In the children who did not attain a satisfactory acuity 
increase after 6 months of patching (n = 6), average compliance was found to be 34% (SD 
31%), (Figure 2).
Compliance was significantly lower in those children who did not reach a sufficient acuity in­
crease according to the criteria than in those who did reach a sufficient acuity increase (Mann­
Whitney; P = 0.038).
During this study we came upon several factors influencing the outcome, which will be con­
sidered further in the discussion section. However, one confounding factor was a 5­year­old 
patient with anisometropia, whose compliance was 5% yet achieved an improvement of acu­
ity in the amblyopic eye 0.63 to 1.25. He was prescribed 2 h of occlusion therapy every day 
and, simultaneously, a pair of spectacles. This was the only patient with no prior adaptation to 
the prescribed spectacles. If this patient were omitted from the analysis the significance of the 
relationship between acuity increase and compliance would increase to P < 0.01. 
In contrast to the general assumption, children with low acuity at the start of the occlusion ther­
apy did not necessarily have low compliance. Of the seven children whose acuity was less than 
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Figure 2. Graphic representation of the relationship between acuity increase during treatment and 
electronically measured compliance. The ordinate represents the ratio between visual acuity in the 
amblyopic eye and the acuity in the good eye. The abscissa represents the months after the start of 
occlusion therapy. On the right: patient number corresponding to the actually measured compliance in 
percentages in parenthesis. Lines with a square ■ represent patients with high compliance; lines with a 
triangle ▲represent low compliance, corresponding to the visual acuity increa e after 6 months of 
occlusion therapy. 
Figure 2. Graphic representation of the relationship between acuity increase during treatment and 
electronically measured compliance. The ordinate represents the ratio between visual acuity in the 
amblyopic eye and the acuity in the good eye. The abscissa represents the months after the start of 
occlusion therapy. On the right: patient number corresponding to the actually measured compliance 
in percentages in parenthesis. Squares represent patients with high compliance; circles moderate 
compliance; triangles represent low compliance, corresponding to the visual acuity increase after 6 
months of occlusion therapy. For colour figure please see ‘ Colour figures’ on page 196.
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0.5 at the start of occlusion therapy, three attained a sufficient acuity increase ­ their compliance 
ranged from 87% to 100%. In the other four children with low acuity at the start of the occlusion 
therapy compliance ranged from 2% to 51% and the acuity increase was insufficient. 
dIScuSSIon
This study has demonstrated that there is a statistically significant relationship between acuity 
increase and compliance measured by objective means. Children with insufficient improve­
ment in the acuity of the amblyopic eye were indeed the children who hardly ever wore their 
patch or not at all. Although our study population was relatively small we were able to identify 
several factors, either confounding or otherwise affecting compliance, that influenced this 
relationship.
Firstly, an outlier in the data was a patient with anisometropia (case number 9), with a compli­
ance rate of 5%, yet an acuity increase from 0.63 to 1.25 as measured with the APK. This patient 
had been prescribed a pair of spectacles, however, in addition to 2 h of occlusion therapy per 
day. This supports Fielder’s argument that first the spectacles should be prescribed, followed 
by occlusion therapy 3­4 months later, if still necessary (Moseley, et al. 1997). In this study this 
patient was the only patient who had been prescribed occlusion without prior adaptation to 
the prescribed spectacles. 
Secondly, patient number 10 visited four orthoptists in different hospitals and received four 
different prescriptions for occlusion tine. After the last of these four visits, to the orthoptist in 
our hospital, she was prescribed 4 h of occlusion every day. Compliance in this case was 2%. 
Apparently, inconsistent prescription of occlusion hours is not conducive for compliance. 
Thirdly, in two cases full days of occlusion were prescribed: in case number 6, 3 days of occlu­
sion per week and in case number 14, 1 day. Here compliance was found to be relatively low: 
51% and 19%, respectively. This low compliance may, of course, be coincidental, but could 
also be the result of the lack of a daily routine with the occlusion therapy. 
A fourth parameter influencing the outcome was age and acuity of the patient at the start of 
therapy. The acuity increase was slightly higher in younger patients and was also higher in the 
children who started with very low acuity. This finding was confirmed by Stewart et al. (Mose­
ley, et al. 2001; Stewart, et al. 2002). 
Finally, it became apparent that the prescription of occlusion, even in similar cases, varies 
considerably among orthoptists and may have varied among the orthoptists treating the chil­
dren in this study. In order to identify the variation, and the determining factors in the pre­
scribing of occlusion therapy, a questionnaire was presented to 177 Dutch and 227 German 
orthoptists. This questionnaire comprised the cases of five sample amblyopic children. The 
orthoptists were asked to decide their prescribed hours of occlusion for the five cases within 
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10 min simultaneously. They were not allowed to discuss the cases with each other. The survey 
showed a wide variation in prescribed hours of occlusion in each of the five cases (Loudon, 
et al. 2002). As a result there is difficulty in expressing compliance in the form of percentages, 
because there is no standardisation of prescription for occlusion therapy. 
All the parents were aware that a recording of the occlusion was being made. This could influ­
ence compliance, in a sense that compliance would be better in the week of electronic mea­
surement. This argument is not confirmed by the data, however; compliance was moderate 
in many cases, despite the fact that the parents were fully informed. It seems that the child’s 
presumably unvarying dislike of the patch plays an important part.
Compliance was measured for only 1 week because of the considerable risk of losing the rath­
er expensive ODM device at the home or outside in the playground: in one case the device 
ended up in the washing machine and tumble dryer. The final outcome of visual acuity of the 
amblyopic eye was not likely to be influenced by 1 week of better compliance out of 13 weeks 
of treatment, however. 
Recently the effectiveness of occlusion therapy for amblyopia has been questioned by Snow­
don & Stewart­Brown (Snowdon and Stewart­Brown 1997). They maintain that occlusion 
therapy has not yet been subjected to formal controlled trials and that much of the improve­
ment in acuity could be spontaneous and unrelated to the therapy. However, they may have 
overlooked the possibility that the lack of evidence for the efficacy of occlusion is due to low 
compliance rather than to ineffectiveness of the treatment. 
Currently we are performing a randomised controlled trial in The Hague among 200 newly 
identified amblyopic children to investigate ways of enhancing compliance cost­effectively 
and identifying certain predictors for non­compliance. 
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Chapter 7
Predictors and a remedy for non-compliance 
with amblyopia therapy in children 
measured with the occlusion dose monitor
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ABSTrAcT 
Purpose: Non­compliance is one of the limiting factors in the success of occlusion therapy 
for amblyopia. Electronic monitoring was used to investigate predictors of non­compliance 
and, in a prospective randomised clinical trial, determined the effectiveness of an educational 
programme.
methods: Compliance was measured electronically during one week every three months 
in 310 newly diagnosed amblyopic children. The family’s demographic parameters and the 
child’s clinical parameters were assessed for their influence on the level of compliance. In ad­
dition to standard orthoptic care, children were randomised to receive an educational car­
toon story, reward stickers, and an information sheet for the parents (intervention group), or 
a picture to colour (reference group). These and the electronic device were distributed during 
home visits by researchers. The primary outcome measure was the percentage of compliance 
(actual/prescribed occlusion time) in the two groups. The secondary outcome measure was 
the influence of demographic and clinical factors on compliance. 
results: Compliance was associated with parental fluency in the national language, country 
of origin, level of education, and initial visual acuity of the child. During the first one­week 
measurement period children in the intervention group had better compliance than the refer­
ence group had (78% ± 32% vs. 57% ± 40%; P < 0.0001), and fewer children were not occluded 
at all (3 vs. 23 in the reference group; P < 0.0001). This difference remained throughout the 
study period.
conclusions: Poor parental fluency in the national language, a low level of education and 
were predictors for low compliance. Education, primarily aimed at the child, improved poor 
acuity at the start of treatment were predictors for low compliance. Education, primarily aimed 
at the child, improved compliance and reduced the number of children who did not comply 
with occlusion at all. 
Additional data for this chapter were collected at the Department of Ophthalmology, 
J.W.Goethe University, Frankfurt am Main, Germany as part of the Dr.med thesis of Larisa 
Pepler and at the Department of Ophthalmolgy of the University of Leicester, Great Britain 
by Musarat Awan.
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InTroducTIon
Amblyopia, with a prevalence of 3.5% (Attebo, et al. 1998; Brown, et al. 2000; Vinding, et al. 
1991), is loss of visual function, usually unilaterally, caused by strabismus, anisometropia and/
or visual deprivation. It is commonly treated with patching of the non­amblyopic eye, prefer­
ably before the age of 6. Approximately one third of the affected children do not reach visual 
acuity of 6/12 in the amblyopic eye (Jensen and Goldschmidt 1986; Vinding, et al. 1991), there­
by increasing the risk of bilateral visual impairment due to loss of vision in the nonamblyopic 
eye (Chua and Mitchell 2004; Fronius, et al. 2005; Rahi, et al. 2002) and decreasing quality of 
life in adulthood (van de Graaf, et al. 2004). Treatment effectiveness was questioned in a report 
published by Snowdon and Stewart­Brown in 1997 (Snowdon and Stewart­Brown 1997) that 
contributed to the setup of five randomised controlled trials (RCTs) (Awan, et al. 2005; Clarke, 
et al. 2003; PEDIG 2002; 2003a; 2003b). These produced evidence of treatment effectiveness. 
Many other studies have suggested that one of the factors influencing outcome with treat­
ment is the level of compliance (Dorey, et al. 2001; Fielder, et al. 1994; Flynn and Cassady 1978; 
Lithander and Sjöstrand 1991; Simmers, et al. 1999; Simons and Preslan 1999; Simonsz, et al. 
1999; Smith, et al. 1995; Stewart, et al. 2004; 2005; Woodruff 1995). Low compliance was found 
to be associated with social deprivation (Smith, et al. 1995) and lower attendance rates were 
reported among amblyopic patients from more deprived areas (Bowman, et al. 1996). 
In general, compliance is referred to as the degree of correspondence between the recom­
mendations from the healthcare provider and the patients’ actual dosage (Urquhart 1992). 
Poor compliance decreases the effectiveness of treatment and increases costs to the health­
care system (Cleemput and Kesteloot 2002). Especially in pediatric patients, low levels of com­
pliance have been found across a range of treatments and are an important obstacle to pro­
viding effective healthcare in long­term treatments (Dunbar 1983; Farley, et al. 2003; Milgrom, 
et al. 1996; Parrish 1986). 
Reported rates of compliance depend on the mode of measurement: pill count, patients’ re­
port, appointment­keeping behavior, blood tracers or electronic measurements, for example 
(Cramer, et al. 1989; Kass, et al. 1986; de Klerk and van der Linden 1996; Urquhart and de Klerk 
1998). Since the development of the Occlusion Dose Monitor (ODM) by Fielder and Moseley 
(Fielder, et al. 1994), compliance with occlusion therapy for amblyopia can be measured elec­
tronically. By means of the ODM, it has been demonstrated that, generally, compliance with 
amblyopia treatment is low and treatment success is related to the level of compliance (Awan, 
et al. 2005; Loudon, et al. 2003; Simonsz, et al. 1999; Stewart, et al. 2004; 2005). Therefore, pro­
grammes designed to improve compliance are being distributed, and it has been concluded 
that increasing parents’ understanding of the disease may contribute to improved compliance 
(Goransson, et al. 1998; Newsham 2002). However, no study has provided evidence of whether 
compliance can be improved in concurrence with the electronic monitoring of that compli­
ance. The primary purpose of this study was, by means of electronic monitoring, to assess the 
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effectiveness of a newly developed educational cartoon story explaining to the child, without 
text, the rationale for treatment, combined with reward stickers and an information sheet for 
the parents. As a secondary purpose, it identified demographic and clinical factors determin­
ing compliance.
mEThodS
Patient selection 
Children were recruited from four clinics by six treating orthoptists in The Hague between July 
2001 and December 2003. The study area consisted of The Hague (approximately 442,000 in­
habitants), the third largest city in The Netherlands. It is a very ethnically and culturally diverse 
city with 58% of the population having Dutch nationality, 10% of Surinam, 6% of Turkish, and 
5% of Moroccan nationality; and 21% of other nationalities. Additional children were recruited 
in Frankfurt am Main (Germany) and in Leicester (United Kingdom). 
Included were all children with newly diagnosed amblyopia (i.e., never treated for amblyo­
pia) with an interocular difference in visual acuity of at least 0.2 logMAR (logarithm of the 
minimum angle of resolution) that persisted after 6 weeks of spectacle correction, strabismus 
and/or anisometropia (>1.0 D), or a deprivation in the absence of additional ocular or neuro­
logical diseases. 
Exclusion criteria were previous treatment for amblyopia, a neurological disorder, other eye 
disorders, and diminished acuity due to medication, brain damage or trauma. The Ethics Com­
mittee of Erasmus University Rotterdam and the boards of the participating clinics approved 
the protocol and informed consent forms. Written informed consent by the parents or guard­
ian was a prerequisite for participation. The research adhered to the tenets of the Declaration 
of Helsinki.
Standard orthoptic care
Eligible children received a routine ophthalmic examination and explanation of diagnosis and 
treatment by the treating orthoptist. Binocular vision, ocular motility, cycloplegic refraction, 
and visual acuity were assessed. For this study, the charts used to assess visual acuity depend­
ed on the age: children aged 2.5 to 4 years: Amsterdam Picture Chart (uncrowded, linear op­
totypes; Medical Workshop, Oculus, Groningen, The Netherlands); children aged 4 to 5 years: 
E­chart (uncrowded, linear optotypes; Medical Workshop, Oculus); children aged 5 and older: 
Landolt­C (uncrowded; linear; Medical Workshop, Oculus). In children younger than 2.5 years, 
or otherwise unable to cooperate with the visual acuity tests, decimal equivalences were used 
for the following categories: far eccentric fixation and no pursuit when looking monocularly, 
91
ch
ap
te
r 7
Predictors and a remedy for non­compliance with amblyopia therapy
fierce protest when covering the better eye, 0.1; eccentric fixation and hardly any pursuit 
when looking monocularly, considerable protest when covering the better eye, 0.3; cannot 
maintain fixation and saccadic pursuit when looking monocularly, some protest when cover­
ing the better eye, 0.5; prefers fixation with the other eye and almost smooth pursuit when 
looking monocularly, 0.7; alternating freely and smooth pursuit when looking monocularly, 
no dominance found in 4­PD base­out tests; 0.9. 
The severity of amblyopia was expressed as the ratio (in decimals) between the acuity in the 
amblyopic eye and the better eye, to minimize the influence of possible differences in testing 
conditions. The acuity data were expressed as decimal scores. 
Anisometropic amblyopia was defined as an amblyopia in the presence of anisometropia 
>1.0D of spherical equivalent or >1.5D difference in astigmatism in any meridian, with no 
measurable heterotropia at distance or near fixation. Spectacles were prescribed in case of 
anisometropia >1.0D, astigmatism >1.5D, hypermetropia (spheric equivalent) >1.5D. Occlu­
sion therapy commenced after a minimum of 6 weeks’ adaptation to the spectacles. 
Few guidelines exist when prescribing a certain number of occlusion hours; therefore, in this 
study, the duration of occlusion (number of hours per day) for the first prescription was stan­
dardized in a focus group consisting of the treating orthoptists, as experts in the field. They 
were given example cases of persons in whom diagnosis, visual acuity, and age varied and 
were asked to prescribe the number of occlusion hours per day. Diagnosis proved to be of 
little importance and the relationship between the two other parameters (visual acuity and 
age) could be represented by: ­6.63 * ratio acuity amblyopic eye/acuity better eye + 0.5 * age 
(years) + 4.97. For example, for a 3­year­old child with an acuity ratio of 0.6, the number of 
hours would then be: ­6.63 * 0.6 + 0.5 * 3 + 4.97, which equals ≈ 2.5 hours of occlusion per day. 
A table was then developed from which the orthoptists could directly read off the daily num­
ber of occlusion hours to be prescribed. It was not possible to standardize subsequent pre­
scriptions of occlusion therapy, as the treating orthoptists wished to proceed on an individual 
basis, dependent on treatment success. All children were seen by the treating orthoptist for 
routine assessment every 3 to 4 months. This schedule continued independently of the elec­
tronic recordings of compliance. After each examination, the treating orthoptist completed 
and forwarded a standard examination form to the research center. Occlusion therapy was 
terminated when the interocular difference in visual acuity was one logMAR line or less on 
two consecutive visits to the orthoptist.
The researchers visited the participating orthoptists at their clinic 10 times over a 1­year pe­
riod (January 2002­January 2003). The total time spent on taking patient history, examining 
the child, and explaining the diagnosis and treatment was recorded per child. A distinction 
was made between children who visited the orthoptist for the first time and follow­up visits.
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randomisation 
After the first visit to the treating orthoptist, parents of children with newly diagnosed am­
blyopia were contacted by telephone by the researchers to obtain verbal consent and an ap­
pointment for a home visit. Before the home visit, each patient was randomised to either the 
intervention group or the reference group, using permuted blocks of length six. That is, when 
six children were randomised, three were allocated to the intervention group and three to 
the reference group, in a random order. Children in the intervention group received the edu­
cational programme; children in the reference group received a picture to colour. During the 
home visit, the researcher explained the nature and possible consequences of the study and 
use of the ODM, and full written informed consent was obtained. 
Compliance was measured with the ODM, in all children during an entire week every 3 
months. It was attached to the front of the occlusion patch with double­sided adhesive tape 
and measured the temperature difference between the front and back of the ODM every 2 
minutes. The device has been extensively tested, including the ability to differentiate between 
measurements on the eye and on other parts of the body, and has been found satisfactorily 
reliable (Chopovska, et al. 2005). In case of an unsuccessful recording due to battery failure (no 
data at all or less than 7 days of data), a broken or lost ODM, the one­week­measurement with 
the ODM was repeated the subsequent week. 
The study was designed as a prospective, single blind, randomised clinical trial. The researcher 
who made the home visits was aware of randomization. The treating orthoptist, however, was 
blind to group assignment, and randomization took place after the first visit to the orthoptist. 
Time spent on each home visit was approximately equal for children in both groups – that is, 
45 minutes for a first home visit and 10 minutes for a following visit, and all parents were given 
the same explanation. The distribution of the ODM via home visits minimized the number of 
withdrawals from the study: home visits continued even when the parents failed to attend 
their clinic appointments.
Assessment of demographic and clinical factors affecting compliance
The socioeconomic and ethnic background of the families was assessed via a 23­item ques­
tionnaire registering the highest level of education of either parent (scores from 1 to 5, with 
1 representing “no education” and 5 “university”); the mother’s native country; material fac­
tors including housing and employment status; religion; family structure; age of the parents; 
and the parents’ marital status. The highest level of education of either parent indicated the 
socioeconomic status. This questionnaire was filled in during the first home visit. The mothers’ 
fluency in the national language was rated by the researchers (scores from 1 to 5, with 1 repre­
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senting “not speaking the national language [Dutch, German, or English] at all”; 3, “moderate 
fluency”; and 5, “excellent fluency” [see also legend Table 1]).
The clinical factors studied included age at start of treatment, cause of amblyopia, visual acu­
ity at start of treatment, binocular vision, and sex. 
Intervention protocol 
Intervention group 
Children received the educational cartoon story, a calendar with reward stickers, and a one­
page information sheet for the parents. 
The cartoon story was designed for this study by two artists specializing in art for sick chil­
dren (José Vingerling and Gerard de Bruyne) together with two specialists from the Municipal 
Health Service, The Hague (Karen Bree and Nicole Goedee). The educational programme was 
developed considering the most efficient way to transmit the message and whether to target 
the parent or the child. It was designed as a cartoon story, without text, as most of the children 
treated for amblyopia are too young to read. The cartoon depicts the orthoptic examination 
of a preschool child, subsequent patching therapy, and the reasons for therapy seen from the 
perspective of the child. As no animal figures were included, the children were more able to 
identify themselves with the child depicted in the story. The cartoons could not be linked to a 
certain ethnic or cultural group. A sheet containing general information about amblyopia and 
its treatment for the parents was made in eight languages and distributed with the cartoon 
story only during the first home visit. 
Reference group 
Children were given a picture to colour (e.g., Mickey Mouse or Winnie the Pooh) that was also 
considered a reward, but did not contain the educational message.
At the three monthly home visits, the ODM was delivered and children were given the next 
episode of the cartoon story (intervention) or a different picture to colour (reference). No spe­
cific instructions were given for the use of the cartoon story, the calendar with stickers, and 
the information sheet or, in case of the reference group, the picture to colour. To determine 
whether the material was used, parents were asked to fill out a short questionnaire assessing 
duration and frequency of usage of the cartoon story and the picture to colour during the 
intervening period. 
outcome measures and statistical analysis
Calculation of the sample size was based upon previous compliance studies of other diseas­
es that used electronic monitoring to measure compliance (Cramer, et al. 1989; Kass et al. 
1986; de Klerk and van der Linden 1996; Urquhart and de Klerk 1998). These results showed 
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a normally distributed relationship between the number of patients and the percentage of 
compliance with a maximum at approximately 80%­90%, an average of 68% and a SD of 22%. 
To reach an effect size of 3%, 2 x 150 was necessary.
The main outcome was the level of compliance in the two treatment groups, defined as the 
actual occlusion time measured with the ODM divided by the prescribed occlusion time and 
expressed as a percentage. This calculation was made for each child separately for each week 
of measurement with the ODM. The recruitment of patients continued for 30 months. On av­
erage, a child received three electronic measurements (ranging from one to a maximum of 
seven measurements) during, on average, 8 months of treatment. The effect of the educa­
tional programme on compliance was determined in a multilevel analysis in which all avail­
able weeks of ODM monitoring were used, corrected for the differences in the number of 
observations during follow­up. This analysis was used to estimate compliance of all included 
children throughout the treatment. The difference in percentages of compliance in the two 
treatment groups was assessed with least­squares regression analysis. Testing for an unequal 
distribution of baseline characteristics between the randomization groups was performed 
with logistic regression (Wald test). 
The second research question was the influence of demographic and clinical factors on the 
level of compliance. We used least­squares regression analysis on the data from the first entire 
one­week measurement with the ODM only, because it was certain that at this moment the 
number of occlusion hours had been prescribed according to protocol and that the orthop­
tist was unaware of randomization. The results of the univariate analysis are presented first; 
the influence of potential confounding is corrected for in the multivariate analysis. P < 0.05 
indicated statistical significance. The percentage of the variation in compliance that could be 
ascribed to the different factors involved was defined as the ratio of the percentage of the 
variance explained by the model, with and without the factor in question.
It would have been desirable to have final visual acuity as an outcome measure; however, the 
statistical noise between compliance and visual acuity increase, as measured in current or­
thoptic practice, would have led to the treatment groups’ becoming excessively large. There­
fore, the primary outcome measure was restricted to electronically measured compliance.
Children were included in the analysis when they had received at least one entire one­
week measurement. When parents refused further participation in the study after the first 
one­week­measurement, they were asked their consent as to whether the previous ODM 
measurement(s) and their child’s baseline characteristics could be used for analysis. Only the 
data of the children, whose parents agreed remained in the study (n = 6; intervention group; 
n = 5; reference group). Children who moved out of the area and consequently received no 
further ODM measurements were included in the analysis.
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Figuren bij Chapter 7. 
 
 
 
Figure 1. The study design. Recruitment of children continued for 30 months (July 2001-December 
2003), and compliance was monitored 1 week every 3 months. The 6-month follow-up with the ODM 
finished in June 2004. It follows that the first children included received most measurements; on 
average, a child received 3 one-week measurements. 
 
Figure 1. The study design. Recruitment of children continued for 30 months (July 2001­December 2003), 
and compliance was monitored 1 week every 3 months. The 6­month follow­up with the ODM finished 
in June 2004. It follows that the first children included received most measurements; on average, a child 
received 3 one­week measurements.
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rESuLTS
Study population
Of the 418 recruited children, 310 (74%) were eligible for analysis (Figure 1). Of these, 20 chil­
dren were recruited in Frankfurt (18 participated) and 4 in Leicester. There was no difference in 
frequency of withdrawal of participants between the clinics. Throughout the study, 12 children 
from the intervention group no longer attended their appointments in the clinic; of those, 5 
also refused further study participation. In all, parents of 13 children refused further study par­
ticipation. In the reference group, 17 children no longer attended their appointments in the 
clinic; of those, 8 also refused further study participation. In all, parents of 19 children refused 
further study participation. During the study, four children (two from either group) were lost 
to follow­up (moved out of the area). 
The birth rate in The Hague was approximately 5,071 children in the year during which most 
of the children in the study were born (i.e., 1997). In this study, 394 were registered for a period 
of 2.5 years, indicating that 3.1% of the children born were included in this study. 
In case the ODM was lost or broken or the recording failed, the one­week­measurement was 
repeated the subsequent week. During the study period, 13 parents lost the ODM and 11 
broke it (e.g., tore it apart when removing the double­sided adhesive tape), and in 29 cases, 
the ODM had incomplete data. Because of measurement failure, 15 parents refused further 
participation, but 40 children received a measurement the subsequent week.
Table 1 depicts the baseline characteristics of the included children according to their ran­
domization; both randomization groups were comparable for the baseline characteristics, in­
cluding the number of prescribed occlusion hours per day by the orthoptist. The mean age of 
the included children was 4.6 ± 2.0 years; 56% were boys. Amblyopia was associated with an­
isometropia in 140 children (mean age, 5.3 ± 1.9), with strabismus in 88 (mean age, 3.5 ± 1.9) 
and with both anisometropia and strabismus in 46 children (mean age, 4.7 ± 1.9). Five children 
had deprivation amblyopia (mean age, 3.9 ± 1.7). In 31 children, a difference in visual acuity 
of only 0.2 logMAR at baseline was found: the treating orthoptist had commenced occlusion 
therapy, although anisometropia was mild (≤1D), and there was no strabismus in these cases 
(mean age, 4.9 ± 1.2). 
Study outcome
Predictors of compliance 
This analysis was performed on the entire study population using the data obtained from the 
first one­week­measurement, as the two treatment groups were comparable for the different 
baseline characteristics (Wald test for logistic regression).
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Fluency in the national language by the mother was a significant predictor of the level of 
compliance (P = 0.018). Mean compliance ranged from 56% in the group who did not speak 
the national language at all to 72% in the group who spoke it excellently (Table 1, right­hand 
column). Univariate analysis also demonstrated the country of origin of the mother to be sig­
nificant (P = 0.018). The highest level of education attained by either parent was also signifi­
cant (P = 0.021). Mean compliance ranged from 60% in the group with no education to 73% in 
the group with an academic education. 
The child’s visual acuity at the start of treatment was the only significant clinical factor (P = 
0.033). Mean compliance ranged from 58% in children with the lowest visual acuity to 79% in 
children with the highest visual acuity. Compliance was not significantly related to the degree 
of binocular vision (P = 0.667), the type of amblyopia (P = 0.219), gender (P = 0.057) and age at 
start of treatment (although the latter was borderline significant: P = 0.050). 
After multivariate analysis the child’s visual acuity (P = 0.031) and country of origin remained 
significant (P = 0.035), level of education and fluency in the national language were not se­
lected. However, the correlation between country of origin and fluency in the national lan­
guage was too strong to be able to separate the effects of either variable (P < 0.001). Adjusted 
analysis for the country of origin demonstrated that per 10% visual acuity increase or de­
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Figure 1. The study design. Recruitment of children continued for 30 months (July 2001-December 
2003), and compliance was monitored 1 week every 3 months. The 6-month follow-up with the ODM 
finished in June 2004. It follows that the first children included received most measurements; on 
average, a child received 3 one-week measurements. 
 
Figure 2. Mean compliance (%) throughout the study for the intervention group and the reference 
group. The ordinate represents compliance (%), and the abscissa is the time after start of treatment. Solid 
regression line: compliance in the intervention group (expressed as y = b + a * x: compliance [%] = 80 
– 0.85 * treatment duration); dashed line: compliance in the reference group (compliance [%] = 55 – 2.35 
* treatment duration). Symbols represent individual children. There was considerable superimposition of 
data, especially at the 0 compliance level.
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crease, compliance would increase or decrease with 2%. Adjusted analysis for visual acuity 
(at a median level of 0.6) demonstrated levels of compliance to be 75%, 51%, 71%, 77%, for 
Native, Turkish, Moroccan or Surinam children, respectively, and 65% for children from other 
countries. 
After correction for the intervention applied, 12% of the variation in compliance could be 
explained by the demographic and clinical factors investigated in this study. 
Effect of the educational programme on compliance 
During the first one­week­measurement, mean overall compliance in the intervention group 
was 78% ± 32% compared with 57% ± 40% in the reference group (P < 0.0001; Table 1). Com­
pliance decreased over the 2­year study period on each subsequent ODM measurement, more 
so in the reference group than in the intervention group (P = 0.003; see Figure 2). 
There was no difference in the number of prescribed occlusion hours per day, neither for the 
first nor for the subsequent measurements. Figure 2 shows the relationship between mean 
compliance (measured with the ODM) and the period of treatment (in months) for the chil­
dren in the two treatment groups. Mean compliance in the intervention group and the refer­
ence group at a certain time point could be calculated using the formulas shown in the legend 
for Figure 2. There was no modification in the effect of the educational programme for visual 
 
 
Chapter 7 
Figure 3. Compliance (%) during the first electronic measurement in the intervention group (■) and the 
reference group (□). A high number of children did not use occlusion at all in the reference group (n = 
23), when compared with the intervention group (n = 3; P < 0.0001). 
Figure 3. Compliance (%) during the first electronic measurement for the intervention group (black 
columns) and the reference group (grey columns). A high number of children were not occluded at all in 
the reference group (n = 23), when compared with the intervention group (n = 3; P < 0.0001).
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acuity of the child (P = 0.59), country of origin (P = 0.57) or fluency in the national language 
(P = 0.48).
There was considerable variation in the level of compliance between the children and within 
each child, as indicated by the ODM measurements. The SD of mean compliance during the 
first one­week­measurement of all children (n = 310) was 37%. The mean of all the standard 
deviations of mean compliance in each child during that week was 28%.
In the intervention group, three children (2%) were not occluded at all during the first ODM 
measurement (mean age, 4.3 ± 0.8) compared with 23 (15%; mean age 4.6 ± 2.0) in the refer­
ence group (P < 0.0001, χ2; Figure 3). Children who were not occluded at all and children who 
did were comparable for clinical parameters. However, there were differences in the level of 
parental education, country of origin and fluency in the national language.
The questionnaire designed to estimate the usage of the educational programme or the pic­
ture to colour showed that the cartoon story was used by 87% of the families. Mean time was 
25 minutes per week (range, 5­180; number of observations, 123). The calendar and stickers 
were used by 80% of the families. Mean time was 10 minutes (range, 2­15; number of observa­
tions, 123). The information sheet was read by 67% of the parents. Mean time was 6 minutes 
(range, 2­10; number of observations, 123). 
In the reference group the colouring picture was coloured by 71% of the children. Mean time 
was 12 minutes (range, 5­20; number of observations, 131).
In 28 patients, the researchers recorded time spent on explaining the diagnosis and treatment 
during the first visit to the orthoptist. It averaged 234 seconds in non­native patients, and 416 
seconds in native patients. During follow­up visits to the orthoptist these averages were 116 
seconds and 233 seconds, respectively (62 patients).
dIScuSSIon
This study identified the following demographic parameters as primary predictors for non­
compliance: parental fluency in the national language, level of education and the country 
of origin. Although country of origin was selected in the multivariate model to be most sig­
nificant, we cannot exclude the possibility that fluency in the national language and level of 
education (being significantly correlated with the country of origin) may be the causal factors. 
The most important clinical parameter was the initial visual acuity of the amblyopic eye. The 
educational programme featuring the cartoon story that explained without words the ratio­
nale for treatment to the child significantly improved compliance throughout the study, limit­
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ing in particular the number of children who were not occluded at all (3 in the intervention 
group vs. 23 in the reference group). The electronic monitoring performed by the researchers, 
who were working independently from the treating orthoptists as they distributed the ODMs 
during home visits, enabled us to detect these striking differences between the two treatment 
groups.
The study was designed as a single­blind, randomised clinical trial. The treating orthoptists 
were unaware of randomization, but the researcher distributing the educational programme 
or the picture to colour was not. Efforts were made to ensure that time spent explaining the 
study was equal in both groups. Randomization took place after the first visit to the orthoptist. 
Main results of this study were based on the data obtained from the first ODM measurement, 
thereby excluding any possible biases of a treating orthoptist later on in the study. 
As compliance was measured in the week after the home visit, it would be reasonable to ex­
pect that compliance would be higher in the week it was monitored, and we cannot exclude 
that the ODM itself acted as an intervention. This bias applied to children in both groups. The 
study found that compliance was moderate despite the fact that parents knew that compli­
ance was being monitored. This finding was also made in one of the previous pilot studies, in 
which compliance was monitored for longer periods (Simonsz, et al. 2001). For this reason, it 
was decided that compliance would be measured on a regular basis: 1 week every 3 months, 
also making the study more feasible for both parents and the researchers. Mean compliance 
in our reference group during the measurements was similar to that reported by the MOTAS 
(Monitored Occlusion Treatment of Amblyopia Study) Cooperative, who objectively moni­
tored occlusion for a longer consecutive period (Stewart, et al. 2004). 
Visual acuity at the start of treatment was the clinical parameter most significantly correlated 
with compliance. This finding is in agreement with other studies (Flynn and Cassady 1978; 
Lithander and Sjöstrand 1991; Smith, et al. 1995; Stewart, et al. 2004; 2005) and is explained 
by the fact that the acceptance of the patch is less when acuity is low. 
The decrease in compliance during treatment, as found in our study, is partly due to a selec­
tion bias: children with low visual acuity at the start of treatment were less compliant, there­
fore wore the patches for a longer period, and consequently were recorded more often. The 
influence of treatment age on compliance has been a point of debate (Flynn and Cassady 
1978; Stewart, et al. 2004; 2005); our study found the treatment age to be borderline signifi­
cant, with younger children tending to have better compliance. 
Having established this large study group of more than 300 children, the research group in­
tends to proceed to an analysis of their visual acuity outcome. For this, the children’s final 
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acuity will be assessed in a standardized fashion by the research orthoptist after the children 
have completed their patching treatment. 
Apparently, native parents received more lengthy explanations at diagnosis and treatment 
than non­native parents did. Several factors may have contributed to this observation (e.g., 
cultural background, language skills, confidence, assertiveness, education, interests). Also, in 
The Netherlands, the time an orthoptist can spend on a patient varies and is sometimes lim­
ited to 15 minutes for a new patient. 
Although occlusion therapy for amblyopia has been the primary treatment for centuries 
(Loudon, et al. 2005; von Noorden and Campos 2002) and clinically is an effective treatment, 
its success is limited, by, among other factors, non­compliance (Awan, et al. 2005; Dorey, et 
al. 2001; Loudon, et al. 2004; Stewart, et al. 2004; 2005). In this study, we confirmed, using 
electronic monitoring, that lack of understanding of the disease and treatment in pediatric 
medicine are obstacles that can be remedied by an educational programme: the cartoon 
story, reward stickers and an information sheet. Important demographic predictors for low 
compliance included poor parental fluency in the national language, country of origin and 
a low level of education. Education, primarily aimed at the child, improved compliance and 
reduced the number of children who did not comply with occlusion at all.
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Chapter 8
The influence of parental attitudes and 
behaviour on compliance with amblyopia 
therapy and the effect of an educational 
programme
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ABSTrAcT 
Purpose: In the context of a randomised clinical trial, in which the effect of an educational 
programme on compliance with occlusion therapy was determined, this study focussed on 
the psychological reasons for failure to comply after 6 months of therapy.
methods: In 310 children with newly diagnosed amblyopia compliance was measured elec­
tronically during one week, every three months. Children were randomly allocated to receive 
an educational programme (intervention group), or a picture to colour (reference group). Af­
ter 6­9 months of treatment, during the third measurement, parents completed a 72­item 
questionnaire based on the Protection Motivation Theory to assess their beliefs about am­
blyopia and occlusion treatment. Parents with compliance less than 20%, received a separate 
semi­structured interview with in­depth questions that was based on differences in answers 
from the 72­item questionnaire between the group with compliance <20% and the compliant 
group. The measures were distributed via home­visits by researchers. 
results: 150 parents had reached the third measurement and 149 completed the question­
naire. A high degree of distress was most predictive for poor compliance (P < 0.001), followed 
by increased vulnerability (P = 0.014), increased stigma (P = 0.017) and poor logistics of treat­
ment (P = 0.044). Twenty­eight (64%) parents who patched less than 20% cooperated with 
a semi­structured interview. This showed lack of knowledge, family distress and logistical 
problems to be the primary reasons for non­compliance. The educational programme posi­
tively influenced the level of distress (P = 0.038), logistics of treatment (P = 0.016) and parental 
knowledge (P = 0.015). 
conclusions: Distress, poor parental knowledge and difficulties implementing the treatment 
into the daily routine seem to be the predominant causes for non­compliance with occlusion 
therapy for amblyopia, part of which were obviated by the educational programme. 
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InTroducTIon
Amblyopia is the most frequent cause of visual deficit in childhood (Attebo, et al. 1998; Brown, 
et al. 2000). The condition is usually unilateral and caused by strabismus, anisometropia and/
or visual deprivation. It is commonly treated with patching of the fellow eye preferably before 
the age of six. Adults with insufficiently treated amblyopia are at an increased risk of bilateral 
visual impairment due to loss of vision in the fellow eye (trauma or other eye diseases), and 
a decreased quality of life in adulthood (Chua, et al. 2004; Fronius, et al. 2005; van de Graaf, 
et al. 2004; Rahi, et al. 2002). The factor most frequently quoted to influence the visual acuity 
is degree of compliance (Cobb, et al. 2002; Dorey, et al. 2001; Lithander and Sjöstrand 1991; 
Loudon, et al. 2003; Simmers, et al. 1999; Simons and Preslan 1999; Smith, et al. 1995; Stewart, 
et al. 2004; 2005). The development of the Occlusion Dose Monitor (ODM) in 1991 enabled 
objective monitoring of compliance (Fielder, et al. 1994) and it was found that the degree of 
compliance averaged 50­60% (Loudon, et al. 2006; Simonsz, et al. 1999; Stewart, et al. 2004; 
2005), which is also found in studies that investigated compliance with prescriptions of medi­
cine (Wright 1993). Since it has been shown that treatment is effective (Awan, et al. 2005; 
Clarke, et al. 2003; PEDIG 2002; 2003a; 2003b; Stewart, et al. 2004; 2005), efforts are underway 
to identify determinants of poor compliance and ways to improve it (Dixon­Woods, et al. 2006; 
Goransson, et al. 1998; Loudon, et al. 2006; Newsham 2002; Smith, et al. 1995; Tripathi, et 
al. 2002). The emotional impact of occlusion therapy (Dixon­Woods, et al. 2006; Hrisos, et al. 
2004; Packwood, et al. 1999; PEDIG 2003) and poor parental understanding (Newsham 2002) 
were factors that affect parental implementation of occlusion therapy. 
A model employed by Searle et al. based on Protection Motivation Theory (PMT) proved to 
be useful to understand psychosocial factors involved with non­compliance with occlusion 
therapy (Norman, et al. 2003; Searle, et al. 2000; 2002). PMT is based on two behavioural adap­
tations that occur when an individual faces a health threat. The first is threat appraisal, which 
focuses on the source of the threat: the individual’s perception of the severity and vulnerabil­
ity to the threat. The second is coping appraisal, which evaluates one’s ability to address the 
threatened danger: that the individual is able to successfully perform an action (self­efficacy) 
and that this action is effective (response efficacy), both increasing the probability of an adap­
tive response (compliance with treatment). Both appraisal pathways contribute to protective 
motivation, followed by a decision to take action or not: protective behaviour. PMT has pro­
vided a coherent framework for exploring the impact and determinants of patching and it was 
concluded that PMT was predictive of compliance intentions and behaviour (Rogers 1975). 
In a large randomised clinical trial, the ERPAG study, we previously found that poor parental 
fluency in the national language, a low level of education and poor acuity at start of treat­
ment were predictors for low compliance, and, also that the educational programme, which 
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explained the reasons for therapy to the child, was very effective in improving compliance and 
reducing the number of children who were not occluded at all (Loudon, et al. 2006). 
Herein, we provide reasons for failure or success to comply with occlusion therapy evaluated 
after 6­9 months of receiving treatment, using a questionnaire based on PMT with additional 
domains on knowledge and logistics of treatment, and give further insight into circumstances 
leading to non­compliance. In addition, the effect of the educational programme on the rea­
sons for failure to comply with therapy was investigated.
mEThodS
The design of this prospective randomised clinical trial and CONSORT statement has been 
reported in detail in a prior publication (Loudon, et al. 2006) and is summarised as follows: 
between July 2001 and December 2003, children were recruited from four clinics by six treat­
ing orthoptists in The Hague; additional children were recruited in Frankfurt (Germany). All 
children with newly diagnosed amblyopia, with an interocular difference in visual acuity of at 
least 0.2 logMAR, strabismus and/or anisometropia (>1.0 Dioptres (D)), or a deprivation in the 
absence of additional ocular or neurological diseases, were eligible. The severity of amblyopia 
was expressed as the ratio (in decimals) between the acuity in the amblyopic eye and the 
better eye and expressed as decimal scores. Compliance was measured electronically in all 
children during an entire week, every three months, using the Occlusion Dose Monitor (ODM) 
(Chopovska, et al. 2005; Fronius, et al. 2006). 
Included children were randomised to either the intervention group or the reference group. 
Children in the intervention group received the educational programme: a cartoon story 
without text, depicting the orthoptic examination of a pre­school child, subsequent patch­
ing therapy and the reasons for therapy seen from the perspective of the child, designed to 
improve compliance. Folded in the back of the cartoon story was a sheet containing general 
information about amblyopia, its treatment and certain guidelines for the parents, available 
in eight languages. Children in the reference group received a picture to colour (e.g. Winnie 
the Pooh) that was also considered a reward, but did not contain the educational message. 
All parents were visited at their home by the researchers to explain nature and possible con­
sequences of the study and to distribute the ODM with either the educational programme or 
the picture to colour. All children received standard orthoptic care. Occlusion was prescribed 
according to a standardised protocol developed for this study and representative of current 
orthoptic practice (Loudon, et al. 2006). The family’s socio­economic status was ascertained 
using a 23­item questionnaire. 
The Ethical Committee of Erasmus University Rotterdam and the boards of the participating 
clinics approved the protocol and informed consent forms. Written informed consent by the 
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parents or guardian was a prerequisite for participation. The research adhered to the tenets of 
the Declaration of Helsinki.
Patching Success questionnaire
To identify reasons for failure to comply with occlusion therapy, an inventory was made using 
a 72­item questionnaire (‘Patching Success Questionnaire’ – PSQ), which was based on com­
ponents of the PMT, 6­9 months after the start of treatment, during the third home­visit.
The PMT items were scored on a 5­point response domain (strongly disagree/strongly agree). 
Reliable measures were identified through factor analyses and internal reliability analyses: 
Cronbach’s α (Norman, et al. 2003; Searle, et al. 2000; 2002). Measures of the variables were 
constructed by averaging responses to individual items such that high scores indicated high 
degrees on the variable of interest. Protection Motivation was assessed using three items 
(α=0.86). Perceived severity of the disease was assessed using six items (α=0.89). Perceived 
vulnerability was assessed using six items (α=0.86). Response efficacy was assessed using five 
items (α=0.83). Self­efficacy was assessed using four items (α=0.88). The perceived distress ex­
perienced by parents when patching their child was assessed using eight items (α=0.90), the 
extent to which patching may interfere or prohibit the child from engaging in every day ac­
tivities was assessed using five items (α=0.62) and the stigma attached to wearing a patch was 
assessed using five items (α=0.78). In addition to the PMT items, information was collected on 
parental knowledge of disease (3 items, all on a 5­point scale; e.g. ‘In general, a lazy eye is an 
eye that sees less clearly than the other’) and treatment (2 items on a 4­point scale; e.g. ‘The 
aim of patching therapy would be: equal vision ­ sufficient vision to read a book ­ decrease 
in the squint ­ not to wear glasses later in life’) and logistic of treatment (4 items on a 5­point 
scale; e.g. ‘I find it difficult fitting patching into my daily routine’). The questionnaire also con­
tained 10 questions about the families’ experience with the eye patch (e.g. ‘after removing the 
eye patch my child’s skin is red and/or painful’). 
Identification of non-compliers
To define the group of non­compliers, data of the first one­week ODM measurement were 
analysed. A cut­off point at compliance of 20% was chosen, which included not only the non­
patchers, but also the low­frequency­patchers (i.e. the eye was occluded less than twice a 
week). As expected, a strong association between compliance and frequency of patching was 
found (Figure 1a & 1b): when compliance was less than 20%, the frequency of patching was 
less than three times a week (sensitivity 0.84, specificity 1.00). 
Parents from the non­compliant group were contacted by phone and an appointment for 
an interview during a separate home visit was made. In case of poor fluency in the national 
language by the parents, an interpreter was present. 
110
Statistical analysis
Descriptive statistics and crosstabs were used to calculate the means, standard deviations and 
inter­correlations of each domain of the questionnaire. These results were then compared to 
the results of the questionnaire reported by Norman et al. (2003). Linear regression analysis 
was used to predict protection motivation and compliance (both as dependent, continuous 
variables). The independent variables were: severity, vulnerability, response efficacy, distress, 
prohibition, stigma, self­efficacy, knowledge, logistics and protection motivation (scored as 
continuous variables).
The non­parametric Mann­Whitney test was used to determine the effect of the educational 
programme on the domains of the ‘Patching Success Questionnaire’. F­values and β­values 
were calculated. The F­value is a test statistic that tests for differences in the variance between 
two groups; F=1 indicates no difference in variance between two groups. The percentage of 
the variation in compliance and motivation to patch their child that could be ascribed to the 
different factors involved was defined as the ratio of the percentage of the variance explained 
by the model with, and the model without the factor in question. Analysis was both Univariate 
and Multivariate. Descriptive statistics were applied to analyse the completed semi­structured 
interviews. P < 0.05 was considered statistically significant.
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Figure 1a. A scatter plot displaying the relationship between the frequency of patching per week and 
electronically measured compliance during the first ODM measurement, the black line indicating the 
chosen cut-off point of 20% compliance. 1b. A histogram presenting compliance during the first ODM 
measurement, with 10% intervals. 
 
 
Figure 2. Flowchart illustrating the study design. After the first one-week measurement, children who 
patched less than 20% were identified as non-compliant. Between November 2004 and March 2005, 
the non-compliant group received a separate semi-structured interview with more in-depth questions 
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chosen cut­off point of 20% compliance. 1b. A histogram presenting compliance during the first ODM 
measurement, with 10% intervals.
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rESuLTS
The study design was prospective, recruiting children for a period of 30 months. On average 
a child received three electronic measurements during, on average, 8 months of treatment. 
Therefore, not all children had reached the moment of the third measurement, the moment 
the questionnaire was distributed. After 6­9 months of treatment, the 150 patients who re­
ceived the third measurement were asked to complete the questionnaire, 75 in the interven­
tion group and 75 in the reference group (Figure 2). The PSQ was completed for 149 parents 
during the third home­visit. Mean age was 4.6 years (SD 1.9) and 53% were boys; the clinical 
and demographic characteristics were similar to those reported for the full study cohort (n = 
310) (Loudon, et al. 2006). 
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Figure 2. Flowchart illustrating the study design. After the first one­week measurement, children who 
patched less than 20% were identified as non­compliant. Between November 2004 and March 2005, the 
non­compliant group received a separate semi­structured interview with more in­depth questions that 
was based on differences in answers from the Patching Success Questionnaire between the compliant and 
the non­compliant group.
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Patching Success questionnaire
The mean scores and standard deviations per PMT domain as observed in this study differed 
from the scores found by Norman et al., for the domains: protection motivation, severity, vul­
nerability, degree of distress and stigma barrier (Table 1). The inter­correlations between the 
domains of the PMT, however, were comparable to those reported by Norman et al. (2003).
Stepwise backward selection demonstrated that the motivation to patch their child (PM) was 
high when self­efficacy (β = 0.51; P < 0.001), response efficacy (β = 0.30; P < 0.001) and severity 
(β = 0.08; P = 0.048) were also high, all three domains explaining 54% of the variation in pro­
tection motivation (adj. R2). Stepwise backward selection showed that compliance increased 
when parents were well capable of implementing the occlusion therapy into their daily rou­
tine (logistics; β = 6.1; P = 0.044) and when they replied that their child’s eye sight would 
get worse if left untreated (β = 9.3; P = 0.014). Compliance decreased when the two barriers 
distress and stigma increased (β = ­22; P < 0.001 and β = ­6.0; P = 0.017, respectively). The four 
domains explained 22% of the variation in compliance (adj. R2).
Visual acuity was significantly and negatively correlated with the domains severity (r = ­0.37; 
P < 0.001) and the degree of distress (r = ­0.17; P = 0.007). Age of the children and cause of 
amblyopia were not correlated with any of the domains, neither was gender. 
Poor fluency in the national language was positively related to stigma (r   = 0.37; P < 0.001), a 
higher degree of distress (r = 0.45; P < 0.001) and severity (r = 0.5; P < 0.001); and negatively 
related to knowledge (r = ­0.22; P = 0.009) and self­efficacy (r = ­0.18; P = 0.03). Level of educa­
tion was positively correlated with knowledge (r = 0.20; P = 0.018); and negatively correlated 
with the domains severity (r = ­0.23; P = 0.005); degree of distress (r = ­0.29; P < 0.001); and 
stigma (r = ­0.21; P = 0.009). 
The clinical and socioeconomic variables studied, explained 11% of the variance in protection 
motivation and 12% of the variation in compliance. 
relationship between Patching Success questionnaire and compliance, and the 
effect of the educational programme
Univariate analysis of the variance demonstrated that an increased degree of distress caused 
by occlusion therapy negatively infl uenced compliance. However, a clear effect of the educa­
tional programme was found (F = 4.15; P = 0.038), in a sense that children and their parents 
who received the programme suffered less distress than the reference group (Table 2). 
Compliance increased when parents found it easier to implement occlusion therapy into their 
daily routine (logistics). The implementation was significantly better in parents who had re­
ceived the educational programme (F = 5.97; P = 0.016). Parental scores on the domain ‘knowl­
edge about treatment’ were significantly higher when they had received the educational pro­
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gramme (F = 6.1; P = 0.015). This, however, did not affect compliance. Compliance increased 
significantly when parents were highly motivated to patch their child, when they thought 
their child’s eye sight would be vulnerable when left untreated, when parents were able to 
adhere to the prescription given by the orthoptist, and decreased when their child was pro­
hibited in his activities by the patch. The educational programme showed no demonstrable 
effect on these domains.
Group of non-compliers
After the first one­week ODM measurement 44 children had electronically measured compli­
ance below 20% (8 intervention group; 36 reference group), of whom 33 could be contacted, 
while 11 (25%) could not be contacted with the available address or telephone numbers. 28 
(64%) were interviewed at their home (5 intervention group; 23 reference group), 5 (11%) 
would no longer cooperate. The interviews were undertaken by two interviewers (LC and SdV) 
who wrote extensive reports of each visit. The time spent on these home­visits was approxi­
mately 30 minutes (range 20­45 min). 
The compliant and non­compliant group were compared concerning the clinical and socio­
economic factors and the answers given to the ‘Patching Success Questionnaire’. The follow­
ing significant differences using ANOVA were found: visual acuity at onset (F = 3.78; P = 0.049), 
fluency in the national language (F = 6.64; P = 0.01), country of origin (F = 3.85; P = 0.047), per­
ceived distress (F = 12.51; P = 0.001), self­efficacy (F = 9.32; P = 0.003), protection motivation (F 
= 12.12; P = 0.001), logistics of treatment (F = 15.1; P = 0.001) and knowledge about amblyopia 
and its treatment (F = 8.13; P = 0.005). The differences found were in favour of the compliant 
group. These differences were used to develop a semi­structured interview with 33 additional 
focussed questions based on these domains, including 6 questions specifically for the child. 
Since compliance was related to fluency in the national language and as communication is an 
Table 1. Mean scores and standard deviation per domain for the study population in The Hague and 
Bristol; * P­value indicating a significant difference in mean scores.
Scales The Hague (n =149) Bristol (n =151) P ­value
PM 4.25 ± 0.68 4.5 ± 0.85 *<0.001
Severity 3.02 ± 0.93 3.57 ± 0.82 *<0.001
Vulnerability 3.2 ± 0.74 3.49 ± 1.00 *<0.001
Response efficacy 4.36 ± 0.5 4.33 ± 0.78 0.252
Distress barrier 2.19 ± 0.84 2.75 ± 1.04 *<0.001
Prohibit barrier 2.07 ± 0.95 1.94 ± 1.05 0.101
Stigma barrier 2.48 ± 0.83 2.85 ± 0.95 *0.001
Self­efficacy 4.04 ± 0.86 3.86 ± 1.2 0.767
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important part in compliance (Loudon, et al. 2006), questions regarding communication and 
relationship with the therapist in general were also included.
The semi­structured nature of the interview made it possible to thoroughly question the par­
ents about amblyopia and its treatment. The reports were objectified by scoring them for 
gauging criteria done by the two researchers separately. These criteria were compiled through 
analyses of the survey. Based on the literature (DiMatteo 2004) and the results of the question­
naire, three main parties involved in the occlusion treatment could be distinguished: i.e. child, 
carer and therapist. Conclusively, 12 gauging criteria were drawn up, 4 for each party involved 
(Figure 3). These criteria refer to reasons for total non­compliance.
The analysis of the interviews was then conducted by scoring each report of the interview on 
the above­mentioned 12 criteria. This was done on a scale from 1 (not present) to 5 (domi­
nantly present or behaviour defining). The two independent scores were analysed with the 
weighed kappa­test to test if the two scores differed significantly. 
All parents interviewed were under the impression they had sufficient knowledge regarding 
the treatment, however, objectively, only 14% had sufficient knowledge. Also, a high degree 
of distress and logistical problems were prevalent. Parents did not regard occlusion therapy to 
be an effective treatment. Interviewed children replied they were often teased by their peers 
whilst wearing the patch (43%, of whom 29% suffered severe teasing), which decreased their 
self­esteem. A third of the parents answered they had received incomplete information from 
the treating orthoptist and that there was little time during the visit to discuss their problems. 
18% of the parents thought that the orthoptist did not sufficiently address the child when 
explaining the eye condition and its treatment. 
The following significant correlations (using Pearson’s chi­square) were found: time and at­
tention spent by therapists to problems regarding the occlusion therapy were correlated with 
Table 2. β­, F­ and P­values of a univariate analysis of the effect of the PSQ domains on compliance. 
* Indicates a significant influence. 
Scales β F P ­value
PM 16.4 14.1 *<0.001
Severity ­3.1 0.8 0.358
Vulnerability 10.9 6.9 *0.009
Response efficacy 5.7 0.6 0.364
Distress barrier ­17 24.2 *<0.001
Prohibit barrier ­8.4 6.8 *0.01
Stigma barrier ­5.9 2.5 0.116
Self­efficacy 12.8 13.4 *<0.001
Knowledge disease 0 0 0.998
Knowledge treatment 2 0.4 0.546
Logistics of treatment 11.1 13.9 *<0.001
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clarity of information, possibility to ask questions and child­orientation of the visits. Parental 
knowledge about amblyopia and its treatment and the perceived feeling of invasiveness of 
therapy were correlated to response efficacy. Confidence in the response efficacy was corre­
lated with time and attention paid by therapists to problems encountered during patching, 
clarity of information given and possibility to ask questions. 
dIScuSSIon
In the context of a prospective, randomised, clinical trial in which the effect of an educational 
programme on compliance was investigated, this study provided reasons for failure to comply 
with occlusion therapy after 6­9 months of treatment. We used a 72­item questionnaire based 
on the PMT components with added domains on knowledge and logistics of treatment and 
separately interviewed parents who did not occlude at all. In addition, the effect of the educa­
tional programme on the domains of the questionnaire was determined. 
In concordance with Searle, et al.(2002) and Norman, et al.(2003) the degrees of response effi­
cacy and protection motivation were high, indicating that most parents thought eye patching 
to be an effective treatment for their child’s amblyopic eye and were motivated to patch their 
child as prescribed by the orthoptist. More than 50% of the variation in protection motivation 
could be ascribed to the following three domains: self­efficacy, response efficacy and sever­
ity; thus parents’ motivation to patch their child increased when they thought patching to be 
an effective treatment, when they were able to patch their child as recommended by the or­
thoptist and when they thought their child’s eye condition to be severe. This finding was also 
that was based on differences in answers from the Patching Success Questionnaire between the 
compliant and the non-compliant group. 
 
 
 
Figure 3. 12 criteria subdiv ded into th  carer, the  and the therapist.
Figure 3. 12 criteria subdivided into the carer, the child and the therapist.
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found in other studies which applied PMT in relation to compliance with therapy in amblyopia 
and other conditions (Abraham, et al. 1994; Flynn, et al. 1995; Fruin, et al. 1991; Norman, et al. 
2003; Rippertoe and Rogers 1987; Rudman, et al. 1999; Searle, et al. 2002; van der Velde and 
van der Pligt 1991). As the parents in The Hague were given the same questionnaire as the 
parents in Bristol, it would be interesting to compare their mean scores. For several domains 
the parents in The Hague scored lower, probably explained by the difference in population 
and country.
Univariate analysis demonstrated that compliance was influenced by protection motivation, 
vulnerability, distress and prohibition barrier, self­efficacy and logistics of treatment. How­
ever, when corrected for potentially confounding factors no effect of protection motivation 
on compliance could be found: though parents may be motivated to patch their child, this 
did not influence compliance. Compliance decreased most drastically when parents reported 
a high degree of distress. This was also found in other studies (Hrisos, et al. 2004; Norman, et 
al. 2003; Packwood, et al. 1999; PEDIG 2003; Parkes 2001; Searle, et al. 2002). However, fami­
lies who were given the educational programme that explained the occlusion therapy to the 
child, suffered less distress and had better compliance. The educational programme had a 
similar positive effect on parental knowledge of treatment and logistics of treatment. This 
finding is in agreement with Newsham’s (Newsham 2002). Somewhat surprisingly, knowledge 
of the disease itself was not affected by the educational programme; perhaps it was still un­
clear for the parents, or they found amblyopia itself not interesting or serious enough. 
The age of the child, depth of amblyopia, gender and cause of amblyopia showed little rela­
tionship with the overall scores. Poor visual acuity at treatment onset caused parents to con­
sider the amblyopia as a serious eye condition and increased the degree of distress. 
Parents who spoke the native language excellently, had better knowledge about the treat­
ment, were confident in their ability to patch their child and were of the opinion that amblyo­
pia was a serious eye condition; they also suffered less distress and stigma.
The questionnaire and interview were carried out on one occasion. It might have been in­
teresting to, in a prospective design, also have distributed the questionnaire and conducted 
the interview immediately after the first visit to the orthoptist for prediction and to compare 
outcomes and any changes in opinions.
When analysing the group who did not occlude at all, it was apparent that there was a clear 
discrepancy of subjective knowledge and the measured knowledge. This indicated that many 
parents were ignorant of their lack of knowledge, therefore could not give feedback or put 
forward any questions, thus leaving the orthoptist unaware of the parents’ problem. For a 
small group of parents the orthoptist was felt as the main reason for failing to patch: when 
there was no attention paid to problems encountered during patching, no possibility to ask 
questions, insufficient or unclear information supplied, parents were most likely to become 
steadfast non­compliers. A number of parents indicated that visits to the orthoptist should 
be more child­focused. Children were poorly involved in the communication between parent 
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and orthoptist and consequently did not understand the reason they had to be patched. The 
interviews were taken at their home, to overcome the problem of dropouts who no longer 
visited the clinic. The interview was open framed, rather than with multiple­choice questions. 
This open framework allowed a focused, conversational, two­way communication. 
This study demonstrated that occlusion therapy for amblyopia is difficult to implement, is ac­
companied by a high degree of distress and is hampered by poor knowledge and understand­
ing by the parents and therapist. If knowledge and understanding is improved, this might di­
minish the effect of the other determinants found in this study. The educational programme, a 
cartoon story explaining without text the reasons for therapy to a 4­year old and the informa­
tion sheet for the parents, partly reduced the influence of these determinants and increased 
the acceptance of occlusion therapy.
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ABSTrAcT
Purpose: To evaluate the physiological and mechanical properties of the eye patch and their 
influence on compliance as part of the prospective randomised clinical trial identifying risk 
factors for non­compliance with occlusion therapy for amblyopia.
methods: For a period of 30 months all children with newly diagnosed amblyopia in The 
Hague were registered. Compliance was measured during 1 week every 3 months with the 
Occlusion Dose Monitor (ODM) that was distributed during home­visits. All children received 
standard orthoptic care by the treating orthoptist. After 6 months of treatment, parents com­
pleted a questionnaire evaluating comfort, size and adhesion of the patch. In the study, four 
brands of patches were used: Opticlude, Orthopad, Pro­Ophta and Beiersdorf. On one occa­
sion the following physiological and mechanical properties were measured: breathing capa­
bility at 23°C (73°F) and 33°C (91°F), resistance to water penetration, opacity and strength of 
adhesion to the skin. 
results: 149 Parents completed the questionnaire, of whom 62% used Opticlude, 24% Ortho­
pad, 11% Pro­Ophta and 3% used Beiersdorf. The brand of patch prescribed was correlated to 
the orthoptist only (P = 0.005). Compliance was neither related to the brand (P = 0.179), nor 
to the use of different colours or designs of patches (P = 0.639). It was, however, related to the 
use of stickers (P = 0.028). Parental satisfaction was moderate. Answers given by the parents 
matched the measured physiological and mechanical properties of the eye patch. There were 
large differences in the properties of the eye patch, especially in opacity and strength of adhe­
sion to the skin. In all brands of patches the breathing capability was minimal. 
conclusions: When prescribing a certain brand the orthoptist needs to consider the wide va­
riety in physiological and mechanical properties of the patch. Further study into these proper­
ties is necessary; especially water permeability and opacity of the eye patch require improve­
ment since children often wear them for a longer period of time. This could contribute to 
increasing parental satisfaction and consequently may improve compliance.
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InTroducTIon
Amblyopia is the commonest visual defect in children with a prevalence of approximately 
3.5% (Attebo, et al. 1998). The condition may be partially or completely treated preferably 
before the age of 6. Traditionally, treatment involves occlusion of the non­amblyopic eye with 
an adhesive patch applied directly to the skin around the eye, thereby forcing the use of the 
amblyopic eye. Occlusion therapy has been the mainstay of treatment for centuries. However, 
it frequently receded into the background when other types of treatment for amblyopia were 
tried. In 1927 it was re­introduced by C.H. Sattler in Leipzig (Sattler 1927). His occluder, called 
“Mastisolverband”, was attached to the skin around the eye with strong adhesive tape and 
remained securely fastened for at least two or three days. Acceptance of this patch was poor 
as it caused localised skin irritation in almost all children. Nowadays, a wide selection in brand 
of patches is available, with patches varying in size, colour, elasticity, and gadgets or gifts 
distributed by the manufacturers. Whether or not a patch remains glued to the skin depends 
on a number of factors, e.g., skin type, the child’s activities while wearing the patch and ad­
hesive strength of the patch. The eye patches are mostly made of non­woven materials. Some 
manufactures assert their brand of patch is hypo­allergen, indicating special glue was used to 
reduce the occurrence of allergies and itching. Nevertheless, it has been reported that parents 
dislike the cosmetic appearance of their child wearing an eye patch. They argue that wearing 
the eye patch is uncomfortable, causes irritation to the skin and leads to considerable distress 
for the child, sometimes even outweighing any benefits from improvement in vision (Hsiros, 
et al. 2004; Norman, et al. 2003; Packwood, et al. 1999; Parkes 2001; PEDIG 2003; Snowdon and 
Stewart­Brown 1997). To date, no study has investigated the physiological and mechanical 
properties of various brands of eye patches and their effect on compliance. Therefore, as part 
of a randomised clinical trial designed to investigate a method to improve compliance and to 
identify certain risk factors for non­compliance, this study investigated the properties of the 
eye patches, focussed on the orthoptists’ choice in prescribing a particular brand, the correla­
tion with compliance and parental satisfaction.
mEThodS
The design of this prospective trial has been reported in detail in a prior publication and is 
summarised as follows (Loudon, et al. 2006): between July 2001 and December 2003, all chil­
dren with newly diagnosed amblyopia in The Hague were recruited from four clinics by six 
treating orthoptists; additional children were recruited in Frankfurt (Germany). Eligible chil­
dren received a routine orthoptic examination and explanation of diagnosis and treatment 
after which a standard examination form was completed and forwarded to the research cen­
tre. The duration of occlusion (number of hours per day) for the first prescription had been 
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standardised and prescribed according to the protocol representative of current orthoptic 
practice (i.e., ­6.63 * ratio acuity amblyopic eye/acuity better eye + 0.5 * age (years) + 4.97).
After the first visit to the orthoptist, parents were contacted by the independent researchers 
who explained the nature and possible consequences of participating in the study and use 
of the Occlusion Dose Monitor (ODM) (Fielder, et al. 1994) during a home­visit. Full written in­
formed consent was obtained. Compliance was measured with the ODM in all children during 
a period of 1 week, every 3 months (Chopovska, et al. 2005; Fronius, et al. 2006). 
In the Netherlands four brands of patches are available: 3M OpticludeTM, Orthopad Master­aid® 
(Regular and Simpathy), Pro­Ophta® or Beiersdorf® (Elastopad and Coverlet­S), all of which 
had also been prescribed in the study. The orthoptists were free in their choice to decide what 
brand of patch they prescribed. After completing the study, in December 2005, the treating 
orthoptists received a semi­structured interview by the researcher. During the open part they 
were asked to motivate their choice for prescribing a particular brand of patch. During the 
structured part they were asked if their choice was influenced by the age of the children, the 
number of prescribed occlusion hours, their idea of compliance with treatment, and by gad­
gets or gifts distributed by the manufacturers. In addition, the pharmacies in The Hague were 
contacted by telephone to document if all patches were in stock, and if not, which brand they 
did have in stock.
questionnaire
Parental experience with the eye patch was evaluated via a 10­item questionnaire; each item 
had 4 or 5 response choices (Table 1, left­hand column). The questions were developed to­
gether with the Consumers’ Organisation, the Netherlands who published a report on all 
available brands of plaster (July 2001) (Consumers’ Organisation the Netherlands 2001). The 
parents completed this questionnaire during the third home­visit after approximately 6­9 
months of treatment. 
Physiological and mechanical properties of the patch
Firstly, breathing capability was tested at 23ºC (73ºF) and 33ºC (91ºF): the patches were glued 
on top of small plastic pots, each containing 20 grams of water. The pots were completely 
sealed off by the patch; the only way of ventilation was through the patch. They were left on 
a rocking table in a stove. The various patches were tested simultaneously at a temperature of 
23ºC (73ºF) and a humidity of 30%. The same procedure was followed at a temperature of 33ºC 
(91ºF) and a humidity of 22%. To make sure these conditions were constant; a separate digital 
thermometer was used to measure the temperature and humidity. After 24 hours the amount 
of water left in the plastic pot was measured. The breathing capability, or ‘water vapour re­
sistance’ (Ret), was calculated using: m² * Pa / W (m = π * r² * time (seconds); Pa = saturated 
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(water) vapour pressure, depending on temperature and humidity; W=difference in amount 
of water (grams) after a certain time, with 1 gram of water equalling 2430 Joule). The Ret is 
classified as follows: an Ret > 40: ‘uncomfortable’, e.g. raincoat and has a restricted wearing 
time; 20 < Ret ≤ 40: ‘somewhat comfortable’; or Ret ≤ 20, which equals ‘comfortable’. 
Secondly, the resistance to water penetration was tested: 1 drop of water was placed on the 
centre of the patch and time necessary for the drop to be absorbed was measured with a 
stopwatch. Material is labelled water­resistant when the drop of water is not absorbed within 
1 minute. 
Thirdly, the opacity of the patches was tested. All patches were glued to a fluorescent lamp of 
18 Watt. We measured the amount of light transmitted through the centre and at the side of 
the patch. 100% light transmission equals ‘no patch present’.
Finally, the strength of adhesion of the patch to the skin was tested using the ‘maximum force 
grab method’. The patches were stuck to the skin and the force necessary to remove the patch 
was measured (expressed in Newton).
The breathing capability was tested at the laboratory of the ErasmusMC University Medical 
Center Rotterdam; the other tests were performed at the Netherlands Organisation for Ap­
plied Scientific Research (TNO), Textile Industry Enschede. All tests were performed by the 
researcher (SL) under supervision of co­author AW.
In addition to the tests, the elasticity of the eye patches, hygiene, available sizes and distrib­
uted gifts per brand, was noted.
Statistical analysis
Chi­square test (Pearson Chi­square in crosstabs) was used to determine the influence of age, 
gender, number of prescribed occlusion hours, cause of amblyopia and socioeconomic status 
on the orthoptists’ choice in prescribing a brand of patch. 
Compliance was measured during 1 week, every 3 months. It was defined as the actual occlu­
sion time measured with the ODM divided by the prescribed occlusion time and expressed 
as a percentage. Differences in compliance between the four groups of patches was assessed 
using least­squares regression analysis, with compliance as the dependent (continuous) vari­
able and the brand of patch as the independent (categorical) variable, using data obtained 
during the first ODM measurement.
To calculate differences in answers to the questionnaire between the four groups, the answers 
were first transformed into rank numbers and then imported in the linear regression analysis 
with the rank number as the dependent variable and the brand of patch as the independent 
variable. 
Whether the answers influenced compliance was also assessed with linear regression analysis. 
P < 0.05 indicated statistical significance. 
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rESuLTS
In the randomised clinical trial, 310 children were eligible for analysis, mean age was 4.6 years 
(SD 2.0), and 56% were boys. At the start of the study 165 children used Opticlude (53.2%), 
100 children used Orthopad (32.3%), 26 children used Pro­Ophta (8.5%), and 19 children used 
Beiersdorf (6%), (Table 2). An 8% deviation from a random prescription was found. 
Overall mean compliance, as measured during the first ODM measurement, was 68% (range 
0­100%; SD 38%). Compliance was not significantly influenced by the brand of patch (P = 
0.179). However, the highly skewed distribution of the prescribed brand of patches prevented 
a reliable statistical analysis. 
questionnaire
After 6 months of treatment 150 children participated in the study, of whom 149 parents 
completed the questionnaire. At that time in the study, 92 children used Opticlude (62%), 35 
children used Orthopad (24%), 17 children used Pro­Ophta (11%), and 5 children used Bei­
ersdorf (3%). Results from the questionnaire are shown in Table 1. The one question to which 
parents responded significantly different was: “The patch stays on my child’s eye: strongly 
agree – strongly disagree” (P = 0.027). To calculate whether the answers given by the parents 
were predictors for compliance we used linear regression analysis; only when the parents re­
sponded positively to the use of stickers, their compliance was significantly better (P = 0.028; 
r = 0.22).
Table 2. Gender, mean age, prescribed occlusion hours and compliance (%) of the 310 children in our 
study, according to the eye patch used by the parents. 
  Opticlude Orthopad Pro­Ophta Beiersdorf 
  n = 165 n = 100 n = 26 n = 19
Characteristic      
Gender  
 Male (%) 61 53 44 39
 Female (%) 39 47 56 61
Mean age ­ years  4.7 4.5 4.1 5.5
Mean prescribed hours of occlusion per day 2:57 3:23 2:51 3:41
Overall compliance (%)  71 62 75 73
127
ch
ap
te
r 9
Physiological and mechanical properties of the eye patch
Physiological and mechanical properties of the patch
The results of the water vapour resistance (expressed as Ret) test showed that none of the 
Table 3. Physiological and mechanical properties, flexibility, hygiene, sizes, and distributed gadgets or gifts 
of the 4 eye patches.
Brand/Type
*1) Breathing 
capability (Ret)
*2) 
Opacity 
centre of 
patch
*3) Water­
resistant
Max. Force to 
remove patch 
from skin (N)
Flexibility/ 
Elasticity
Packed a 
piece
Size 
availability Gifts
23°C 33°C
3M Opticlude 3.2 broadwise 
only, very 
limited
no
mini, midi, 
maxi
Sponge 
Bob
 skin coloured 64.1 34.9 89% > 1 min
 blue 79% > 1 min
 red 82% > 1 min
 green 78% > 1 min
Orthopad 5.9 broadwise 
only
yes mini, maxi
Gift 
voucher
 Regular ­ skin 21.8 15.2 49% 10­15 sec
 Regular ­ white 54% > 1 min
 Simpathy ­ red 42% < 1 sec
 Simpathy ­ black/
white 51%
black: 10 
sec; white: 
> 1 min
 Simpathy ­ blue 43%
Pro­Ophta 30.1 14.5 62% > 1 min 2.6 lengthways 
only
no 1 size -
Beiersdorf 8.8 yes mini, maxi Disney 
DVD or 
Video Elastopad 53.9 29.7 19% > 1 min
broadwise 
only
 Elastopad ­lite 39.9 21.8 29% > 1 min
broadwise 
only
 Coverlet ­ S 55.7 33.3 > 1 min very flexible 
in all 
directions
 Coverlet ­ S with 
sticker 70.8 37.8
 *1) Ret: water vapour resistance and classified as follows: Ret > 40 = uncomfortable (e.g. raincoat) and has 
a restricted wearing time 20 < Ret < 40 somewhat comfortable
Ret < 20 = comfortable to wear
*2) Opacity: 100% equals ‘no patch present’
*3) Material is labelled water­resistant when the drop of water is not absorbed within 1 minute
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various brands of patches were ‘comfortable’ to wear at a temperature of 23˚C (73ºF) (= Ret < 
20; Table 3). Beiersdorf and Opticlude were actually ‘very uncomfortable’ to wear (Ret > 40). At 
a temperature of 33ºC (91ºF) and a humidity of 22%, Pro­Ophta and Orthopad were ‘comfort­
able’ to wear and Beiersdorf and Opticlude were ‘somewhat comfortable’.
All brands, except Orthopad, were water­resistant. 
Only one brand was able to eliminate more that 70% of the light transmitted by a fluorescent 
lamp (Beiersdorf ), whereas other brands eliminated 50% (Orthopad), 48% (Pro­Ophta) and 
20% (Opticlude) of the light.
  
To remove the patches from the skin an average maximum force of 8.8 Newton (Beiersdorf ), 
5.9 N (Orthopad), 3.2 N (Opticlude) and 2.6 N (Pro­Ophta) was needed (Figure 1).
The measured physiological and mechanical properties matched the answers given by the 
parents on the questionnaire, e.g. Beiersdorf patches were the most difficult to remove from 
the skin (using the maximum force grab method), in correspondence with all parents (strong­
ly) agreeing to the question that the patch remained on their child’s eye.
The brand of patch prescribed was not significantly influenced by the age (P = 0.428), gender 
(P = 0.147) or the socioeconomic status (P= 0.072) of the children, the cause of amblyopia (P = 
 
Chapter 9 
Figure 1. To remove the patches form the skin an average maximum force of 8.8 Newton (Beiersdorf – 
Elastopad), 5.9 N (Orthopad), 3.2 N (Opticlude) and 2.6 N (Pro-Ophta) was needed. 
 
Figure 1. To remove the patches from the skin an average maximum force of 8.8 Newton (Beiersdorf ), 5.9 
N (Orthopad), 3.2 N (Opticlude) and 2.6 N (Pro­Ophta) was needed. For colour figures please see ‘Colour 
figures’ on page 197.
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0.093) of the number of prescribed hours of occlusion (P = 0.923). It was, however, significantly 
related to the prescribing orthoptist (P = 0.005). Reasons for the six orthoptists to prescribe a 
particular brand included: (1) parent and child preference for the various motifs and coloured 
patches (n = 6); (2) Opticlude was the only brand that had a medium size available (n = 3); 
(3) personal experience (n = 2); and (4) out of habit (n = 1). Opticlude, Orthopad and Beiers­
dorf distributed gifts for the children when they handed in 2 or 3 barcodes from the box of 
patches.
The survey conducted of the pharmacies, showed 10% had all brands in stock, 5% had none, 
29% Opticlude, 33% Opticlude and Orthopad and 14% had three brands in stock. In case chil­
dren had been prescribed a patch that was not in stock, 19% of the pharmacies changed the 
orthoptists’ prescription into the prescription of a patch they did have in stock. 
dIScuSSIon
This study evaluated the physiological and mechanical properties of the eye patch and the 
influence on compliance and parental satisfaction. In addition, reasons for prescribing a cer­
tain brand of patch by the orthoptist were recorded. The tests performed on the eye patches 
demonstrated large differences in these properties between the four brands. The breathing 
property of all patches was minimal at room temperatures; some patches could be compared 
to wearing a raincoat in the sun and would therefore clearly be more suited only when oc­
cluding for shorter periods of time. There was also considerable difference in strength neces­
sary to remove the patch from the skin. As a consequence, when prescribing occlusion for a 
longer period of time, one might consider to prescribe the patch that was the most difficult to 
remove from the skin. No patch was able to eliminate 100% of the light, however, it is unclear 
whether the patch must exclude all light and form, or that it is sufficient to exclude form, but 
allow the passage of some light. The differences in properties did not seem to influence the 
orthoptists’ choice in prescription. There was a clear preference to prescribe Opticlude patch­
es, though when testing them they were not of a higher quality. The orthoptists alleged that 
overall they left it to the parent and child to decide and because Opticlude had the largest 
assortment this would thus increase the change of choosing an Opticlude patch. Moreover, 
differences in publicity and Public Relations of the patch manufacturers might also influence 
the decision to prescribe a particular brand of patch.
Consequently, the high prevalence of Opticlude patches in our study population made it dif­
ficult to statistically analyse differences in answers given by the parents. No correlation could 
be found between the electronically measured compliance and the brand of patch or the use 
of the different coloured patches. In addition, the answers given by the parents were com­
parable to the measured physiological and mechanical properties of the patch. Parents were 
moderately satisfied with the eye patches. Therefore, as children often wear the eye patches 
130
for longer periods of time, it seems reasonable to expect orthoptists to take comfort of wear 
into consideration when prescribing a certain brand of patch and for manufacturers to spend 
more time and effort on improving the properties of their patches. 
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Account of the study population in The 
hague: prevalence of occluded children, 
causes of amblyopia and final visual acuity
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Account of the study poulation in The Hague
AccounT oF ThE STudy PoPuLATIon In ThE hAGuE: PrEVALEncE oF 
occLudEd chILdrEn, cAuSES oF AmBLyoPIA And FInAL VISuAL AcuITy
This chapter gives an account of three aspects of our study population in The Hague area. First 
of all, we determined the prevalence of occluded children in The Hague and we considered 
to what extent our study group represented a true coverage of the amblyopic children. Sec­
ondly, the diagnoses given to the children and the causes of amblyopia in our study group 
are analysed. Finally, the visual outcome of the children in our study group is evaluated and 
the possibility of having visual acuity as primary outcome measure instead of compliance is 
discussed. 
Prevalence of occluded children
Estimates of amblyopia’s prevalence in the literature have ranged from 0.5% to 5.3%. This 
broad range is caused by differences in the approach to studying the prevalence. Studies have 
differed in terms of study population (e.g. pre­school children, 6­year old children, and mili­
tary recruits), the applied examination methods and the visual acuity criterion used to diag­
nose amblyopia. In addition, these criteria are different at the start of occlusion treatment, the 
end of the occlusion treatment and in adulthood. This study defined amblyopia at the start of 
occlusion treatment as follows: 
­ A difference of visual acuity between the sound eye and the amblyopic eye of >2 logMAR 
lines or acuity <20/40 in the amblyopic eye.
­ Strabismic amblyopia: Amblyopia in the presence of a heterotropia at distance and/or near 
fixation, with anisometropia of 1.00 D or less of spherical equivalent.
­ Anisometropic amblyopia was defined as an amblyopia in the presence of anisometropia 
>1.0D, with no measurable heterotropia at distance or near fixation.
­ Combined mechanism amblyopia: Amblyopia in the presence of any heterotropia at dis­
tance and/or near fixation and anisometropia >1.00 D spherical equivalent or >2D difference 
in astigmatism in any meridian, which persists after at least 4 weeks of spectacle correction.
Our study population encompassed all children with newly diagnosed amblyopia in the mu­
nicipality of The Hague (with the exception of the areas Voorburg, Leidschendam, Wassenaar, 
Nootdorp, Ypenburg and Rijswijk). The Hague, being the third largest city in the Netherlands, 
harbours four main ophthalmology clinics with six treating orthoptists. Between July 2001 
and December 2003, the six treating orthoptists recruited children who had been diagnosed 
with amblyopia, using the above mentioned criteria, and had consequently been prescribed 
occlusion therapy. In this study 361 children with newly diagnosed amblyopia were registered 
for a period of 2.5 years, which equals 144 children per year. Also included in this number are 
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the families who refused study participation and those who could not be contacted before 
the second visit to the orthoptist and were therefore excluded from the analysis. 
The birth rate in the defined area of The Hague averaged 4,262 children / year in the years 
during which most of the children in the study were born (i.e. 1997, 1998 and 1999). Thus, 
the prevalence of occluded children in The Hague would be 144 / 4,262, which equals 3.38%. 
However, in 25 children the cause of amblyopia was undetermined. When correcting for these 
children, the prevalence of occluded children would be 3.15%.
We analysed the coverage of the eligible children in our defined area of The Hague, and it be­
came apparent that not all orthoptists had recruited the same number of children per work­
ing hour. In some cases this could be explained by the fact that in one clinic several children 
had already been prescribed occlusion therapy by an ophthalmologist, therefore, these chil­
dren could not be included in the study. We calculated an estimate of the eligible number of 
children, based on the number of children recruited, divided by the number of working hours 
per recruiting orthoptist. This estimate recruitment ratio was 10 newly diagnosed amblyopic 
children per 4 working hours per orthoptist per year, resulting in a total estimate of 230 eli­
gible children per year in our defined study area of The Hague. In our study 144 children had 
been included, implying 63% coverage. Based on the 230 eligible children per year, the preva­
lence of occluded children in our defined study area of The Hague would be 230 / 4,262, which 
equals 5.4%. As discussed in Chapter 4, the prevalence of occluded children in the population 
is higher than the prevalence of amblyopia in adulthood (defined as acuity >0.3 logMAR). 
This is possibly caused by over­treatment of amblyopia in childhood, because after cessation 
of occlusion therapy (at the age of app. 8) the visual acuity may increase or decrease until 
adulthood. The orthoptist is unaware in which child the visual acuity will increase or decrease 
and will therefore treat all children that have any chance of reaching an acuity of 0.5 or less 
in adulthood. 
cause of amblyopia 
Of the 361 occluded children in The Hague, the diagnoses were marked on the standard ex­
amination form by the treating orthoptists. In our study 35 possible diagnoses could be given. 
The cause of amblyopia was assessed after cessation of occlusion therapy by the researchers. 
We thought it important to register for each patient all the diagnoses of the amblyopia; there­
fore a distinction between the diagnoses and the cause of amblyopia was made. 
The cause of amblyopia in the 361 occluded children was assessed as anisometropia in 132 
children (37%), strabismus in 81 (22%), both strabismus and anisometropia in 42 (12%), hyper­
metropia in 12 (3%), both strabismus and hypermetropia in 18 (5%), both anisometropia and 
hypermetropia in 8 (2%), astigmatism in 27 (7%), both strabismus and astigmatism in 9 (3%), 
and deprivation in 7 (2%). The cause of amblyopia in 25 children (7%) was undetermined. 
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In the 361 children the orthoptists marked a diagnosis a total of 701 times, varying from 132 
children who had only one diagnosis marked, to one child who had six different diagnoses. 
The three most frequent diagnoses in our study population were anisometropia > 1D (n = 156; 
22%), hypermetropia > 3D (n = 145; 21%) and astigmatism (n = 135; 19%). Infantile esotropia 
was diagnosed in 21 children (3%), accommodative esotropia in 35 children (5%) and micro­
strabismus in 64 children (9%). 
On further analysis of the children with the diagnosis hypermetropia, 33 children were also 
diagnosed with a micro­strabismus, 20 with an accommodative esotropia and 10 with an in­
fantile esotropia. In 42 children with anisometropia, strabismus was also present, mainly mi­
cro­strabismus (n = 27). This also applies to the children with astigmatism: in a quarter of these 
children (n = 36) strabismus was present, mainly micro­strabismus (n = 23). 
When analysing the children with the diagnoses micro­strabismus, half of these children also 
had hypermetropia (n = 34), 27 an eccentric fixation, 27 an anisometropia, 23 astigmatism 
and 4 a latent nystagmus. In half of the children with an infantile esotropia, hypermetropia 
was present (n = 10), 6 children also had astigmatism, 5 a latent nystagmus and 4 had aniso­
metropia.
Figuren bij Chapter 10. 
 
 
 
Figure 1.a. The distribution of the 10 possible causes of amblyopia per diagnose. Each bar represents a 
diagnosis. In our study population 23 diagnoses were given by the treating orthoptist and more than one 
diagnosis may be given to one child. Each bar was subdivided into the cause of amblyopia (assessed by 
the researchers), e.g. the diagnosis ‘late-onset esotropia’ was present in the following three causes of 
amblyopia: strabismus, strabismus & anisometropia and strabismus & hypermetropia.  
 
Figure 1.a. The distribution of the 10 possible causes of amblyopia per diagnose. Each bar represents 
a diagnosis. In our study population 23 diagnoses were given by the treating orthoptist and more than 
one diagnosis may be given to one child. Each bar was subdivided into the cause of amblyopia (assessed 
by the researchers), e.g. the diagnosis ‘late­onset esotropia’ was present in the following three causes of 
amblyopia: strabismus, strabismus & anisometropia and strabismus & yperm tropia. For colour figur  
please see ‘Colour figures’ on page 198.
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Figure 1a shows the distribution of the 10 causes of amblyopia per diagnosis, of the 361 oc­
cluded children in The Hague. In our study population 23 out of the possible 35 diagnoses 
were given by the treating orthoptist. The diagnoses given by the treating orthoptist may not 
necessarily be the only cause of amblyopia. For example, of the 21 children who were given 
the diagnosis ‘infantile esotropia’ (Figure 1a, bar on the left­hand side), only in 14 of those, the 
infantile esotropia, i.e., strabismus was indeed the cause of amblyopia. In 3 out of those 23 
children, a combined anisometropia and strabismus was the cause of amblyopia; in 3 children 
the cause of amblyopia was strabismus and hypermetropia and one child had diagnosis ‘in­
fantile esotropia’, but had amblyopia caused by both strabismus and astigmatism. 
Figure 1b shows the distribution of the 23 diagnoses given to the children in our study popu­
lation per cause of amblyopia. As mentioned before, a child may have more than one diag­
nosis. For example, in the 81 children in whom the amblyopia was caused by strabismus, 108 
diagnoses were given: see bar on the left­hand side. In 42 children the amblyopia was caused 
 
 
Figure 1.b. The distribution of the 23 diagnoses in our study population per cause of amblyopia. Each 
bar represents 1 of the 10 causes of amblyopia, which was subdivided in the diagnoses given in our 
study population. One child may have more than one diagnosis, but only one cause of amblyopia. For 
example, anisometropia was assessed as the cause of amblyopia in 132 children; however, 6 children 
with anisometropic amblyopia also had the diagnosis ‘ ophoria’ and 11 ‘ xophoria’. These diagnoses 
were not the main cause of amblyopia. The number above the bar corresponds with the number of 
children whose cause of amblyopia is represented in that bar. 
 
Figure 1.b. The distribution of the 23 diagnoses in our study population per cause of amblyopia. Each 
bar represents 1 of the 10 causes of amblyopia, which was subdivided in the diagnoses given in our 
st dy population. One child may have more than one diagnosis, but only one ca s  f ia. For 
example, anisometropia was assessed as the cause of amblyopia in 132 children; however, 6 children with 
anisometropic amblyopia also had the diagnosis ‘esophoria’ and 11 ‘exophoria’. These diagnoses were not 
the main cause of amblyopia. The number above the bar corresponds with the number of children whose 
cause of amblyopia is represented in that bar. For colour figure please see ‘Colour figures’ on page 199.
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by strabismus and anisometropia; in this group a diagnoses was given 142 times to these 
children. 
This manner of visualisation was chosen to facilitate a comparison with other studies that 
investigated causes of amblyopia.
Visual acuity as treatment outcome
When designing the study it was intended to have the visual acuity of the children as pri­
mary outcome measure. However, the referees objected to this outcome measure because of 
the statistical noise between compliance and visual acuity increase, as measured in current 
orthoptic practice. When measuring visual acuity in young children the testability and co­
operation is often limited. Consequently, when having visual acuity as the primary outcome 
measure, the treatment groups would need to be excessively large. Therefore, the primary 
outcome measure was restricted to electronically measured compliance. Now, we contem­
plated whether visual acuity could have been used as primary outcome measure as we have 
included almost three times the primary target (which was 110 patients). 
Visual acuity was assessed in children whose occlusion treatment was either ‘completed’ by 
the orthoptists or ‘terminated’ by the parents, and in children who had reached the age of 
six, using standard protocols (n = 203). The independent research orthoptist tested the best 
corrected visual acuity using Landolt­C chart 2.6’. At least 3 out of 5 optotypes had to be an­
swered correctly per line. The luminance was measured during the tests. This ranged from 160 
cd/m² to 320 cd/m², which is in accordance with the norm. To correct for a difference in testing 
distance, a correction factor was applied (e.g. when the distance to the chart was 5.7m, a cor­
rection factor of 1.14 was applied). 
Figure 2 shows the relationship between visual acuity of the amblyopic eye (logMAR) at the 
start of treatment, at the end of treatment (both measured by the treating orthoptist) and 
the moment the acuity was assessed in a standardised fashion (measured by the treating or­
thoptist), per category compliance. Visual acuity as measured by the orthoptists at the end 
of treatment was comparable to that measured by the research orthoptist in a standardised 
fashion at follow­up. There was no significant difference in age of the children between the 
four categories of compliance. The graph illustrates that children with poor visual acuity in 
their amblyopic eye at treatment onset have low compliance. Despite their low compliance, 
visual acuity improves to an average of 0.7 (= 0.21 logMAR). This supports the idea that visual 
acuity improves with little patching, but could also be due to the natural course of visual acu­
ity development. 
In general, having established this large study group of over 300 children, it was possible 
to provide an evaluation of visual acuity outcome, despite the critical note of the referees. 
However, we feel that testability and co­operation of young children in the current everyday 
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orthoptic practise may be too unreliable a variable and unsuitable as primary outcome mea­
sure for our study design. Nevertheless, when applying standard protocols, e.g. one very ex­
perienced orthoptist using only one acuity test (all logMAR scale) for all children in the same 
consultation room with sufficient testing time available, to measure visual acuity at treatment 
onset, during treatment and at end of treatment, visual acuity could be used as primary out­
come measure.
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Figure 2. The relationship between visual acuity of the amblyopic eye (logMAR) at the start of treatment as 
measured by the treating orthoptist, at the end of treatment and the moment the acuity was assessed in a 
standardised fashion by the research orthoptist, per category compliance. The red line represents patients 
with poor compliance, the green line with high compliance. The graph illustrates that despite a low level of 
compliance, visual acuity improves.
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General discussion and future prospects 
GEnErAL dIScuSSIon And FuTurE ProSPEcTS
Amblyopia (a lazy eye) is the most common eye disorder in children. It is usually treated with 
patching of the non­amblyopic eye preferably before the age of 6. Since Child Health Care 
Centres in the Netherlands check for strabismus in infants and measure visual acuity at age 
3, untreated amblyopia has become a rarity. Nevertheless, one third of the affected children 
do not reach visual acuity of 6/12 in their amblyopic eye (acuity necessary to read) primarily 
caused by non­compliance: children and/or their parents do not patch the non­amblyopic eye 
as prescribed by the orthoptist. This increases the risk of bilateral visual impairment due to 
loss of vision in the non­amblyopic eye and decreases their quality of life in adulthood. 
To date, no study has provided information on which factors influence compliance and wheth­
er compliance with occlusion therapy can be improved, in concurrence with the electronic 
monitoring of that compliance. Therefore, all children with newly diagnosed amblyopia in The 
Hague were registered in order to determine the effect of clinical, socioeconomic and psy­
chometric factors on compliance. To investigate whether compliance could be improved, an 
educational programme was developed: included children were randomised to receive either 
the educational programme (intervention group) or a picture to colour (reference group). The 
main findings of our research will be discussed and the clinical relevance and future prospects 
will be considered. 
occlusion therapy
Occlusion therapy for amblyopia has been the mainstay treatment for centuries (Chapter 2). 
In current orthoptic practice, prescribed occlusion hours range from 15 minutes per day to all 
waking hours (Tan, et al. 2003). Nevertheless, few guidelines for the prescription exist. Differ­
ent orthoptists prescribe very different regimens of prescriptions for the same patient and no 
consistently strict or consistently lenient orthoptists could be identified (Chapter 3). Our study 
in The Hague found a borderline significant relationship between the number of occlusion 
hours prescribed by the orthoptist and the actual hours patched by the parents: when the 
number of prescribed hours increased, compliance decreased and the variation in compliance 
was larger (P = 0.058; r = 0.512) (Loudon, et al. 2004). On average, when 6 hours/day had been 
prescribed, the actual dose received was 3 hours/day. These findings were confirmed by Awan 
et al. (Awan, et al. 2005). The relationship between the actual hours of patching and the visual 
acuity improvement was objectively documented by Stewart et al. (Stewart, et al. 2004). They 
found that 82% of the improvement was achieved during the first 6 weeks of treatment, and 2 
hours/day had a similar effect as 6 hours/day, although the children with a higher number of 
occlusion hours attained a successful outcome level more rapidly. The authors suggested that 
occlusion regimens of 1 hour/day would have a similar effect on the visual acuity outcome as 
2 hours/day or more (Stewart, et al. 2005); a result also found by the recent Amblyopia Treat­
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ment Study who compared the visual acuity outcome of 2 hours/day with 6 hours/day (PEDIG 
2003). In addition, it seems as though the dose­response appears to be saturated at a level of 
100 cumulative hours of occlusion (Stewart, et al. 2005). These findings all emphasise the idea 
that when compliance is poor, or is expected to be poor, a more flexible approach towards 
treatment and less intensive patching regimens could offer a solution. 
Group at risk for non-compliance
Several studies have provided evidence that the initial visual acuity of the amblyopic eye is a 
prognostic factor of outcome of treatment (Hiscox, et al. 1992; Lithander and Sjöstrand 1991; 
Smith, et al. 1995; Stewart, et al. 2005). Children with severe amblyopia have significantly 
greater residual amblyopia at the end of the treatment than children with mild or moderate 
amblyopia. This is not unexpected, since we found the initial visual acuity of the amblyopic 
eye to be the most important clinical parameter for compliance: poor visual acuity caused 
poor compliance with treatment, explained by the fact that the acceptance of the patch is less 
when acuity is low (Chapter 7).
In our study population in The Hague the following socioeconomic parameters as predictors 
for non­compliance were identified: poor parental fluency in the national language, a low 
level of education and the country of origin. Although country of origin was selected in the 
multivariate model to be most significant, we cannot exclude the possibility that fluency in 
the national language and level of education may be the causal factors (both being strongly 
correlated with the country of origin). Nonetheless, we were able to conclude that families 
from Surinam, who were either native speakers or otherwise fluent in the Dutch language, 
showed the same level of compliance as the Dutch families. Therefore, in practice, the fluency 
in the national language appeared to be the most important factor. In concordance, time 
spent on explaining the diagnosis and treatment was shorter in patients who were scarcely 
fluent or did not speak the national language at all, compared to patients who were native or 
good speakers of the national language. Several factors may have contributed to this obser­
vation, e.g. language skills, confidence, assertiveness, education, interests, etc. Patients who 
lack the confidence to converse in the national language might be inhibited to ask questions, 
assuming they understand the care givers’ explanation of disorder and treatment. Also, in the 
Netherlands, the time an orthoptist can give a patient varies and is sometimes limited to 15 
minutes for a new patient, allowing the orthoptist very little extra time for those less fluent in 
the native language. 
Another common theme of studies into factors affecting compliance with occlusion therapy 
is that eye patching causes considerable distress for both the family and the child, sometimes 
with adverse psychological impact on the child. However, outcomes of behavioural measure 
did not suggest any adverse effect on the child’s general well­being either during or after 
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cessation of treatment (Hrisos, et al. 2004; Parkes 2001). A model employed by Searle et al. 
based on Protection Motivation Theory (PMT) by Rogers in 1983 proved useful to understand 
psychosocial factors involved with non­compliance (Norman, et al. 2003; Rogers 1975, 1983; 
Searle, et al. 2000; 2002). They concluded that many parents experienced distress related to 
patching therapy and also, that past compliance behaviour was predictive for future compli­
ance behaviour. In our study in The Hague we used this PMT questionnaire to identify the 
most important psychometric factors influencing compliance. We found the prohibition bar­
riers ‘degree of distress’ and ‘stigma’ to negatively influence compliance: when the child cried, 
got upset or was teased while wearing the patch, parents were afraid this might have a nega­
tive influence on their relationship with their child and consequently the patch would come 
off. An increased ability to ‘implement the occlusion therapy into their daily routine’ positively 
influenced compliance, and finally, the ‘vulnerability’ of their child’s eye condition also influ­
enced compliance: when parents were of the opinion that if the eye was left untreated it 
would affect their child’s abilities later in life, compliance increased (Chapter 8). Dixon­Woods 
et al. interviewed 25 parents whose child was being treated with occlusion therapy for the am­
blyopic eye (Dixon­Woods, et al. 2006). They described many parents experiencing tensions 
due to the treatment and were likely to non­comply when no or insufficient improvement in 
acuity was found. Therefore, they recommended that interventions applied to improve com­
pliance should focus on strategies that parents often already applied themselves. 
Improving compliance
Current compliance enhancing programs, aimed at the parents, have been proven to be effec­
tive in increasing their understanding of the disease (Goransson, et al. 1998; Newsham 2002). 
The existing programs aimed at the children contain animal figures that wear eye patches and 
have exciting adventures. José Vingerling, an artist specialised in art for sick children, thought 
it was necessary to develop a fully self­explanatory cartoon written from the perspective of a 
child. The child follows the same course of events as children do in real life: the ophthalmolog­
ic examination and the subsequent occlusion therapy. Hence, this made it easier for them to 
identify themselves with the child in the cartoon. The programme was intended for children 
from all ethnic, social and cultural backgrounds and was not gender specific. Furthermore, it 
had no text, as most of the children treated for amblyopia are too young to read. Objective 
monitoring of compliance in the amblyopic children in The Hague revealed mean compliance 
to be 78% in the group who received our educational programme as compared to 57% in the 
group who did not (reference group). Compliance decreased over the 2­year study period on 
each subsequent electronic measurement, more so in the reference group than in the inter­
vention group, partly due to a selection bias: children with low visual acuity at the start of 
treatment were less compliant, were therefore patched for a longer period of time and, con­
sequently, were monitored more often. There was considerable variation within and between 
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the children; we found past compliance behaviour to be an unreliable predictor for future 
compliance behaviour. The most striking finding of our study was the number of children who 
did not occlude at all: 3 in the intervention group as compared to 23 in the reference group 
(Chapter 7). At present, these children are expensive in terms of diagnoses and treatment and 
in the future, in case the vision in their better eye is lost or decreases. Children who were not 
occluded at all and children who were, were comparable for clinical parameters. However, 
there were differences in the level of parental education, country of origin and fluency in 
the national language. On further examination of the children in whom compliance was less 
than 20%, it was apparent that there was a clear discrepancy of objective knowledge and the 
measured knowledge of the parents. This indicated that parents were unaware of their lack of 
knowledge, therefore could not give feedback or put forward any questions, thus leaving the 
orthoptist oblivious to the parents’ problem. For a small group of parents that what happened 
at the orthoptists’ was the main reason for failing to patch: when no attention could be paid 
to problems encountered during patching, no questions could be asked or answered and only 
poor information was supplied, parents were most likely to become non­compliers. A number 
of parents indicated that visits should be more child­focused. Children were poorly involved 
in the communication between parent and orthoptist and consequently did not understand 
the reason they had to be patched. However, the children and families who received the edu­
cational programme had better knowledge of the treatment, suffered less distress, and were 
more able to implement the treatment into their daily routine (Chapter 8). 
Therefore, we suggested that the educational programme, explaining reasons for therapy to 
the child, partially obviated the poor communication between parent and orthoptist. 
Future prospects
The research described in this thesis focussed on a method to improve compliance with occlu­
sion therapy for amblyopia and to identify certain risk­factors for non­compliance. We aimed 
to treat the included children according to standard orthoptic care in The Netherlands. How­
ever, performing house­visits and measuring compliance with an ODM the child had to wear 
on the eye patch during one week, every three months, are not part of standard orthoptic 
care. Our method had the advantage of the researchers being seen as working independently 
from the treating orthoptists and, also, that children who no longer visited the clinic remained 
in the study, but naturally may have affected compliance. For future studies it would be desir­
able to have visual acuity as primary outcome measure. This would also preclude the problem 
that in our study compliance was measured only one week out of a possible 12. 
The educational programme employed in this study and the risk­factors identified should be 
made widely available. Future research should therefore focus on the implementation and 
distribution of the educational programme in the current orthoptic practice. Furthermore, the 
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orthoptists should be made aware of, and be able to identify the group most at risk for non­
compliance and take the appropriate action. 
Since the most significant factors that affect compliance were not disease specific (i.e. com­
pliance was found only to be influenced by the initial visual acuity of the amblyopic eye), it 
seems validated that subsequent research should focus on the development of an education­
al programme for other enduring treatments for young children, based on the same principles 
as the programme used in this thesis.
In this thesis the influence of clinical, socioeconomic and psychometric factors on compliance 
was calculated. The analysis demonstrated that 12% of the variation in compliance could be 
explained by the socioeconomic and clinical factors. Another 22% of the variation in com­
pliance was explained by the psychological variables. These present results suggest that ad­
ditional factors need to be included in further studies into compliance behaviour models. 
Eventually, we aim to proceed to the development of a structural model, exploring the rela­
tionships between the factors influencing compliance and the final visual acuity outcome.
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SummAry
In this thesis the following questions concerning the occlusion treatment for amblyopia using 
an eye patch, were addressed: guidelines for prescribing a certain number of occlusion hours, 
the course of visual acuity after cessation of occlusion therapy, and the relationship between 
compliance and visual acuity increase. Then it was determined which factors influenced com­
pliance with occlusion therapy for amblyopia and whether compliance could be improved.
Compliance is an important factor for treatment success. It is generally referred to as the de­
gree of correspondence between the patients’ dosage or behaviour and recommendations 
from the health care provider. Poor compliance decreases the effectiveness of treatment and 
increases costs to the health care system. Amblyopia (a lazy eye, prevalence 3.25%) is defined 
as a diminished acuity in one eye. It is caused by strabismus, anisometropia and/or visual 
deprivation. By occluding the non­amblyopic eye for several hours per day, preferably before 
the age of six, a permanent deterioration in the acuity of the amblyopic eye can be prevented. 
Despite screening at the Child Health Care Centres and an effective treatment by the orthop­
tist, the amblyopia persists in approximately a third of the affected children, primarily caused 
by non­compliance. 
Since the development of the Occlusion Dose Monitor (ODM) by Fielder and Moseley in 1991, 
compliance with occlusion therapy for amblyopia can be measured electronically and there­
fore objectively. The design of the Fielder­ODM was modified by the Medical Technical De­
partment of the Academic Medical Center Amsterdam. It measures the temperature differ­
ence between the front and the back of the ODM every two minutes and is attached to the 
front of the patch on the eye by double sided tape. 
In the introduction, chapter 1, the objective of this thesis is discussed and special attention is 
given to previous studies of other (eye) diseases that used electronic monitoring to measure 
compliance. 
chapter 2 provides an historical overview of the discussion, which has continued for the past 
three centuries, as to the optimal treatment for amblyopia. The first treatment described for 
amblyopia, as found in the literature, was the eye patch. This was described by Charles de 
Saint­Yves in Paris in 1722, and not by the person usually credited for the introduction of oc­
clusion therapy: George Comte de Buffon (1743). Besides the eye patch, various other treat­
ment methods have been ventured (i.e. atropine treatment).
Few guidelines exist when prescribing a certain number of occlusion hours and the treat­
ment is more or less ‘practice based’. Consequently, for a child with a given age and acuity, 
the prescribed occlusion hours may vary from a few minutes per day to all waking hours. An 
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inventory of the variation in the prescription of occlusion therapy is described in chapter 3. 
A questionnaire was designed with five case examples of amblyopic children. It was complet­
ed by 404 orthoptists simultaneously and in complete silence during two national orthoptic 
meetings in the Netherlands and Germany. The variation in the number of prescribed hours of 
occlusion was large. In addition, the orthoptists were not consistently strict or lenient in their 
prescription of occlusion therapy. 
There is a world­wide discussion on the subject of the course of the visual acuity after ces­
sation of occlusion therapy at the age of approximately eight years. chapter 4 describes a 
historical cohort of 137 patients who were treated for their amblyopia 30 years ago and were 
orthoptically re­examined in 2003. In general, in most patients the acuity in the amblyopic eye 
had increased after cessation of occlusion therapy. However, when the amblyopia was caused 
by both strabismus and anisometropia, or when the anisohypermetropia had increased dur­
ing the years, acuity in the amblyopic eye had decreased. 
chapter 5 considers the reliability and limitations of the ODM. The ODM was found satisfacto­
rily reliable to be able to differentiate between measurements on the eye and on other parts 
of the body. However, the ODM placed elsewhere on the head (i.e. the forehead) and a high 
ambient temperature (> 33°C) prevented a reliable ODM measurement. 
chapter 6 describes a pilot study that preceded the study in The Hague. This study confirmed 
the assumption that a higher level of compliance was correlated with a better improvement 
in visual acuity. 
chapters 7 to 10 describe the main study of this thesis, in which risk factors for non­compli­
ance are analysed and the effect of a newly developed educational programme is assessed. 
The study was designed as a prospective randomised clinical trial. For 30 months all children 
with newly diagnosed amblyopia were registered in The Hague, with additional children from 
Frankfurt and Leicester. Compliance was measured electronically with the ODM. The ODM was 
distributed by means of home visits by the researchers after the child had been randomised to 
either the intervention or control group. Children in the intervention group received the new­
ly developed educational programme designed to improve compliance. It was developed by 
two artists who are specialised in art for sick children: José Vingerling and Gerard de Bruyne. 
The programme consisted of a cartoon story without text that explained to the child why it 
should patch, a calendar with stickers and an information sheet for the parents. Children in 
the control group received a picture to colour that was also considered a reward, but did not 
contain the educational message. Because of the home visits and not distributing the ODM in 
the out­patient clinic, the researchers were seen as working independently from the treating 
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orthoptist. Therefore, the ODM was less likely to be interpreted as a lie detector and, also, that 
non­compliant patients or patients who no longer visited the clinic remained in the study. 
All parents, in both groups, completed the socio­economic questionnaire. After six months 
of treatment they completed a second questionnaire assessing possible reasons for failure or 
success of treatment. 
chapter 7 evaluates which clinical and socio­economic factors influence compliance and the 
effect of the educational programme on compliance. The most important socio­economic 
factors included parental fluency in the national language, country of origin and the level of 
education. However, the correlation between country of origin and fluency in the national 
language was too strong to be able to detect the effect of either variable. Nonetheless, it was 
found that children from mothers born in Surinam, who were either native speakers or oth­
erwise fluent in the Dutch language, showed the same or even higher levels of compliance 
as the children from mothers born in the Netherlands. Therefore, the fluency in the national 
language appeared to be the most important factor. The most important clinical factor was 
the initial visual acuity of the child: children with low visual acuity were less compliant. 
Children who received the educational programme had better compliance than the control 
group had (78% vs. 57%), and fewer children were not occluded at all (3 vs. 23 in the control 
group). The educational programme, explaining reasons for therapy to the child, partially ob­
viated the main risk factors for non­compliance with occlusion therapy for amblyopia. 
In chapter 8 the most important reasons for failure or success of occlusion therapy are as­
sessed by means of a questionnaire. It was concluded that a high level of distress caused 
by occlusion therapy, poor parental knowledge about disease and treatment and difficulties 
implementing the treatment into the daily routine were strongly correlated with non­compli­
ance. 
In the study in The Hague, four brands of patches were used: Opticlude, Orthopad, Pro­Ophta 
and Beiersdorf. chapter 9 describes a study into the properties of the eye patch, parental 
satisfaction and the influence of the different patches on compliance. There were large differ­
ences in the properties of the eye patch, especially in opacity and strength of adhesion to the 
skin. In all brands of patches the breathing capability was minimal. These differences however, 
did not influence the orthoptists’ choice in prescribing a certain brand of patch; one orthoptist 
mainly prescribed one brand of patch, without taking into account, for example, the occlu­
sion duration or skin type. Compliance was not influenced by the brand of patch. In general, 
parental satisfaction was moderate. 
chapter 10 gives an account of to what extent the study group represented a true coverage 
of the amblyopic children in The Hague and describes the diagnoses given to the children and 
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the causes of amblyopia. Finally, the possibility of having visual acuity as primary outcome 
measure instead of electronically measured compliance is discussed. The visual outcome of 
the children was evaluated. This analysis demonstrated that children who patched less than a 
quarter of the prescribed occlusion time showed practically no improvement in visual acuity 
in the amblyopic eye.
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In dit proefschrift worden de volgende punten ten aanzien van de behandeling van het luie 
oog met de afplakpleister aan de orde gesteld: richtlijnen voor het voorschrijven van de duur 
van het afplakken, het verloop van de gezichtsscherpte na het beëindigen van het afplakken, 
en de relatie tussen de therapietrouw en verbetering van de gezichtsscherpte. Vervolgens 
wordt de vraag gesteld welke factoren van invloed zijn op de therapietrouw bij de afplakbe­
handeling en wordt er gekeken of de therapietrouw verbeterd kan worden. 
Therapietrouw is één van de belangrijkste factoren voor een succesvolle behandeling. Over 
het algemeen wordt therapietrouw gedefinieerd als de mate waarin de patiënt zich houdt aan 
de voorgeschreven dosering of gedragsregels van een zorgverlener. Therapieontrouw leidt 
niet alleen tot een verminderde effectiviteit van de behandeling, maar ook tot een verhoging 
van de kosten ervan. Amblyopie (lui oog, prevalentie 3,25%) is een verminderde gezichts­
scherpte in één van beide ogen, wat ontstaat door een onderbreking van de normale visu­
ele ontwikkeling. De belangrijkste oorzaken zijn scheelzien, een refractie afwijking (ongelijke 
plussterkte in de bril) of, meer zeldzaam, aangeboren staar. Door het goede oog enkele uren 
per dag vóór de leeftijd van zes jaar af te plakken door middel van een oogpleister kan een 
permanente achteruitgang in de gezichtsscherpte van het luie oog voorkomen worden. On­
danks het screenen op een lui oog op het Consultatiebureau en een effectieve behandeling 
ingezet door de orthoptist, blijft ongeveer één derde van deze kinderen een lui oog houden, 
waarvan de hoofdoorzaak therapieontrouw is. 
Sinds de introductie van de Occlusion Dose Monitor (ODM) door Fielder en Moseley in 1991 
kan de therapietrouw bij de afplakbehandeling van kinderen met een lui oog elektronisch 
gemeten worden. De ODM is door de afdeling Medisch Technisch Onderzoek van het Acade­
misch Medisch Centrum aangepast en kleiner gemaakt. Het meet iedere twee minuten het 
temperatuurverschil tussen de voorkant en de achterkant en wordt met dubbelzijdig plak­
band aan de buitenkant van de oogpleister mee op het oog geplakt.
In de inleiding, hoofdstuk 1, wordt de vraagstelling behandeld en wordt nader inge­
gaan op eerdere studies die elektronisch de therapietrouw bij de behandeling van andere 
(oog)aandoeningen onderzocht hebben. 
In hoofdstuk 2 wordt een historisch overzicht gegeven van een al meer dan drie eeuwen 
durende discussie over de beste behandelmethode van een lui oog. De eerst beschreven be­
handeling voor het luie oog was de afplakpleister. Deze werd voor het eerst beschreven door 
Charles de Saint­Yves in Parijs in 1722 en niet, zoals door velen wordt gedacht door de George 
Comte de Buffon (1743). Tal van andere behandelmethoden worden besproken waarbij de 
pleister niet gedragen hoeft te worden (bijv. Atropine behandeling).
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Er zijn nauwelijks richtlijnen voor het voorschrijven van het aantal uren per dag dat een kind 
afgeplakt moet worden gegeven een bepaalde gezichtsscherpte en leeftijd. Voor paramedi­
sche behandelingen bestaan over het algemeen nauwelijks richtlijnen en is de behandeling 
vaak ‘practice based’. In hoofdstuk 3 wordt een studie beschreven waarin deze variatie in 
het voorschrift van de orthoptist werd geïnventariseerd. Tijdens twee nationale orthoptisten 
vergaderingen, in Nederland en in Duitsland, werd een enquête met vijf standaard amblyope 
kinderen door alle 404 aanwezige orthoptisten tegelijkertijd en in stilzwijgen ingevuld. De 
variabiliteit in het plakvoorschrift was enorm. Bovendien waren er geen orthoptisten die con­
sequent streng voorschreven en orthoptisten die consequent niet­streng voorschreven. 
Wereldwijd is het al jaren een punt van discussie wat het verloop is van de gezichtsscherpte 
na het beëindigen van de afplakbehandeling rond ongeveer het achtste levensjaar. In hoofd-
stuk 4 wordt een historisch cohort beschreven wat 30 jaar geleden de afplakbehandeling 
heeft ondergaan en in 2003 opnieuw orthoptisch onderzocht is. Over het algemeen was de 
gezichtsscherpte in het luie oog bij de meeste mensen na het stoppen van de behandeling 
toegenomen. Echter, als het luie oog veroorzaakt werd door zowel scheelzien als een onge­
lijke brilsterkte of als er gedurende de jaren een toename was van het verschil tussen de bril­
lenglazen, was er juist een daling van de gezichtsscherpte in het luie oog.
In hoofdstuk 5 worden de betrouwbaarheid en de beperkingen van de ODM, het elektroni­
sche apparaatje, uiteengezet. De ODM werd voldoende betrouwbaar gevonden om onder­
scheid te kunnen maken tussen de locatie op het oog of elders op het lichaam. Alleen wan­
neer de ODM ergens anders op het hoofd werd geplakt (bijv. voorhoofd) en er sprake was van 
een hoge omgevingstemperatuur (> 33°C) was een betrouwbare meting vrijwel onmogelijk.
In hoofdstuk 6 wordt een pilot­studie beschreven, die vooraf ging aan het onderzoek in Den 
Haag, waarin bevestigd werd dat een betere therapietrouw gecorreleerd was met een snellere 
stijging van de gezichtsscherpte. 
hoofdstuk 7 tot en met 10 zijn gewijd aan de hoofdstudie van dit onderzoek, waarbij risi­
cofactoren voor therapieontrouw zijn geanalyseerd en het effect van een nieuw ontwikkeld 
educatief programma is onderzocht. Het was een prospectief, gerandomiseerde studie waar­
bij gedurende 30 maanden alle kinderen in Den Haag, inclusief enkele kinderen in Frankfurt 
en Leicester, die voor het eerst een afplakbehandeling ondergingen meededen. De therapie­
trouw werd elektronisch gemeten met de ODM. Deze werd rondgebracht door middel van 
huisbezoeken door de onderzoeker, nadat het kind was ingedeeld in de interventie groep of 
de controle groep. Kinderen in de interventie groep kregen het speciaal, door twee kunstena­
ren gespecialiseerd in kunst voor het zieke kind (José Vingerling en Gerard de Bruyne) voor de 
studie ontwikkelde educatieve programma, bedoeld om de therapietrouw te verbeteren. Het 
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programma bestond uit een tekstloos stripverhaal, zonder dierfiguren, gericht op het kind, 
dat aan het kind uitlegt waarom er geplakt moest worden. Daarnaast kregen de kinderen 
een kalender met stickers en de ouders een informatiefolder, beschikbaar in zes talen, over 
de aandoening en de behandeling. De kinderen in de controle groep kregen een kleurplaat 
die volledig los stond van de behandeling, maar wel door de kinderen werd ervaren als een 
beloning. De onderzoekers werden door de ouders en kinderen als onafhankelijk van de be­
handelende orthoptist gezien. Dit kwam mede doordat de onderzoekers via huisbezoeken de 
metingen verricht hebben en niet in het ziekenhuis op de polikliniek. Hierdoor werd de ODM 
niet door de ouders als een leugendetector gezien en bleven ook therapieontrouwe mensen 
en de mensen die niet meer op controle in het ziekenhuis kwamen toch in de studie.
Alle ouders, zowel in de interventie als in de controle groep, vulden tijdens het eerste huis­
bezoek een sociaal­economische enquête in. Na zes maanden behandeling werd een tweede 
enquête ingevuld waarin redenen voor het falen of succesvol zijn van de behandeling werden 
geïnventariseerd. 
hoofdstuk 7 beschrijft welke klinische en sociaal­economische factoren van invloed waren 
op de therapietrouw en het effect van het educatieve programma op de therapietrouw. De 
belangrijkste factoren voor therapieontrouw waren de vaardigheid van de ouders in de Ne­
derlandse taal, het land van herkomst en de hoogst genoten opleiding van een van beide ou­
ders. Echter, de correlatie tussen het land van herkomst en de vaardigheid in de Nederlandse 
taal was te sterk om het aparte effect van één van beide parameters te bepalen. Wel werd er 
gevonden dat kinderen van moeders geboren in Suriname, met een goede beheersing van 
de Nederlandse taal, net zo een goede therapietrouw hadden of zelfs beter, dan de kinderen 
van moeders geboren in Nederland. Dit lijkt de indruk te bevestigen dat de vaardigheid in de 
Nederlandse taal de belangrijkste rol speelt. De belangrijkste klinische factor voor de thera­
pietrouw was de gezichtsscherpte in het luie oog van het kind bij het begin van de behande­
ling: hoe slechter de gezichtsscherpte hoe slechter er geplakt werd. 
De kinderen die het educatieve programma met het stripverhaal kregen hadden een betere 
therapietrouw dan de kinderen in de controle groep (respectievelijk 78% en 57%). Het meest 
opvallende verschil was het aantal kinderen dat helemaal niet afplakte: 3 in de interventie 
groep en 23 in de controle groep. 
Het educatieve programma, wat aan het kind uitlegt waarom hij of zij geplakt moet worden, 
lijkt de belangrijkste redenen voor therapieontrouw te ondervangen.
In hoofdstuk 8 is achteraf, door middel van een vragenlijst, gekeken wat de belangrijkste 
redenen zijn waarom de afplakbehandeling wel of niet succesvol verlopen is. Hieruit bleek dat 
een hoge mate van stress in het gezin, gebrek aan kennis over de aandoening en behande­
ling en moeite met de dagelijkse implementatie van de afplakbehandeling sterk gecorreleerd 
waren met de therapieontrouw. 
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In de studie in Den Haag werd gebruik gemaakt van vier merken afplakpleister: Opticlude, 
Orthopad, Pro­Ophta en Beiersdorf. In hoofdstuk 9 wordt een onderzoek beschreven waarin 
aandacht is besteed aan de kwaliteit van de afplakpleister, de tevredenheid van de ouders 
erover en de invloed van de pleistersoort op de therapietrouw. Er werden grote verschillen 
gevonden tussen de pleistermerken wat betreft de eigenschappen. Vooral in lichtdoorlaat­
baarheid en plakkracht waren de verschillen aanzienlijk. In alle pleisters was het ademende 
vermogen minimaal. Deze verschillen in eigenschappen lieten zich echter niet vertalen in het 
voorschrift van de orthoptist; een orthoptist schreef voornamelijk één merk voor zonder reke­
ning te houden met bijvoorbeeld de duur van het afplakken of het huidtype. 
Er kon niet aangetoond worden dat de therapietrouw gecorreleerd was met een merk pleister. 
Over het algemeen waren de ouders matig tevreden over de door hen gebruikte pleister.
In hoofdstuk 10 wordt een verantwoording gegeven van in hoeverre de studie populatie 
in Den Haag representatief is voor de kinderen in Den Haag met een lui oog en worden de 
resultaten van de verschillende oorzaken van het luie oog (scheelzien, verschil in brilsterkte, 
etc.) weergegeven. Tot slot wordt besproken of, achteraf gezien, ook de stijging in gezichts­
scherpte van de kinderen als uitkomstmaat voor de studie gebruikt had kunnen worden, in 
plaats van elektronisch gemeten therapietrouw. Uit deze analyse kon geconcludeerd worden 
dat kinderen die minder dan een kwart van de voorgeschreven uren hadden afgeplakt, vrijwel 
geen stijging hadden in de gezichtsscherpte van het luie oog.
171
dankwoord
Onderzoek doen is boeiend, verrijkend en leuk. Toch is een woord van dank zeker nodig, want 
promotieonderzoek doe je nooit alleen en hoewel alleen mijn eigen naam op de voorkant 
van dit proefschrift staat, hebben veel mensen aan het onderzoek bijgedragen. De interesse 
en betrokkenheid van iedereen heeft mij altijd goed gedaan, daarvoor mijn hartelijke dank. In 
het bijzonder wil ik graag de volgende mensen bedanken.
Mijn promotor en begeleider, Prof. dr. H.J. Simonsz. Beste Huib, je vroeg of ik kon borduren en 
of ik al een richting voor verdere specialisatie had gekozen. Vervolgens leerde jij mij zodanig 
naar ogen kijken waardoor ik zeker wist dat ik in die richting verder wilde. Je gedrevenheid, 
passie voor het vak en voor onderzoek waren voor mij reden genoeg om na een bespreking 
weer met goede moed verder te gaan. Waar ook ter wereld en op welk tijdstip dan ook, ik 
mocht je altijd bellen: “The sky is the limit”. Zeer veel dank voor dit alles! Ook je hulp bij het 
opzetten van een onderzoek in Boston waardeer ik zeer.
Prof.dr. G. van Rij, mijn andere promotor, hartelijk bedankt voor de mogelijkheid die ik gekre­
gen heb om deel te nemen aan het onderzoek, uw interesse daarin en begeleiding daarbij. 
Voor de juiste woorden op die zo cruciale momenten. Daarnaast wil ik u bedanken om na het 
onderzoek de opleiding tot oogarts te mogen volgen.
De leden van de kleine commissie, Prof.dr. Passchier en Prof.dr. van der Maas, hartelijk bedankt 
voor het beoordelen van het manuscript en de discussies die op vele plaatsen terug te vinden 
zijn. Dr. Merrick Moseley, thank you very much for critically reading the manuscript and the 
pleasant discussions we had during the sunny conferences. 
Ich möchte mich auch bei Frau Dr. Fronius bedanken für Ihre Gastfreundlichkeit während mei­
nes Aufenthaltes im Goethe Institut Frankfurt, Deutschland und für die konstruktive Zusam­
menarbeit. Vielen Dank für die kritische Beurteilung des Manuskriptes. 
De mensen van de afdeling Medisch Technisch Onderzoek van het AMC in Amsterdam, in 
het bijzonder Ruud Voorn en Hugo Molenaar; dankzij jullie technisch vernuft en doorzett­
ingsvermogen hebben we als één van de eersten de therapietrouw op een zo grote schaal 
elektronisch kunnen meten. Zeer hartelijk dank daarvoor. 
Ik zou geen resultaten hebben kunnen verzamelen zonder ook de grote inzet van de orthop­
tisten in Den Haag: Ellen van Minderhout, Marleen Vermeulen, Roberta Delle Site, Janine van 
Zon, Eline Deelstra en Jorrien Bouma­van Wondergem. Hartelijk bedankt voor al jullie hulp, 
172
jullie rekrutering was overweldigend! Dr.Maurits Joosse, de oogarts, bedankt voor je hulp en 
je relativerende vermogen als het even niet liep zoals gepland.
Grote dank gaat uit naar alle kinderen en hun familieleden in Den Haag die aan het onderzoek 
hebben meegewerkt.
Gerard de Bruyne en José Vingerling, jullie originele ideeën en creativiteit mondde uit in het 
stripverhaal met stickers en mede daardoor is deze studie een succes geworden. Hartelijk 
dank daarvoor. De omslag van het proefschrift is prachtig.
Bregje van Dijk­Verhoef, mijn fiets­maatje in Den Haag. Mede dankzij jouw grote inspannin­
gen hebben we het onderzoek in Den Haag kunnen opzetten. Het memorabele fietstochtje 
naar Stompwijk zal mij altijd bijblijven.
Brigitte Simonsz­Tóth, mijn auto­maatje in Den Haag. Herzlichen Dank voor het voortzetten 
van het onderzoek in Den Haag en je orthoptische expertise bij de analyse van de database. 
Dank ook voor de gezelligheid bij jullie thuis met Annika en het goede eten, kortom: het 
Zwitserleven gevoel!
Caspar Looman, ik kon altijd even bij je binnenlopen voor een statistische vraag. Hartelijk be­
dankt voor je input en correcties, de manuscripten zijn er significant beter door geworden! 
Graag wil ik mijn directe collega’s van “de 16e” bedanken voor de collegialiteit en de prettige, 
ontspannen sfeer op de afdeling. Het afwisselen van de co­schappen met het onderzoek en 
vice versa was niet altijd even gemakkelijk, maar dankzij jullie kon ik altijd snel mijn draai weer 
vinden. Emine, samen AiO zijn schept een band! Dat was super! Walter, onze figuur deskundi­
ge en grootste afnemer van het legal­addictive­stimulant­apparaat: Douwe Egbert’ s Senseo! 
Het succesvol afronden van je promotie moet nu zeker lukken! Michael, we hebben ongeveer 
even lang op de 16e mogen bivakkeren, bedankt voor je gezelligheid en je traktatie op de 
swirl ijsjes. Jan Roelof, bedankt voor je swingende bijdrage op de donderdagochtenden. Eliza­
beth, de woensdag begon pas echt als jij er ook was, there was never a dull moment. Hartelijk 
bedankt voor je interesse en het lezen van mijn abstracts. Angela, ik ben erg blij dat jij met 
de behaalde resultaten een nieuw project gaat uitvoeren. Heel veel succes daarmee, samen 
met Elizabet, go for it girl! Hanneke en Jolanda veel succes met het oogmelanomenonderzoek. 
Dominiek (ook een beetje van de 16e), heel veel succes met je onderzoek en ik kijk er naar uit 
om je als collega beneden te kunnen begroeten. 
Sander Schutte, mister sjoette, je technische blik op het arts­zijn opende voor mij een tot nu 
toe onbekende wereld. Ik respecteer je ongedwongenheid en openheid over tal van zaken. 
Je gezelligheid en hulp bij de voorbereidingen voor congressen en op de congressen zelf 
maakte alles een stuk leuker. Heel veel succes met je promotie, en ik hoop dat ik later je uitvin­
dingen in de praktijk kan brengen. 
173
Dankwoord
De (oud­)assistenten en stafleden van de oogheelkunde, bedankt voor jullie interesse en kri­
tische vragen tijdens alle besprekingen. Joan Boller en Nicole van Basten, bedankt voor jul­
lie snelle reactie, hulp en organisatorische talenten als ik weer eens hulpeloos over de gang 
struinde. 
Jacqueline Willemse, bedankt voor het wijzen van de goede weg als ik dan weer op een zij­
spoor beland was.
Ylian Liem. Lieve Yls, je enthousiasme, betrouwbaarheid, systematiek en betrokkenheid heb 
ik vanaf de eerste dag dat ik je leerde kennen altijd bewonderd. Mensen als jij zijn schaars en 
moeten gekoesterd worden. Veel succes met je onderzoek en de opleiding, en de opmerking: 
“So you’re not a statistician then?” houden we in gedachten!
Mijn paranimfen, Jan Roelof Polling en Emine Kiliç. Jan Roelof, jij was het die mij introduceerde 
in ‘de wereld van de orthoptie’ en ‘de wereld van de wintersport’. Je was van het begin af aan 
betrokken bij het onderzoek. Niet alleen bij de uitvoering ervan, maar ook voor de mentale 
ondersteuning kon ik altijd op je rekenen. Je mening en hulp zijn voor het tot een succesvol 
einde brengen van het onderzoek absoluut onontbeerlijk geweest. Heel veel dank daarvoor. 
Emine, zowel op de 16e, als op congressen, als thuis voor de buis of achter de laptop, was het 
altijd goed toeven met jou! Je optimisme, kritische en nuchtere kijk op de zaken hebben zeker 
ook aan mijn ontwikkeling een positieve bijdrage geleverd. Ik verheug me op de dag dat ik 
samen met jou arts­assistent mag zijn en ik hoop nog lang met je te mogen samenwerken.
Mijn vrienden, dichtbij en ver weg, bedankt voor de momenten van ontspanning en jullie 
interesse in de vorderingen van het onderzoek. Ik kom nu weer uit mijn grot.
Mum & Dad, thank you for giving me roots and wings! You deserve a whole thesis of thanks 
and respect. The never ceasing support, encouragement and love have played a very central 
part in who I am and what I have accomplished. This book is for you, I hope you like it! 
Stephanie & Oliver, mijn zus en broer, bij jullie kon ik altijd gewoon mijn verhaal kwijt. Dank 
jullie wel daarvoor! 
Allerliefste Gerard, I am always on the lookout for a way to tell you how special you are!
Oneindig veel dank voor al je hulp, je geduld, je humor en bovenal je liefde. 
Next stop: Boston!

175
About the author
Sjoukje Loudon was born in Huddersfield in the United Kingdom on the 30th October 1978. In 
1982 she moved with her family to the Netherlands. She graduated from the “Professor Zee­
man” Secondary School in 1997 and started her medical study at the ErasmusMC University 
Medical Center Rotterdam that same year. In her third year she spent a one­month clinical 
exchange at the First Internal Medicine Department in Kurume University Hospital in Japan. 
During her studies she participated in arranging the international clinical exchanges and was 
president of the local committee of the International Federation of Medical Students’ Associa­
tions (IFMSA). In 2003 she was secretary of the Organising Committee of the IFMSA Confer­
ence “Medical Ethics” and August Meeting 2003. After obtaining her master’s degree in July 
2001, she started the research described in this thesis at the Department of Ophthalmology; 
supervisors were Prof. dr. G. van Rij and Prof. dr. H.J. Simonsz. In 2005 she received the ‘Jonkers 
Prize’ for the most innovative research leading to important new insights in the field of or­
thoptics. In February 2007, she will become a medical doctor. 
After this PhD research she will participate in a research project at the Department of Ophthal­
mology, Children’s Hospital Boston, USA, supervised by Prof. dr. D.G. Hunter. 
In January 2008 she will start her training as an ophthalmologist at the Department of Oph­
thalmology ErasmusMC University Medical Center Rotterdam (head Prof. dr. G. van Rij).

177
List of publications
S.E. Loudon, J.R. Polling, H.J. Simonsz Electronically measured compliance with occlusion ther-
apy for amblyopia is related to visual acuity increase. Graefes Arch Clin Exp Ophthalmol 2003 
Mar;241(3):176­80
S.E. Loudon, J.R. Polling, B. Simonsz, H.J. Simonsz Objective survey of the prescription of occlu-
sion therapy for amblyopia. Graefes Arch Clin Exp Ophthalmol 2004 Sep;242(9):736­40
S.E. Loudon, H.J. Simonsz The history of the treatment of amblyopia.
Strabismus 2005 Jun;13(2):93­106
Y. Chopovska, S.E. Loudon, L. Cirina, A. Zubcov, H.J. Simonsz, M. Luchtenberg, M. Fronius Elec-
tronic recording of occlusion treatment for amblyopia: potential of the new technology. Graefes 
Arch Clin Exp Ophthalmol 2005 Jun;243(6):539­44
S.E. Loudon, M. Fronius, C.W.N. Looman, M. Awan, B. Simonsz, P.J. van der Maas, H.J. Simonsz 
Predictors and a remedy for non-compliance with amblyopia therapy in children measured with 
the Occlusion Dose Monitor. Invest Ophthalmol Vis Science 2006 Oct;47(10):4393­400
B. Simonsz­Tóth, S.E. Loudon, H. van Kempen­du Saar, E.S. van de Graaf, J.H. Groenewoud, 
H.J. Simonsz Visusevaluierung in einer historischen Kohorte von 137 okkludierten Patienten, 30-
35 Jahre nach Ende der Okklusionsbehandlung / Evaluation of visual acuity in a historic cohort of 
137 patients treated for amblyopia by occlusion 30-35 years ago. Accepted for publication in Klin 
Monatsbl Augenheilkd 2006
S.E. Loudon, L. Chaker, S. de Vos, M. Fronius, J. Passchier, R.A. Harrad, C.W.N. Looman, B. Simon­
sz, H.J. Simonsz Effect of an educational programme on attitudes and behaviour with occlusion 
therapy and reasons for total non-compliance. (submitted)
S.E. Loudon, A.W. Wypekma, C.W.N. Looman, M. Fronius, B. Simonsz, H.J. Simonsz Physiological 
properties of the eye patch and influence on compliance with occlusion therapy. (submitted)
S.E. Loudon, J.R. Polling, H.J. Simonsz A preliminary report about the relation between visual acu-
ity increase and compliance in patching therapy for amblyopia. Strabismus 2002 Jun;10(2):79­
82
178
S.E. Loudon Charles de Saint-Yves (1677-1736). Strabismus 2005 Sep;13(3):143­4
M. Fronius, Y. Chopovska, J. Nolden, S.E. Loudon, M. Luchtenberg, A. Zubcov, L. Pepler Occlu-
sion treatment for amblyopia: assessing the performance of the electronic occlusion dose monitor. 
Strabismus 2006 Jun;14(2):65­70
ch
ap
te
r 1
ch
ap
te
r 2
ch
ap
te
r 3
ch
ap
te
r 4
ch
ap
te
r 5
ch
ap
te
r 6
ch
ap
te
r 7
ch
ap
te
r 8
ch
ap
te
r 9
ch
ap
te
r 1
0
ch
ap
te
r 1
1
A
dd
en
da
Appendix / Colour figures
 Evaluation of visual acuity in a historic 
cohort of 137 patients treated for amblyopia 
by occlusion 30-35 years ago
(English translation chapter 4)

181
Evaluation of visual acuity in a historic cohort
InTroducTIon
Treatment of amblyopia with occlusion therapy has been a long established method of treat­
ment. The value of occlusion therapy can be found mainly in the prevention of costs which 
may arise when patients with insufficiently treated amblyopia lose their dominant eye later in 
life (Neubauer and Neubauer 2005).
The time such a patient spends with a diminished visual acuity in both eyes (acuity both eyes 
>0.3 logMAR) increases from 8 months to 15.5 months (van Leeuwen, et al. 2002).
With the introduction of screening, amblyopia could be detected at an earlier age, making 
treatment more effective, so that the number of patients who were unable to read with the 
amblyopic eye could be reduced. Since health centres in the Netherlands test children for 
strabismus and amblyopia and measure the acuity at the age of 3 and 3 years and 9 months 
an undetected amblyopia rarely happens. 
In spite of this, the occlusion therapy fails in almost one third of all patients with amblyopia 
(acuity in the amblyopic eye >0.3 logMAR) (Jensen and Goldschmidt 1986).
The literature quotes a prevalence of amblyopia of 3.25% (Attebo, et al. 1998). Formerly, failure 
of the occlusion therapy was thought to be due to a late diagnose (Bowman 1998), nowadays 
non­compliance with occlusion therapy (Dorey, et al. 2001; Loudon, et al. 2003) is held primar­
ily responsible. The long­term success of occlusion therapy varies according to literature. Most 
studies include groups of patients with varying inclusion criteria: recruitment of patients from 
different clinics (Woodruff, et al. 1994) or in the context of pre­school screening (Bowman, 
et al. 1998), only patients who attended all check up appointments (Levartovsky, et al. 1995; 
Malik, et al. 1975), who had total occlusion treatment only (Scott and Dickey 1988) or were 
also treated with pleoptics, spectacle occlusion or inverse occlusion (Schröpfer and Meinert 
1975; Sparrow and Flynn 1977). In addition, the moment for the follow­up examination after 
cessation of the occlusion therapy varies from a couple of months (Malik, et al. 1975) up to a 
maximum of twenty years (Leiba, et al. 2001).
Some authors suggested that the acuity more or less stayed the same after cessation of the oc­
clusion therapy (Ohlsson, et al. 2002; Scott and Dickey 1988), or improved (Leiba, et al. 2001), 
whilst other authors demonstrated a slight decrease in acuity of one to two lines (Levartovsky, 
et al. 1995; Schröpfer and Meinert 1975).
Factors negatively influencing the course of visual acuity after cessation of therapy, included 
a relatively high age (Ham, et al. 1985; Levartovsky, et al. 1995; Meyer, et al. 1991; Stewart, et 
al. 2004) and a low start acuity (Meyer, et al. 1991; Scott and Dickey 1988; Sparrow and Flynn 
1977; Woodruff, et al. 1994), an eccentric fixation (Ham, et al. 1985; Sparrow and Flynn 1977) 
and a combined cause, strabismus and anisometropia, for the amblyopia (Levartovsky, et al. 
1995; Woodruff, et al. 1994).
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We examined the current visual acuity and analysed the influence of certain factors on the 
current acuity after cessation of occlusion therapy in a total of 137 patients, who, 30­35 years 
ago, were treated for amblyopia with occlusion therapy in Waterland, a rural region in Holland. 
At that time only one ophthalmologist and one orthoptist (less than 0.5 Fte) provided for that 
region. All children suspected of amblyopia were referred to this orthoptist (HvK) by health 
care centres and general practitioners who screened the children for amblyopia. Together 
with this orthoptist these patients were examined once more in 2003.
mATErIAL And mEThodS
Background
At the time of the research the Waterland hospital took care of the medical service to the 
townships of Purmerend, Waterland, Zeevang, Wormer, Edam and Volendam. The population 
consisted of people originating from these areas and families with young children who had 
come to live there from Amsterdam.
data
All files from patients who had been treated in the orthoptic department of the Waterland 
hospital in Purmerend, short term or long term, between 1968 and 1975 were analysed (n = 
1250). 471 (38%) of these children received occlusion therapy. From the files we derived the 
demographic data of the patients (sex, date of birth, telephone number) and orthoptic data 
(age at start and end of occlusion therapy, acuity at start and end of occlusion therapy and 
cause of the amblyopia, fixation, binocular vision, ocular motility and cycloplegic refraction).
Treatment 30 years ago
Amblyopia was treated with occlusion therapy when, after an adequate spectacle prescrip­
tion, an acuity difference of one line together with other amblyogenic factors, was present. 
Up to the age of four, acuity was tested monocularly with pictures (Amsterdam Picture Chart; 
acuity range 6/30 to 6/5). From the age of four, acuity was tested with Landolt­C and from 
about the age of seven Letters (Snellen) were used and noted down in decimals. 
In both these tests the distance between the lines of the chart was linear; the distance be­
tween the optotypes was larger than 2.6”and was described as ‘single’. All visual acuity out­
comes were converted into logMAR (Table 1).
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Follow- up re-examination in 2003
Of the 471 patients, 203 (42%) could be traced and contacted by telephone. These patients 
were sent a questionnaire to establish their quality of life with amblyopia and/or strabismus; 
the amblyopia & strabismus questionnaire (A&SQ) (van de Graaf, et al. 2004). The other pa­
tients could, for different reasons, not be reached: two patients had died, of the other patients 
telephone numbers could not be traced or they could not be contacted. 174 patients returned 
the completed questionnaire.
In the autumn of 2003, 137 of them could be re­examined by the orthoptist and the ophthal­
mologist at the orthoptic department of the Waterland hospital in Purmerend.
Of the 174 patients who had returned the questionnaire, 27 patients could not be re­exam­
ined, 11 could not be contacted, six refused participation and nine could not attend as they 
were in hospital, abroad or had a long way to travel.
We now had acuity measurements taken at three different moments in time (at the start of 
occlusion therapy, end of occlusion therapy and in 2003, 30­35 years after cessation of the 
occlusion therapy).
The following parameters were determined at the follow­up examination: binocular vision 
was tested using the Bagolini at 6m and 0.4m distance, stereo vision using the Titmus­Fly 
Table 1 . Table of conversion: acuity in decimals to acuity in logMAR.
conversion table
acuity in decimals - acuity in logmAr
Visus LogmAr
1.6 ­0.2
1.25 ­0.1
1.0 0.0
0.8 0.1
0.63 0.2
0.5 0.3
0.4 0.4
0.32 0.5
0.25 0.6
0.2 0.7
0.16 0.8
0.12 0.9
0.1 1.0
0.08 1.1
0.06 1.2
0.05 1.3
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test, the stereo­test from Lang II and TNO­Test. The angle of the strabismus was measured by 
means of the cover­uncover and alternating cover test at 6m and 0.3m distance.
Cycloplegic refraction was tested by means of retinoscopy without atropine. It was tested, 
however, in a darkened room and according to subjective equations.
Visual acuity was tested by means of a projector (OCULUS, Medical Workshop, the Nether­
lands) with linear acuity lines monocularly at 6m numbers analogue DIN EN ISO 8596 with the 
best possible spectacle correction and noted in decimals.
The reading ability was determined by means of a Dutch reading text that consisted of five 
acuity gradations (D=0.5; D=0.8; D=1; D=1.25; D=2) D=1 is similar to newspaper print size.
In addition fixation was tested. The macula and front segment were assessed.
All acuity outcomes, the reading text test excepted, were converted into logMAR for the analy­
sis. Anisometropia was defined as a difference of more than 1D spherical equivalent between 
the right eye and the left. A combination of both causes (strabismus and anisometropia) was 
defined as combined amblyopia.
Statistical analysis
We applied a regression analysis to determine the influence of the measured parameters on 
current visual acuity. The influence of potential confounding is corrected for in the multivari­
ate analysis. SPSS, version 10.0 was used for the statistical analysis. P < 0.05 indicated statisti­
cal significance.
rESuLTS
Study population
Of the 137 patients, 65 were female. Mean age at start of occlusion therapy was 5.4 ± 1.9 years 
and 7.4 ± 1.7 years at the end of treatment. Of the 137 children twelve (9%) were occluded 
before the age of three (mean age 2.4 years); all had amblyopia caused by strabismus.
Amblyopia was associated with strabismus in 98 patients (71%), with anisometropia in 16 
patients (12%) and with both anisometropia and strabismus in 23 patients (17%). 
Mean acuity in the amblyopic eye at start of treatment was 0.6 ± 0.7 logMAR and 0.3 ± 0.5 
logMAR at the end of treatment.
At the start of occlusion therapy, 116 patients had an acuity difference of at least 0.5 logMAR 
between the dominant and the amblyopic eye. 13 patients had an acuity difference of 0.2­0.5 
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logMAR, 8 patients of < 0.2 logMAR. Five patients were too young to be able to cooperate with 
the visual acuity tests. Therefore, the orthoptist recorded the pursuit and fixation behaviour. 
In all five patients amblyopia was caused by strabismus: two patients had hardly any pur­
suit when looking monocularly, three preferred fixation with the dominant eye. The following 
decimal equivalences were used: 0.4 logMAR and 0.2 logMAR, respectively. In these cases, the 
acuity at start of treatment was used only to determine the correlation between the acuity at 
treatment onset and the current acuity, however not for the prognostic factors. This decimal 
equivalence could be interpreted in different ways. However, it should be noted that it only 
concerned five patients and that nevertheless, the acuity at treatment onset was strongly cor­
related to the current visual acuity. 
Patients with amblyopia caused by strabismus were occluded from the mean age of 5.1 ± 1.9 
years; for an average of 2.3 ± 1.3 years.
Patients with clear anisometropic amblyopia were on average 7.2 ± 2.2 years of age at the 
start of treatment and were occluded for an average of 1.4 ± 1.0 years.
Patients with amblyopia caused by strabismus and anisometropia were occluded from the 
mean age of 5.8 ± 0.7 years, for an average of 1.6 ± 1.3 years (see also Table 2). 
Binocular vision improved slightly in the total study population (Figure 1).
Table 2. Acuity at treatment onset, cessation and 30­35 years after cessation of occlusion therapy, the age 
at start of treatment, duration of occlusion and fixation for each cause of amblyopia. 
Parameters
strabismus-amblyopia    
(n = 98)
anisometropic-
amblyopia (n = 16)
combined amblyopia   
(n = 23)
acuity start occlusion
(logmAr)
0.69* ± 0.5 0.53* ± 0.3 0.82* ± 0.54
acuity end occlusion (logmAr) 0.29 ± 0.3 0.17 ± 0.23 0.52 ± 0.54
acuity at follow-up (logmAr) 0.27 ± 0.3 0.21 ± 0.23 0.65 ± 0.54
age start occlusion (years) 5.1 ± 1.9 7.2 ± 2.2 5.8 ± 0.7
time of occlusion (years) 2.3 ± 1.3 1.4 ± 1.0 1.6 ± 1.3
Fixation
 central n=63* n=16 n=14
 eccentric n=35* n=0 n=9
In both the univariate and multivariate analysis, acuity in the amblyopic eye at start of treatment 
(P < 0.0001), the cause of the amblyopia (P = 0.001) (strabismus, anisometropia, combined amblyopia) 
and an eccentric fixation (P < 0.0001) with strabismus, were significantly correlated with the current visual 
acuity in 2003.
*Significant parameter for the acuity in 2003 in logMAR in the regression­analysis.
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relationship between visual acuity and the cause of amblyopia
Since the cessation of occlusion therapy visual acuity had deteriorated from a mean of 0.52 ± 
0.54 to 0.65 ± 0.54 logMAR in patients with a combined cause of amblyopia and from a mean of 
0.17 ± 0.23 to 0.21 ± 0.23 logMAR in patients with an anisometropic amblyopia. 
Visual acuity had improved from 0.29 ± 0.3 to 0.27 ± 0.3 logMAR in patients with strabismic 
amblyopia (Figure 2). This improvement was significant (P < 0.001). The acuity of the dominant 
eye of these patients had also improved from 0.01 ± 0.15 to 0.05 ± 0.07 logMAR, this was also 
significant (P = 0.04). 
In general, in 14 patients (10%) the acuity in the amblyopic eye was unchanged. In 70 patients 
(51%) acuity had improved. In 54 patients (39%) acuity had deteriorated, of which 18 patients 
had an acuity loss of >50% compared to acuity at the end of treatment.
Of the 137 patients, 47 (34%) had an acuity in the amblyopic eye at distance (6m) of > 0.3 log­
MAR lines at the end of treatment, on average 0.48 ± 0.6 logMAR. 
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Figure 1. Binocular vision of the total study population during occlusion treatment and at the time of the 
follow­up re­examination in 2003.
The degree of binocular vision (abscissa) was arranged into seven categories 
1: Bagolini negative, 2: Bagolini positive, 3: Bagolini and Titmus­Stereotest Fly positive, 4: lowest Titmus­
Stereotest circle 200”­140” positive, 5: lowest Titmus­Stereotest circle 100”­40” positive, 6: Stereotest from 
Lang or lowest TNO­Test figure V (480” & 240”) positive, 7: TNO­Test figure VI or VII (120”­15”) positive. The 
black bars show the degree of binocular vision during the occlusion treatment (n=137), the grey bars at 
the time of the follow­up re­examination. The ordinate represents the number of patients. 
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Of the 137 patients, 55 (40%) were unable to read with the amblyopic eye (>D=1).
Patients with profound deterioration in visual acuity
18 Patients had an acuity loss >50% compared to acuity at the end of treatment. Of these, 
15 showed an increase of anisohypermetropia. Of these 15 patients, nine had developed an 
anisohypermetropia of 2.2 ± 1.7D. In six patients, an anisohypermetropia had already been 
present (mean was 2.9D), which had increased to 3.5 ± 1.8D. 
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Figure 2 
Figure 2. Acuity in the amblyopic eye at treatment onset and at follow­up re­examination in 2003, for each 
cause of amblyopia.
The ordinate shows the acuity at the time of the follow­up re­examination in logMAR lines, the abscissa 
shows the acuity in logMAR lines at treatment onset. Patients with a combined amblyopia are represented 
by a black square ß, patients with anisometropic­amblyopia by a triangle p and patients with strabismic­
amblyopia by a white square ˙. The solid regression line represents the combined amblyopias, the dashed 
regression line those of the anisometropic­amblyopias and the dotted line those of the strabismic­
amblyopias.
Both patients with strabismic­amblyopia and those with combined amblyopia had a poor acuity at 
treatment onset, patients with strabismic­amblyopia, however, had a better acuity at the follow­up re­
examination in 2003. 
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In the 18 patients the spherical equivalent of the amblyopic eye had increased from +2.7D 
to +2.8D. The spherical equivalent had decreased from +1.9D to +0.7D in the dominant eye. 
Only five of the 18 patients wore adequate spectacles at the time of the follow­up re­examina­
tion. Three of these five patients were myopic in the dominant eye, and two were on average 
+2.75D hyperopic.
correlations
The univariate analysis showed a statistically significant correlation between the current vi­
sual acuity and the acuity at the start of the occlusion therapy (P <0.001), an eccentric fixation 
(P <0.001) and the cause of the amblyopia (strabismus, anisometropia or combined cause), (P 
= 0.005) (see also table 2). No significant influence could be found for the duration of occlu­
sion therapy (P = 0.622), the age at start of occlusion treatment (P = 0.320) and at the end of 
occlusion treatment (P = 0.119).
When correcting for potentially confounding factors in the multivariate analysis, the visual 
acuity at the start of treatment, the cause of the amblyopia and the fixation remained signifi­
cant (P < 0.001; P = 0.018; P = 0.004, respectively).
Prognostic factors
Patients with anisometropic amblyopia had, compared to patients with strabismic amblyopia 
and patients with combined amblyopia, a significantly better visual acuity at the start of the 
occlusion therapy. Patients with combined amblyopia had the poorest acuity at the start of 
treatment and also at the follow­up re­examination. Only patients with strabismic amblyopia 
showed a slight acuity improvement, compared to acuity at the end of the treatment.
In patients with strabismus, the fixation was correlated with the acuity. A correlation could be 
found between the decrease in acuity and the loss of binocular vision (r = 0.38).
Prevalence of occlusion therapy
We aimed to establish whether the historical cohort was representative of the number of chil­
dren receiving occlusion therapy at that time; i.e. if any selection bias had occurred. The preva­
lence of amblyopia has been quoted to be approximately 3.25% (Attebo, et al. 1998). It was 
expected to find a lower prevalence rate, as our historical cohort was comprised of a biased 
under­representation. Of the 471 occluded children, 66, 64 and 68 children were born in 1965, 
1966 and 1967, respectively (Figure 3). In the whole of the Waterland hospital region 1286, 
1328 and 1355 births were registered in 1965, 1966 and 1967, respectively. This would concur 
with a prevalence of 5.0% occluded children.
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Figure 3.  
Overview of the total number of patients for their year of birth: all patients occluded in the Waterland 
hospital (n = 471, light grey) and of the historical cohort (n = 137, black). Also for the historical cohort 
start of occlusion (white) and cessation of occlusion (dark grey) has been given. Of the 471 occluded 
children 66, 64 and 68 were born in 1965, 1966 and 1967, respectively. This corresponded to 5.0% of 
the registered births in the total region of the Waterland hospital in those years.  
 
 
Figure 3. Overview of the total number of patients for their year of birth: all patients occluded in the 
Waterland hospital (n=471, light grey) and of the historical cohort (n=137, black). Also for the historical 
cohort start of occlusion (white) and cessation of occlusion (dark grey) has been given. Of the 471 
occluded children 66, 64 and 68 were born in 1965, 1966 and 1967, respectively. This corresponded to 5.0% 
of the registered births in the t tal region f the Waterland hospital in hose years. 
In hindsight, the amblyopia could not be confirmed in seven of the 137 children. These pa­
tients had an acuity difference of <0.2 logMAR lines between the dominant and the amblyopic 
eye, an anisometropia <1D, and/or an alternating strabismus.
After the necessary correction, the prevalence of occluded children was approximately 4.7%. 
Theore ically, i  could be possible that children living outside the region were also treated in 
the Waterland hospital. This, however, was not the case in our group.
dIScuSSIon
For this study we were able to establish an evaluation of the visual acuity in 137 patients more 
than thirty years after the cessation of occlusion therapy. We found that a poor acuity in the 
amblyopic eye at the start of treatment, an eccentric fixation and a combined cause of ambly­
opia were correlated with the current visual acuity measured at the follow­up re­examination. 
That a poor visual acuity in the amblyopic eye at start of treatment and the cause of amblyo­
pia were predictors for a poor outcome has also been described by other authors, even when 
a lengthier period of observation time was examined. A combined cause of amblyopia and an 
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increase of the anisohypermetropia were, after 30 years, associated with a decrease in visual 
acuity after the end of the occlusion therapy.
In most of the children, due to the school age, acuity could be tested using the Landolt­C 
chart, both at the start and the end of treatment. The acuity at treatment onset, in which the 
largest variation was to be expected, was merely used in the analysis of the correlation with 
the current acuity. When analysing the prognostic factors the acuity at the end of treatment 
was used. The acuity was determined with different acuity charts. This could cause the out­
comes to be not entirely comparable (Gräf 2004), as acuity tests with optotypes can only score 
similar outcomes as when using Landolt­C, when acuity is higher. When acuity is poor, a slight 
overrating of the acuity will occur when it is measured using optotypes (Rassow and Wang 
1999). Nevertheless, we found a strong significance that could be even stronger, when acuity 
is tested in equal testing conditions. 
After cessation of occlusion therapy a slight improvement of the acuity was found in both the 
amblyopic eye and the dominant eye in patients with strabismic amblyopia. We presumed 
this to be the natural development of the acuity. Information is scarce concerning the devel­
opment of the acuity in the dominant eye. In general, when not taking into account the cause 
of amblyopia, a slight improvement of the acuity was found (Ohlsson, et al. 2002). Studies of 
the natural course of the acuity in patients with untreated amblyopia, showed a worsening 
of the acuity in the amblyopic eye both at pre­school age (Simonsz and Preslan 1999) and in 
adulthood (Haasse and Wenzel 1996).
It should be taken into account, however, that an inclusion criteria for the study was poor 
acuity (>0.18 logMAR lines; n = 18) and that children with a slight decrease in acuity were 
excluded, making a selection bias probable.
In agreement with other studies (Levartovsky, et al. 1995; Woordruff, et al. 1994) we were un­
able to demonstrate a correlation between the age at treatment onset, the age at the end 
of treatment and the current visual acuity in 2003. However, it could not be concluded that 
a patient may not be treated more successfully if occlusion in this patient had started at an 
earlier age.
In our study group the age at the start of the occlusion therapy was relatively high, probably 
caused by the fact that, at that time, screening for amblyopia had not altogether been prop­
erly introduced. With the exception of the cities, health centres and general practitioners did 
not carry out acuity measurements, causing amblyopia without a notable strabismus to be 
first diagnosed at the age of 5­7 years. Nowadays, in the Netherlands, the Child Health Care 
Centres screen for the presence of strabismus and measure visual acuity at the age of three. 
The current mean age at treatment onset is 4.6 years (Loudon, et al. 2006).
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Fifteen of the 18 patients, in whom acuity had decreased >50% after the cessation of the oc­
clusion therapy, had an increase of the anisohypermetropia. At the time of the follow­up re­
examination it seemed important to remark that only five of these were wearing spectacles or 
contact lenses. They indicated they stopped wearing the spectacles from the age of 14/15. It 
may be possible that, after the latest spectacle correction, these patients started to see out of 
focus again with their amblyopic eye, because of the increase in anisometropia and, for that 
reason, did not like to wear the spectacles.
It is therefore recommendable to check patients that had anisometropic amblyopia and show 
an increase of the anisometropia more often and to adjust the spectacles accordingly.
In other studies (Attebo, et al 1998; Leiba, et al. 2001; Levartovsky, et al. 1995; PEDIG 2002; 
Woodruff, et al. 1994), amblyopia caused by a pure anisometropia is approximately 30%, vary­
ing, however, between 11% (Leiba, et al. 2001) and 50% (Attebo, et al. 1998). In our study, only 
the children who received occlusion therapy for their amblyopic eye were included. Therefore, 
children who had been treated for their anisometropic amblyopia using a spectacle correc­
tion were not included. 
Surprisingly, we found the prevalence of occluded children (4.7%) to be higher than the prev­
alence’s of amblyopia mentioned in other studies (3.25%), (Attebo, et al. 1998). How could this 
discrepancy be explained? The prevalence of amblyopia in most studies is determined among 
adult patients with untreated amblyopia. Our study demonstrated that in most patients the 
acuity after the cessation of the occlusion therapy improves slightly; in only few it deterio­
rates. At the start of occlusion therapy the orthoptist is unaware which children, who have 
been referred by health centres or paediatricians because of a slight reduction in acuity (>0.1 
logMAR), will have a spontaneous improvement of acuity and may therefore, over­treat.
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The educational programme, developed by José Vingerling and Gerard de Bruyne, to improve compliance 
with occlusion therapy for amblyopia. It consisted of a cartoon story without words, explaining to the 
child why he or she should patch. There were no animal figures included, making it easier for the child 
to identify him or herself with the child in the story. It was bolstered by an immediate reward system 
(calendar and stickers). © Vingerling & De Bruyne.
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Bruyne. 
 
195
 
colour figures
chAPTEr 1
chAPTEr 3
Figuren bij Chapter 5 
1a 1b 1c 1d 
Figure 1. The development of the Occlusion Dose Monitor. a Year 1991: first model developed by 
Fielder and Moseley in Birmingham, UK (with permission of M. Moseley). The ODM was a miniature 
datalogger, which logs the patch-skin contact resistance every 64 s. b Year 1997: The Academic 
Medical Center Amsterdam modified the design into an ODM containing two thermistors connected to 
either the front or the back of the ODM (35x23x4 mm, 6 g). c The 2001 type used in the Netherlands 
(24x12x3.6 mm, 1.8 g). d The 2002 type used in Germany (31x15x3.5 mm, 2.3 g) 
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Figure 2. Examples of recordings with the ODM, with measured temperature difference on the 
ordinates. a A week’s recording. Abscissa: date of the recording. The temperature difference was about 
"0" (0; 0.0625) while the child was not patched (baseline value) and higher during the periods of 
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Figure 1. a the first model of the ODM developed by Prof. Alistair Fielder and Dr. Merrick Moseley in 
London, United Kingdom b: in 1997 the department of Medical Technical Development at the Academic 
Medical Center Amsterdam modified the design and made it smaller: it now measures temperature 
difference between the front and the back c & d the ODM as used in the study in The Hague: it weighs 1.8 
g and measures 24 x 12 x 3.6 mm.
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Chapter 3 
Figure 1. Median and interquartile range of the prescribed hours of occlusion per day of the non-
amblyopic eye per regimen per case. The abscissa represents the five cases and the chosen regimen. 
The total number of orthoptists prescribing a regimen is given below or above each whisker. 
Figure 1. Median and interquartile range of the prescribed hours of occlusion per day of the non­
amblyopic eye per regimen per case. The abscissa represents the five cases and the chosen regimen. The 
total number of orthoptists prescribing a regimen is given below each whisker.
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Chapter 6 
Figure 2. Graphic representation of the relationship between acuity increase during treatment and 
electronically measured compliance. The ordinate represents the ratio between visual acuity in the 
amblyopic eye and the acuity in the good eye. The abscissa represents the months after the start of 
occlusion therapy. On the right: patient number corresponding to the actually measured compliance in 
percentages in parenthesis. Blue lines represent patients with high compliance; red lines represent low 
compliance, corresponding to the visual acuity increase after 6 months of occlusion therapy. 
Figure 2. Graphic representation of the relationship between acuity increase during treatment and 
elect onically measured complia ce. T e ordinate re resents the ratio between visual acuity in the 
amblyopic eye and the acuity in the good eye. The abscissa represents the months after the start of 
occlusion therapy. On the right: patient number corresponding to the actually measured compliance in 
percentages in parenthesis. Blue lines represent patients with high compliance; red lines represent low 
compliance, corresponding to the visual acuity increase after 6 months of occlusion therapy.
197
Colour figures
chAPTEr 9
 
 
 
Chapter 9 
Figure 1. To remove the patches form the skin an average maximum force of 8.8 Newton (Beiersdorf – 
Elastopad), 5.9 N (Orthopad), 3.2 N (Opticlude) and 2.6 N (Pro-Ophta) was needed. 
Figure 1. To remove the patches from the skin an average maximum force of 8.8 Newton (Beiersdorf ), 5.9 
N (Orthopad), 3.2 N (Opticlude) and 2.6 N (Pro­Ophta) was needed.
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Chapter 10 
Figure 1.a. The distribution of the 10 possible causes of amblyopia per diagnose. Each bar represents a 
diagnosis. In our study population 23 diagnoses were given by the treating orthoptist and more than one 
diagnosis may be given to one child. Each bar was subdivided into the cause of amblyopia (assessed by 
the researchers), e.g. the diagnosis ‘late-onset esotropia’ was present in the following three causes of 
amblyopia: strabismus, strabismus & anisometropia and strabismus & hypermetropia.  
Figure 1.a. The distribution of the 10 possible causes of amblyopia per diagnose. Each bar represents 
a diagnosis. In our study population 23 diagnoses were given by the treating orthoptist and more than 
one diagnosis may be given to one child. Each bar was subdivided into the cause of amblyopia (assessed 
by the researchers), e.g. the diagnosis ‘late­onset esotropia’ was present in the following three causes of 
amblyopia: strabismus, strabismus & anisometropia and strabismus & hypermetropia. 
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Chapter 10 
Figure 1.b. The distribution of the 23 diagnoses in our study population per cause of amblyopia. Each 
bar represents 1 of the 10 causes of amblyopia, which was subdivided in the diagnoses given in our 
study population. One child may have more than one diagnosis, but only one cause of amblyopia. For 
example, anisometropia was assessed as the cause of amblyopia in 132 children; however, 6 children 
with anisometropic amblyopia also had the diagnosis ‘esophoria’ and 11 ‘exophoria’. These diagnoses 
were not the main cause of amblyopia. The number above the bar corresponds with the number of 
children whose cause of amblyopia is represented in that bar.  
 
Figure 1.b. The distribution of the 23 diagnoses in our study population per cause of amblyopia. Each 
bar represents 1 of the 10 causes of amblyopia, which was subdivided in the diagnoses given in our 
study population. One child may have more than one diagnosis, but only one cause of amblyopia. For 
example, anisometropia was assessed as the cause of amblyopia in 132 children; however, 6 children with 
anisometropic amblyopia also had the diagnosis ‘esophoria’ and 11 ‘exophoria’. These diagnoses were not 
the main c use of amblyopia. The numbe  above th  bar corre ponds with the n mber of children whose 
cause of amblyopia is represented in that bar. 

